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AIM OF THE PhD THESIS 
The aim of  this PhD work was to establish the synthetic procedures for new families of  
biocompatible and biodegradable and/or bioeliminable biomaterials that can be dif f erently 
processed to obtain nanoparticles, core-shell nanof ibres and hydrogel slabs or conduits, 
respectively. Depending on composition, size and morphology, these biomaterials may be 
intended for applications as drug delivery systems and/or tissue regeneration.  
Specif ically, the research project has been developed along two main lines: 
 Synthesis of  poly(lactic-glycolic acid)-g-poly(1-vinylpyrrolidin-2-one) (PLGA-g-PVP) 
copolymers whose architecture consisted of  a long PLGA backbone with oligomeric PVP 
pendants. These were obtained by the radical polymerisation of  1-vinylpyrrolidin-2-one  
in molten PLGA 50:50, acting as chain transf er agent. The procedure was a single pot 
- single step one. Copolymers were characterized by FTIR, 1H- and 13C-NMR and 
thermal analyses. They were saponif ied giving, besides PLGA degradation products, 
also un-degraded PVP. This was isolated and analysed by size exclusion 
chromatography, to evaluate the molecular weights of  graf ted PVP chains. MALDI-
TOF analysis allowed identif ying the chemical structure of  PVP terminals and 
unambiguously establishing that PVP chains had been graf ted onto PLGA backbone 
PLGA-g-PVP with dif f erent PVP content  were formulated as drug nanocarriers by 
dif f erent procedures. Doxorubicin-loaded nanoparticles were prepared by the solvent 
dif fusion method and fully characterised. In vitro drug release kinetics were studied and 
in vitro biological activity evaluated on several antitumoral cell lines.  
PLGA-g-PVP were also used as coatings of  lipid nanocapsules for the delivery of  
curcumin and artemisinin as antimalarials. Drug loaded-lipid micro-dispersions were  
f irst prepared by oil in water emulsion. The lipid drops were converted into nanometric 
ones by high pressure homogenization and f inally surface coated by adding a 
DMSO/acetone PLGA-g-PVP solution. Growth inhibition assay were conducted on 
plasmodium falciparum (3D7) cultures. Haemoltic assays were conducted on healthy 
red blood cells. 
PLGA-g-PVP- and PLGA-based scaf folds consisting of  nanof ibrous mats were  
produced by electrospinning. Starting materials were electrospun and their morphology 
was evaluated by scanning electron microscopy and wettability by contact angle 
measurements. Coaxial electrospinning of  two materials, in which PLGA formed the 
core and PLGA-g-PVP the shell of  f ibres, were also conducted and compared with those 
obtained by mixed solutions of  staritng materials. Chemical composition was evaluated 
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by TGA, morphology by scanning electron microscopy  and wettability by contact angle 
measurements. Nanofabric scaf fold produced will be evaluated for drug release and tissue 
engineering applications. 
 
 Synthesis of  a new classes of  poly(saccharide)-poly(aminoamine)s 3D-network intended 
as scaf folds for the regeneration of  liver.  
In particular, hyaluronic acid-polyamidoamine and hyaluronic acid-gelatin- 
polyamidoamine hydrogels were synthesised by amidation reaction between the carboxylic 
acid group of  hyaluronic acid and amine groups of  gelatin and or an NH2-functionalized 
PAA, promoted by 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium 
chloride (DMTMM) as coupling agent. Chemical-physical characterization were carried 
out on hydrogels. In order to promote hepatic cell prolif eration serotonin was bonded to 
both hydrogels, adding it to the initial recipe, exploiting the above reaction between 
carboxylic acid group of  hyaluronic acid and amine group of  serotonin . Serotonin-loaded 
hydrogels were tested in vitro to evaluate biological ef f icacy.  
 
In “Introduction” the broad def initions, classif ication and roles of  biomaterials have been 
discussed. In the following chapters, chapter is launched with a brief  and more narrow 
introduction on the chapter matter. 
  
CHAPTER 1 




INTRODUCTION TO BIOMATERIALS 
 
 
1.1 BIOMATERIALS: DEFINITION 
“A biomaterial is a nonviable material used in a medical device, intended to interact with 
biological systems.”i 
David Franklyn Williams, 1987 
The increase in global average life expectancy, particularly in industrialised 
countries, a more active lifestyle and the onset of a large number of diseases, 
have generated a rising demand of medical devices, allowing to return the 
recovery of functionality of compromised body parts resulting in patient's 
survival. In order to build effective medical devices capable to perform these 
functions, the constituting materials must have the ability to interact with 
biological systems. These materials are named biomaterials. A number of 
definitions has been developed for this term.  
At Consensus Conference of the European Society for Biomaterials (1987, 
Chester, England), D.F. Williams gave the most famous and used definition, 
reported at the begin of this paragraphs. These definition do not include 
materials for controlled drug and biological active molecules deliveries, as much 
as, all material-cell combinations.ii,iii,iv The currently accepted broader definition 
of biomaterial, always defined by D.F. William in 1991, is: i 
“A biomaterial is a man-made or man-modif ied viable or non-viable material intended to 
interface with biological systems to evaluate, treat, augment, or replace any tissue, organ, or 
function of  the body.” 
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1.1.1 Generations of biomaterials 
As for the definition of biomaterials, also their purpose has changed over time, 
leading to three different generations. These three generations are not only a 
chronological sequence, but, mainly a conceptual evolution carrying change of 
requirements and properties of the materials involved. A first generation of 
biomaterials was developed starting from 1960-1970s, with the goal of “achieve a 
suitable combination of  physical properties to match those of  the replaced tissue with a min imal 
toxic response in the host”.v They consisted in implanted prostheses that must be 
biological inert or have a minimal interaction with its surrounding tissue once 
putted in the body. By the mid-1980s, a second generation of biomaterials was 
reported with the peculiarity to be bioactive, meant as the ability to interact with 
the biological environment through the establishment of tissue-biomaterial 
surface bonding in order to enhance a specific biological response. During those 
years various compositions of bioactive glasses, ceramics, glass-ceramics and 
composites underwent clinical trials. The third generation biomaterials 
combined bioactivity with progressive and controlled chemical breakdown and 
resorption. This generation was created to aid both regeneration or restoration,  
and not simply replacement, of injured or lost tissues or body functions and 
delivery of biochemical factors and drugs. Thus, temporary structures that 
stimulate cellular invasion, attachment and proliferation fall in this area.vi,vii,viii 
It is important to underline that new generation biomaterials do not necessarily 
override the use of those of a previous generation, but have only a different 
“modern” application. For example, bioinert materials are used to build 
temporary urinary catheter, bottles or body fluid containers and needles;  
bioactive materials for body implants and grafts; bioresorbable one are used in 
drug delivery and tissue engineering. 
1.1.2 Biocompatibility 
Bioinertness, bioactivity and bioresorbability are features describing how the 
host tissue interacts with an implanted or injected biomaterial, and how it 
impacts the biomaterial. Host response and how the host response impact 
biomaterials are two subjects of a single matter: biocompatibility.iv,ix,x 
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Biocompatibility is the most important property of a biomaterial and also the 
essential one to define a material as biomaterial. It is defined as “the ability of  a 
material to perform with an appropriate host response in a specif ic application”.xi  
For a lay person this definition is very general and so self-evident that it is not 
of any real help in advancing knowledge of biocompatibility concept, but it is 
the only one always true and that takes in account all specific and different 
mechanisms involved in the interaction between biomaterials and tissues.  
Table 1.1. Host response and host variables influence host response 
Major characteristic of the generic 
response to biomaterials 
Most material variables that could influence 
the host response 
Protein adsorption and desorption 
characteristics 
Generalized cytotoxic effects 
Neutrophil activation 
Macrophage activation, foreign body giant 
cell production, granulation tissue formation 
Fibroblast behaviour and fibrosis 
Microvascular changes 
Tissue/organ specific cell responses  
Activation of clotting cascade 
Platelet adhesion, activation, aggregation 
Complement activation 
Antibody production, immune cell responses 
Acute hypersensitivity/anaphylaxis 
Delayed hypersensitivity 
Mutagenic responses, genotoxicity 
Reproductive toxicity 
Tumour formation 
Bulk material composition, micro-(or nano)-
structure, morphology 
Crystallinity and crystallography 
Elastic constants 
Water content, hydrophobic-hydrophilic 
balance 
Macro-,micro-, nano-porosity 
Surface chemical composition, chemical 
gradients, surface molecular mobility 
Surface topography 
Surface energy 
Surface electrical/electronic properties 
Corrosion parameters, ion release profile, metal 
ion toxicity (for metallic materials) 
Degradation profile, degradation product form 
and toxicity (for polymeric materials) 
Leachable, additives, catalysts, contaminants 
and their toxicity (for ceramic materials) 
Wear debris release profile 
These specific mechanisms and the consequent host response depend on the 
general application and specific context. As an example, for long term bone 
implants, where the goal is bone integration of biomaterials, biocompatibility 
needs to take in account the rate of release of corrosion or degradation products 
and the tissue response to them, the rate of wear debris release and the tissue 
response to this debris. For systems injected in the bloodstream, host response 
may be acute, sub-acute and chronic inflammation, partially due to the 
mechanical injury of injection, but mainly to the presence of foreign substances 
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in blood that activate immunological response, leading high concentration of 
monocytes and macrophages in circulation. In the above cited examples , the 
main requirements of biomaterials is that they do not generate negative effects ,  
that is, do not generate release of chemical substance, debris formation, 
inflammation phenomena and immune response, or that these phenomena are 
minimised. Major generic host response and major biomaterial variable 
influencing the host response are listed in Table 1.1 (A and B) and some test to 
evaluate biocompatibility depending on body tissue contact and contact  
duration, regulated by ISO 10993·1, are listed in Table 1.2.xii,xiii 
Table 2. ISO 10993·1. Biocompatibility testing selection criteria. 
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a) The “X” indicates data endpoint that can be necessary for a biological safety 
evaluation, based on a risk analysis. The “o” indicates data endpoint that can be 
advisable for a biological safety evaluation. Where existing data are adequate,  
additional testing is not required. b) A= limited (≼ 24h); B= prolonged (from > 
24h to 30d); C= permanent (> 30d). 
1.2 MATERIALS USED AS BIOMATERIALS 
The majority of biomaterials are classifiable into three main classes: metals, 
ceramics and polymers. All others are composites and biologically-derived  
materials.  
 
Figure 1.1. Biomaterial market by composition. Figure adapted from 
reference.xiv 
The worldwide biomaterials market is poised to reach USD 130.57 Billion by 
2020, growing at a CAGR (Compounded Average Growth Rate) of 16% during 
the forecast period between 2015 and 2020.xv As shown in Figure 1.1, the 
metallic segment accounted for the largest share of the market in 2014. The 
growth of this segment is driven by the benefits of metal biomaterials, such as 
strength and resistance to breakage, which makes them suitable for usage in 
various medical applications requiring strength and toughness. However,  
polymeric biomaterials form the fastest-growing segment in the coming years  
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owing to continuous research and advancements for highly biocompatible 
polymers and the increasing application areas of these biomaterials.  
1.2.1 Polymeric biomaterials 
Strong points of polymeric biomaterials compared to metal or ceramic materials  
are ease of manufacturability to produce various shapes (latex, film, sheet, fibres,  
etc.), reasonable cost and availability with desired mechanical and physical 
properties. These benefits have been evident since the dawn of polymer science.  
Virtually every new synthetic polymer found its way into biomedical 
experimental studies soon after its invention.xvi,xvii Nylon sutures were reported  
in the early 1940s, after only 5 years from the invention, by Wallace Hume 
Carothers.xviii 
Polymers are macromolecules composed of a combination of many small units 
that repeat themselves along the long chain. The small starting molecules are 
called monomers, and unit, which repeats itself along the chain is called the 
repeating unit. Polymeric biomaterials can be produced by polymerization of 
one or more monomers, used to impart desirable chemical, physical, and 
biological properties to biomaterials. It is possible to produce polymers 
containing specific hydrophilic or hydrophobic entities, biodegradable repeating 
units, or multifunctional structures that can become points for three-
dimensional 3D network. Moreover, many properties the chemical structure of 
the bulk polymer is unable to impart can be reached by chemical or physical  
modification of polymer surface.xix,xx,xxi 
Considering the multitude of available polymers and of their applications, it may 
be useful to classify them into categories that highlight important aspects for 
their practical application. 
In this section, polymers will be classified based on the presence or absence of 
degradation phenomena in a biological environment, that is , depending on their 
belonging to the second or third generation biomaterials (see section 1.1.2).  
Non-degradable polymers have been extensively used in medicine as fillers,  
orthopaedic implants, ocular lens, heart valves, bone cements, vascular grafts, 
and tissue engineering scaffolds for long term devices.xiii,xxii Degradable 
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polymeric biomaterials are preferred candidates for developing therapeutic 
temporary devices such as prostheses, resorbable three-dimensional porous 
structures as scaffolds for tissue engineering and as drug delivery vehicles with 
controlled/sustained release.xv,xxiii,xxiv,xxv  
1.2.2 Degradation and erosion of polymers in biological environment 
According to the International Union of Pure and Applied Chemistry (IUPAC), 
polymer degradation is defined as “changes in the values of  in-use properties of  the 
material because of  macromolecule cleavage and molar mass decrease”. In contrast, erosion 
refers to “degradation that occurs at the surface and progresses f rom it into the bulk”. xxvi 
Prefix bio- is added to both terms when degradation is due to cell-mediated or 
bacteria-mediated phenomena.xxvii,xxviii,xxix 
In biological environment, hydrolysis is the most common chemical process by 
which polymers degrade, but degradation can also occur via oxidative, 
photodegradative, and enzymatic mechanisms. iii Hydrolytically degradable 
polymers are generally preferred because they are not affected by site-to-site and 
patient-to-patient variations, compared to enzymatically degradable ones.xxx  
1.2.3 Hydrolically degradable polymers 
Hydrolytic cleavage is dictated by the nature of the chemical bonds that make 
up the polymer backbone. In general, a carbon-carbon bond is chemically and 
biological inert. The C-C bond inertia can be decreased by oxidation of the 
carbon backbone. Therefore, an ester and urethane bond is easier to degrade 
than a ketone or a sulfone bond, which is easier to degrade than an ether bond. 
Other important factors are molecular weight, porosity and morphology 
(crystalline, amorphous forms). In particular, degradation phenomena slow 
down increasing the molecular weight and crystallinity of polymer and 
decreasing its porosity (a low ratio of exposed surface area to volume).xlix,xxxi 
In extracellular fluids hydrolysis are promoted by the presence of ions, such as, 
H+, Na+, K+, Mg2+, Ca2+, OH−, Cl−, HCO3−, PO43−, and SO42−. It has been 
shown that certain ions are effective hydrolysis catalysts, enhancing, for 
example, reaction rates of polyesters by several orders of magnitude.xxxii Ion 
catalysis can be enhanced increasing hydrophilicity percentage of the polymer. 
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Very hydrophobic polymers absorb negligible concentrations of ions. Whereas  
hydrogels, absorbing large amounts of water, act as ions sieves with consequent 
bulk hydrolysis via acid, base or salt catalysis. iii  
1.2.4 Enzymatically degradable polymers 
Enzymatically degradable polymers are materials possessing bonds that are 
hydrolytically sensitive, but require catalysis to degrade in physiological 
conditions. Most of the naturally occurring polymers undergo enzymatic 
degradation, like protein (e.g. silk, collagen, gelatin, fibrinogen), polyaminoacids 
(e.g. poly-γ-glutamic acid) and polysaccharides (cellulose, hyaluronic acid,  
dextran, alginate). Most of these polymers contain ether, amide or glycosid ic 
bonds, which have hydrolytic degradation rates much lower than the polymers 
discussed before.xxxiii As an instance, polyurethanes biodegradation degree in the 
presence of cholesterol esterase enzyme is about 10 times higher than in the 
presence of buffer alone.xxxiv Hydrolytic reactions may be catalysed by enzymes 
known as hydrolases. These include proteases, esterases, glycosidases, and 
phosphatases, among others. 
Enzymatically induced hydrolysis is a heterogeneous process, affected by the 
mode by which enzymes and polymeric chains interact. It typically involves four 
steps: (1) diffusion of the enzyme from the bulk solution to the polymeric 
surface, (2) adsorption of the enzyme on the surface with the following 
formation of the enzyme-polymer complex, (3) occurrence of the hydrolysis 
reaction, and (4) diffusion of the soluble degradation products from the solid 
surface to the solution.xxxv The slowest step controls the reaction rate. 
In order to affect the enzymatic degradation rate, chemical modifications of 
polymers (crosslinking, removal, or introduction of chemical groups in the 
polymer chain) are usually done. Practically these modifications may 
compromise the ability of the enzyme to recognize the modified substrate. For 
instance, lysozyme (enzyme responsible for the degradation of peptidoglycan 
and also chitin materials) exhibited low activity toward chitosans with high 
degrees of deacetylation or crosslinked chitosan.xxxvi,xxxvii,xxxviii 
The hydrolitically and enzimatically degradable polymers employed in this PhD 
work are briefly described below. 
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1.2.3.1 Poly(α-esters) 
Due to the relative ease of their synthesis (via ring-opening or condensation 
polymerization)xxxix,xl and commercial availability, poly(α- esters)xli,xlii have been 
the most researched degradable polymers. They contain aliphatic bonds in their 
backbone. Only polymer having short aliphatic chains can be utilized as 
degradable polymers for biomedical applications. 
Poly(glycolic acid)xliii,xliv(PGA), poly(lactic acid)xlv,xlvi,xlvii (PLA), poly(lactic-co-
glycolic acid)xlviii,xlix,l (PLGA) and poly (caprolactone)li,lii,liii (PCL) are the most 
common poly(α- esters) used (Figure 1.2). 
PGA’s rapid degradation and insolubility in many common solvents limited 
research for drug delivery devices. Typical application field that involving PGA 
is the short-term tissue engineering, in which it acts as filler material coupled  
with other degradable polymer networks.liv The additional methyl group in PLA 
causes polymer to be much more hydrophobic and stable against hydrolysis than 
PGA. PLA is extensively utilized in drug delivery and in tissue engineering 
applications ranging from scaffolds for bone, cartilage, tendon, neu ral, and 
vascular regeneration.lv,lvi PLGA is the most investigated degradable polymer for 
biomedical applications and has been used in sutures, drug delivery devices and 
tissue engineering scaffolds.lvii,lviii,lix,lx PCL has very low in vivo degradation rate 
and high drug permeability, it has found favour as a long-term implant delivery 
device.lxi 
 
Figure 1.2. Structure of the most common poly(α-esters) used as biomaterials. 
1.2.3.2 Polysaccharides 
The term polysaccharides refers to a class of compounds consisting of 
monosaccharide units linked together by glycosidic linkages.lxii,lxiii They are 
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normally obtained by biosynthesis in plants (including algae) or in 
microorganisms. Therefore, they are produced by extraction and purification  
from renewable sources.lxiv A great share of polysaccharides constitutes a source 
of biomaterials for the most varied applications, especially in the domain of 
tissue engineering,lxv,lxvi drug delivery,lxvii,lxviii visco-supplementation lxix. The list 
of polysaccharides commonly used for biomedical applications include 
cellulose,lxx chitin/chitosan,lxxi starch,lxxii alginate,lxxiii hyaluronic acid, lxxiv 
pullulanlxxvand glycosaminoglycanlxxvi (Figure 1.3). Many natural polymers are 
found in the extracellular matrix components of organisms, including humans, 
and participate in inter and intracellular cell signalling, contributing to cell 
growth.lxxvii Thanks to these features, polysaccharides are often used to impart 
materials biological recognition ability, biocompatibility, and bioactivity. In spite 
of many benefits, they suffer from several drawbacks, including variation in 
material properties based on source, microbial contamination, uncontrolled  
water uptake, poor mechanical strength, and unpredictable degradation 
pattern.lxxviii Many polysaccharides have been chemically modified to achieve 
consistent physicochemical properties including mechanical stability, 
degradation, and bioactivity and processed into microparticles, hydrogels, and 
3D porous structures for tissue regeneration applications. lxxix,lxxx 
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Figure 1.3. Structure of the most common polysaccharides used as biomaterials. 
1.2.3.3 Polyamidoamines  
PAAs are a family of biodegradable and biocompatible polymers with 
recognised potential in the pharmaceutical field. lxxxi,lxxxii,lxxxiii,lxxxiv, PAAs are 
obtained by stepwise Michael type polyaddition reaction of primary or bis -
secondary amines to bisacrylamids (Figure 1.4). The polymer obtained presents 
tert-amino and amido groups regularly arranged along the main chain.  
Polymerization reaction takes place in protonated solvents, such as water and 
alcohols, without catalysts. Amphoteric PAAs can be prepared using starting 
monomers, carboxyl groups not influencing the polyaddition reaction. lxxxv,lxxxvi 
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Figure 1.4. Reaction scheme of linear PAAs. Reaction was conducted in inert 
atmosphere to avoid radical polymerization of acrylamides. 
It is possible to obtain cross-linked PAAs using polyfunctional monomers, such 
as bis-primary amine, by totally or partly replace the bis-functional amine 
monomer during the reaction (Figure 1.5). An alternative crosslinking method 
consists of triggering the radical polymerization of vinylic terminated PAA by 
UV irradiation, water soluble diazocompounds, or redox systems. In both cases  
crosslinked scaffolds were obtained, mostly used as inorganic pollutants 
adsorbents for water purification, lxxxvii,lxxxviii,lxxxix as optical dyes for metals 
detection,xc for the release of bioactive moleculexci and as scaffold for cell  
proliferation in tissue engineering application.xcii,xciii,xciv Conversely, linear PAAs 
were used as DNA,xcv proteinxcvi carriers, in drug delivery for anticancerxcvii and 
antimalarialxcviii treatments, and also as macromolecular drug for 
antimetastaticxcix and antiviral applicationsc. Linear PAAs showed complex 
forming properties versus metallic ions dissolved in aqueous solutions.  
 
Figure 1.5. Reaction scheme of crosslinked PAAs. Reaction was conducted in 
inert atmosphere to avoid radical polymerization of acrylamides.  
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All PAAs are degradable in aqueous solution. The mechanism seems to be 
purely hydrolytic as no vinyl groups, such as those which would have derived  
from a β-elimination reaction, could be determined. Degradation rate in aqueous 
media is strongly influenced by pH and temperature. Degradation seems not to 
be affected by the presence of isolated lysosomal enzymes at pH 5.5.ci,cii,ciii 
1.3 BIOMATERIALS: APPLICATIONS 
The main applications of biomaterials can be classified into the categories ,  
depending on the tissue or organ that they repair or, more generally, with which 
they come in contact. Each category has a different weight on global market 
(Figure 1.6). In particular, cardiovascular and orthopaedic application segments 
are the most revenue-bearing fields. The first dominates the global biomaterials 
market in terms of share due to the high prevalence rates of cardiovascu lar 
diseases, above all in rich countries like USA. The orthopaedic segment is the 
second largest market thank to health problems due to advancem ent of 
population average age.xli,xlii 
 
Figure 1.6. Biomaterials market by applications. 
Typical applications in these fields are related to substitution, scaffolding or 
splinting of tissues that are not able to self-renew. In this way, a great number 
of implants and grafts have been produced.civ,cv,cvi Examples are heart valves, 
endovascular stents, vascular grafts, stent grafts, reconstructive implants, 
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fracture management products, arthroscopy products, electrical stimulation 
products for cardiovascular and orthopaedic application areas.cvii,cviii,cix,cx 
Adhesive and sealant biomaterials are used to fill a space, replacing some part of 
lost natural tissue, as bone cements in orthopaedics, or to protect surfaces or 
prevent leakage, as pit and fissure sealants in dentistry.cxi,cxii,cxiii 
Biomaterials are not only intended for internal body applications but also as 
device constituents for external body applications. They are used for drugs, 
organs and blood packaging, but also for many disposable medical devices, such 
as syringes, injection pipes, surgical gloves, lancets, cotton pads , and in vitro 
biological devices, such as pipette, micropipette, well-plates, test tubes.cxiv 
A broad class of biomaterials is used to provide bioelectrodes and 
biosensors.cxv,cxvi,cxvii Bioelectrodes are sensors used to transmit information into 
or out of the body. Surface or transcutaneous electrodes used to monitor or 
measure electrical events that occur in the body, like in electrocardiography,  
electroencephalography, and electromyography. A biosensor is a sensor that 
uses biological molecules, tissues, organisms or principles to measure chemical 
or biochemical concentrations. Biosensors can work by changes in pH, ions, 
blood gases (O2, CO2 and etc.), drugs, hormones, proteins, viruses, bacteria. 
1.3.1 Tissue engineering and regenerative medicine 
When tissues and/or organs fail, their replacement is usually the only solution. 
Regrettably, the number of compatible donors and the consecutive number of 
organs is really limited. For these reason, artificial prostheses are essential to save 
and improve lives of millions of patients.  
At first, implants were made of materials well known in the technological field, 
but not in origin thought for biomedical applications. Stainless steel, alloys and 
high-density polyethylene were used for bone implant, methacrylate polymers as 
bone cement in dental medicine, polyethylene tetraphthalate fibres for the 
production of grafts for blood vessel reconstructions. These materials had initial 
problem with integration of host tissues, by triggering a host immune response 
compromising the healthy tissue around the implant.cxviii 
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By modifying the chemical composition of either the bulk or the surface of 
implants, tissue-implant interactions are improved with a remarkable reduction 
of inflammations, immune responses, systemic toxicity and imminent infection.  
On the other hand, due to the normal cellular and tissue activity, materials are 
subject to continue stress that over time produces damage in the implant, 
eventually leading to its failure. Fatigue fracture and wear combined with the 
formation of debris, have been identified as some of the major problems 
associated with implant failure in long term. These events force patients to 
frequent substitution of implanted prostheses, resulting in a great bother.  
A solution for this problem may be developing procedures that do not replace 
the damaged tissue/organ but favour their regeneration. 
The goal of regenerative medicine is the healing (or at least partially restoring) 
of damaged tissue, supporting the regeneration of diseased or injured organs. 
Regenerative medicine usually takes advantage of tissue engineering 
materials.cxix,cxx,cxxi,cxxii 
Tissue engineering is defined as: “the creation (or formation) of  new tissue for the 
therapeutic reconstruction of the human body, by the deliberate and controlled stimulation of  
selected target cells through a systematic combination of  molecular and mechanical signals”.i 
Tissue engineering takes advantage of 3D structures, named scaffolds, that 
provide a template for cells to attach, proliferate, maintain their differentiated  
function and organize in order to restore structure and function to damaged 
tissues. Essentially, scaffolds act as a synthetic analogue of the natural 
extracellular matrix. cxxiii 
Two main strategies have been used in tissue engineering: transplantation of a 
in vitro grown tissue, and in situ tissue regeneration. The first consists of in vitro 
cultured cells on an artificial scaffold in presence of growth factors until forming 
a natural tissue followed by transplantation. The second is a combination of an 
artificial scaffold and growth factors used as a template to induce host cell  
regeneration of the tissue in vivo. In this case the host’s body works as a 
bioreactor to construct new tissues.  
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In general, an ideal scaffold should have: i) three-dimensional highly porous 
structure with an interconnected pore network to facilitate cell/tissue growth 
and diffusion of nutrients, metabolic waste, and paracrine factors; ii) a 
biodegradable or bioresorbable network with degradation and resorption rates  
that match tissue growth both in vitro and in vivo; iii) a suitable surface 
chemistry for cell attachment, proliferation, and differentiation; iv) mechanical 
properties similar to those of tissues at the site of implantation; v) easy 
manufacturing, in order to be able to produce a variety of shapes and 
sizes.cxxiv,cxxv 
1.3.1.1 Types of scaffolds 
Large numbers of scaffolds from different biomaterials are available for clinical 
use with the aim of repair and regenerate lost or damaged tissue and organs. 
These scaffolds include porous scaffold, fibrous scaffold, hydrogel scaffold and 
solid free form one. The fabrication technique for scaffolds depends almost 
entirely on the bulk and surface properties of the biomaterial and the proposed 
function of the scaffold (Figure 1.7). 
As before mentioned, the formation of a highly porous structure is the main 
goal of scaffold fabrication. Most usual methods used to made porous scaffolds,  
including particulate leaching,cxxvi freeze drying,cxxvii gas infusion,cxxviii and phase 
separation.cxxix Porous are developed by introducing particles or gas bubbles 
when the scaffold is in a fluid form and are later removed by solvent action 
(organic one, water) or under vacuum after scaffold solidification, leading an 
interconnected network of pores. The porosity and pore structure is dependent 
on the amount of porogen the size of porogen dissolved in the material, and the 
diffusion rate of it through the material.cxxx Phase separation is based on 
thermodynamic demixing of a homogeneous polymer-solvent solution into a 
polymer-rich phase and a polymer-poor phase, by exposure to an immiscible 
solvent or by cooling the solution below a binodal solubility curve. Solvents are 
removed by freeze-drying, leaving behind the polymer as a foam. These 
techniques are relatively simple but suffering of uncontrolled pore size and 
connectivity, poor mechanical strength, and residual solvent/porogens. cxxxi 
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Figure 1.7. Snapshot of techniques for preparing porous polymer scaffolds for 
tissue engineering. Figure from reference.cxxxii 
Fibre-based scaffold are highly studied due to the possibility to have high surface 
area to volume ratio, leading to a microporous structure that favours cell  
CHAPTER 1 
INTRODUCTION TO BIOMATERIALS 
26 
adhesion, proliferation, migration, and differentiation. All of these features are 
highly desired ones for tissue engineering applications.cxxxiii Three techniques are 
mostly used for them synthesis: electrospinningcxxxiv, self-assembly,cxxxv and 
phase separationcxxxvi. Of these, electrospinning is the most widely studied 
technique, at contrary, nanofibres synthesized by self-assembly and phase 
separation have had relatively limited studies. By electrospinning of polymers, 
continuous micro- or nanoscale diameter fibres can be generated. In addition, it 
is possible to control orientation of fibres. However, it is difficult to control the 
distance between fibres and impossible to produce scaffold with volume and 
usually mechanical properties of collected scaffolds are poor.cxxxvii  
Solid free form fabrication techniques are based on computerized modelling to 
produce highly complex three-dimensional physical objects.cxxxviii The result is a 
porous scaffold with enhanced control over its three-dimensional organization. 
Specifically, a two-dimensional image of a target specimen was acquired by a 
non-destructive imaging, then was later developed in a three-dimensional 
architecture with software and finally fabrication of the three-dimensional 
matrix with highly precise and automated layer-by-layer SFF processes. cxxxix 
Typical processes include laser-based, ink-jet type printing-based, and nozzle-
based approaches. These methods offer precise control of the three-dimensional 
structure of the scaffolds; however, they are associated with higher costs and 
require more complex equipment compared to classical methods. 
Hydrogels are hydrophilic polymer networks which may absorb up to thousands 
of times their dry weight in water. Hydrogels are formed when the network is 
covalently crosslinked.cxl In general, polymers with reactive moieties are 
polymerized into three-dimensional networks in the presence of cross-linkers .  
Photo-crosslinkable or thermo-crosslinkable hydrogels are the most frequently 
used.cxli Hydrogel properties can be tuned in order to satisfy a range of 
application needed by controlling the structure with defined cross-linking 
density, mechanical properties, mass transport, and degradation characteristi cs .  
In particular the degradation rates of hydrogel scaffolds must be matched to the 
rate of various cellular processes in order to optimize tissue regeneration.cxlii, cxliii 
Hydrogels are appealing scaffold because they are structurally similar to the 
extracellular matrix of many tissues, can often be processed under relatively mild 
conditions, and may be delivered in a minimally invasive manner.cxliv 
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Furthermore, hydrogels can be chemically modified to improve cell adhesion 
and proliferation on the gel matrices through inclusion of adhesion peptides. 
However, major problems with using hydrogels include structural instability and 
overall inferior mechanical properties for placement within dynamic 
environments.cxlv 
1.3.2 Drug delivery systems 
Delivery systems are mainly intended to achieve either a temporal or spatial 
controlled delivery of some pharmacological interesting molecules, such as 
drugs, proteins, DNA, RNA, growth factors and hormones. Delivery systems 
offer numerous advantages compared to conventional dosage forms, in 
particular when they have a “sustained” or “prolonged” molecule release.  
1.3.2.1 Type of delivery systems 
Different types of drug delivery systems have been developed with a wide range 
of sizes from tens of micrometres to tens or hundreds of nanometres. cxlvi,cxlvii 
Drug carriers can be divided in three categories by its composition: lipid carriers ,  
polymeric carriers and inorganic ones as also depicted in Figure 1.8. Lipid and 
polymeric carriers are below examined. 
Liposomes, micro/nano-emulsions, solid lipids nanoparticles are the most 
frequently used lipid carriers. Liposomes are spherical structures composed of a 
phospholipid bilayer surrounding an aqueous reservoir. Liposome vesicles are 
composed of unilamellar or multilamellar lipid bilayers which alternate aqueous. 
In general, hydrophobic compounds are well entrapped in liposomes compared  
to hydrophilic compounds.cxlviii Micro/nano-emulsions consist in oily drops 
dispersed in an aqueous surfactants solution, leading to a milky suspensions. cxlix 
Solid lipid nanoparticles (SLN) are similar to liposome, but they have only a 
single membrane and are based on solid lipids stabilized by surfactants. SLN 
have a mean particle size of 50-1000 nm. Different types of solid lipids such as 
glycerides, waxes, and fatty acids have been used in the fabrication of SLN.cl 
Polymeric carriers count several types of micro or nanosized particles with 
different structures. Nanocristals (nanotized particles), drug-polymer 
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conjugates, solid micro or nanoparticles, micelles, layer by layer conjugates,  
dendrimers and polymersomes are the most famous.  
Nano-crystals consist in large insoluble drug crystals are milled to form nano-
sized particles with less than 2 µm. To prevent particle aggregation, surfactants  
such as surface active agents and polymers are normally required for 
stabilization.cli Polymer-drug conjugates are based on drug molecules linked on 
hydrophilic polymers. The drugs remain attached to the polymer and are not 
activated until the enzymes associated with the diseased tissue are present.clii 
Nanoparticles consist in polymeric aggregates in a solid state suspended in water 
solution, in presence or not of surfactants. Two kind of nanoparticles are usually 
described: nanosphere and nanocapsules. Nanospheres have a homogeneous 
structure in the whole particle, in which the drug is dissolved.  Nanocapsules are 
nano-vesicular systems that exhibit a typical core-shell structure; the drug is 
confined to a reservoir or a cavity.cliii Micelle are organized self-assembled 
aggregates composed of amphiphilic macromolecules, in general amphiphilic di- 
or tri-block copolymers made of hydrophilic and hydrophobic blocks. Micelles  
are characterized by critical micellar concentration, (CMC), that is the minimum 
concentration of polymer in solution to reach micelle structure. Therefore,  
micelle formation and stability are concentration-dependent.cliv Dendrimers are 
monodispersed macromolecules with highly branched structures around an 
inner core. The terminal groups of dendrimers mostly control the dendrimer 
interactions with the molecular environment. The interior of a dendrimer can 
show hydrophilic characteristics while the exterior surface of a dendrimer is 
hydrophobic or vice versa.clv Polymersomes are made using amphiphilic block 
copolymers to form the vesicle membrane, with radii ranging from 50 nm to 5 
µm or more. Most reported polymersomes contain an aqueous solution in their 
core and are useful for encapsulating and protecting sensitive hydrophilic drugs. 
They are the polymeric alternative to liposomes.clvi 
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Figure 1.8. Nanosized carrier mainly used in drug delivery. Figure take from 
reference.cxlvi 
A significant technological and medical breakthrough in the evolution of drug 
carriers is the shift in size from tens of micrometres to tens or hundreds of 
nanometres. Thanks to their sub-cellular and sub-micron size, nanocarriers can 
penetrate deep into tissues through fine capillaries, cross the fenestration present 
in the epithelial lining and are generally taken up efficiently by the cells. clvii, clviii 
For instance, nanoparticles 100 nm in size showed 2.5-fold higher uptake in 
Caco-2 cells compared to 1 µm particles and 6-fold higher compared to 10 µm 
particles.clix  
1.3.2.2 Drug loading 
A successful carrier should have a high drug-loading capacity in order to reduce 
the number of administrations. Drug can be loaded or be conjugated into the 
carrier. Drug conjugation allows high degree of incorporation. Physical 
incorporation of drugs may take place on nanoparticle preparation obtained by 
incubating them with a concentrated drug solution; c) by chemical conjugation 
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of drug into carriers. It is evident that a larger amount of drug is entrapped  
passing from method to incorporation one to conjugation one.clx,clxi,clxii 
Drug loading depends on the solid-state drug solubility in polymeric matrix 
(solid dissolution or dispersion), which is related to polymer composition, 
molecular weight, drug polymer interaction (hydrophobic/hydrophilic 
interaction and ionic interaction)clxiii,clxiv, and presence of end-functional 
groups.clxv,clxvi,clxvii 
1.3.2.3 Time control 
These systems are related to all devices able to maintain a desired tissue (blood) 
concentration within the molecule therapeutics index (TI) for long periods of 
time. Focusing upon drugs, TI is the ratio of two concentrations limits: the 
higher one, above which the drug produces undesirable (e.g., toxic) side-effects ,  
and the lower one, below which it is not therapeutically effective. Drug delivery 
systems with prolonged release are able to release drugs for long periods of time 
without reaching a toxic level or dropping below the m inimum effective level 
(Figure 1.9).clxviii,clxix 
 
Figure 1.9. Kinetic profiles of standard dose forms (green line), sustained 
release systems (purple line). 
Drug solubility and diffusion and biodegradation of the matrix materials govern 
the release process. clxx In the case of nanospheres, where the drug is uniformly 
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distributed, the release occurs by diffusion or erosion of matrix under biological 
conditions. If the diffusion of the drug is faster than erosion, the release 
mechanism is largely controlled by diffusion. The rapid initial release or ‘burst’ 
is mainly attributed to weakly bound or adsorbed drug to the large surface of 
nanoparticles. 
1.3.2.4 Spatial control  
Spatial controlled release is achieved thanks to two targeting mechanisms, i.e. 
passive and active. Passive targeting is dependent on the physicochemical 
properties of the drug-carrier system. Tailoring delivery system properties, it is 
possible to profit of physiological properties of target tissues, minimizing uptake 
into undesired tissues. Surface charge, hydrophobicity, size and shape of the 
carrier system are usually take in account.clxxi For instance, large macromolecule-
drug conjugates and nanoparticles take advantage of the enhanced permeability 
and retention (EPR) effect, usually present in solid tumours. EPR is due to the 
presence in blood vessels of poorly aligned defective endothelial cells with wide 
fenestrations and the absence of effective lymphatic drainage that allow 
accumulation of drug carrier in the tumour tissue much more than in normal 
tissues.clxxii,clxxiii 
Active targeting is achieved by conjugating a tissue- or cell-specific ligand to the 
carrier.clxxiv,clxxv The ideal active targeting is attained when the target receptor is 
not expressed in significant quantities anywhere else in the body or is over-
expressed in diseased cells. Targeting ligands are either monoclonal antibodies 
(mAbs) and antibody fragments or non-antibody ligands (such as peptidic 
one).clxxvi Usually after internalization, nanocarriers escape the endo-lysosomes 
and enter the cytoplasm. Other organuli can be reached adding specific ligand, 
as, for example, by conjugating NLS (nuclear localization signal) for nuclear 
compartment cell. clxxvii 
1.4 BIOMATERIALS: PROPERTIES 
Properties (physical, mechanical and surface properties) of biomaterial are 
designed and modelled as a function of the application and of the host tissue. 
Examples of biomaterial properties affecting their performance in drug delivery 
and tissue engineering are reported in Figure 10.  
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Figure 10. Physical, mechanical and surface requirements. 
1.4.1 Size and shape 
In the field of drug delivery, size and shape of carriers are fundamental for 
several in vivo functions. These include circulation times, extravasation, targeting,  
immunogenicity, internalization, intracellular trafficking, degradation, flow 
properties, clearance and uptake mechanisms (Figure 1.11, panel 
A).clxxviii,clxxix,clxxx,clxxxi A problem usually observed during intravenous injection of 
some kind of drug carriers is the phagocytosis by macrophages of the reticulo -
endoplasmatic system (RES). Phagocytosis represents an immunological 
response of body that recognises as foreign these carriers and eliminate them 
from the bloodstream. To promote long persistence in the blood, phagocytosis  
must be avoided. Some carrier properties are modified to reach this target.  
Phagocytosis mechanism is influenced by particles size instead of particle shape 
influences phagocytosis outcomes and kinetic. Particles greater than 500 nm can  
be phagocytised by macrophages. Instead, smaller particles can be endocytosed  
by phagocytic or non-phagocytic cells.clxxxii,clxxxiii Encountering a fully pointed 
end of an elliptical particle, macrophage internalizes the particle in a few 
minutes, while if it hits the flat region of the same elliptical particle, phagocytosis  
does not occur for over 12 hrs. As shown in Figure 1.11-panel B, the local shape 
of the particle, characterized by an Ω angle, influences the start of phagocytosis  
(Figure 1.11-panel C).clxxxiv In particular, phagocytosis velocity decreased with 
increasing Ω. 
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Figure 1.11. A) In vivo functions influenced by particle size. B) A schematic 
diagram illustrating how membrane progresses tangentially around an elliptical 
particle. T represents the average of tangential angles from θ = 0 to θ = π/2. Ω 
is the angle between T and membrane normal at the site of attachment, N. (C) 
Membrane velocity (distance traveled by the membrane divided by time to 
internalize, n ≥3; error bars represent SD) decreases with increasing Ω for a 
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1.4.2 Mechanical properties 
In tissue engineering, mechanical properties represent important features.clxxxv,  
To help in selecting biomaterials, mechanical property maps, known as Ashby 
maps, are used to compare a large amount of physical properties from various 
material groups and compared with those of biological systems (Figure 1.12, A 
and B panels).clxxxvi,clxxxvii Human tissues have a wide range of modulus values, 
from soft materials (brain, about 0.5 kPa), to moderately stiff (skin and muscles, 
around 10 kPa) to stiff ones (precalcified bone, >30 kPa). Scaffold s for 
regenerative medicine should ideally have the same strength and Young’s 
modulus of the tissue they will restore.clxxxviii,clxxxix This general law is valid for all 
the kinds of mechanical moduli. As shown in Figure 1.13, the scaffold elasticity 
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Figure 1.12. A) Young’s modulus and tensile strength of engineering material;  
B) Young’s modulus and tensile strength of natural material on exactly the same 
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Figure 1.13. (A) Solid tissues exhibit a range of stiffness, as measured by the 
elastic modulus, E. B) Naive MSCs of a standard expression phenotype are 
initially small and round but develop increasingly branched, spindle, or 
polygonal shapes when grown on matrices respectively in the range typical of 
Ebrain(0.1–1 kPa), Emuscle(8–17 kPa), or stiff crosslinked-collagen matrices (25–
40 kPa). Scale bar is 20 mm. Figure adapted from reference.cxc 
1.4.3 Surface properties 
Surface is the biomaterial section in contact with neighbouring tissues and, 
subsequently, it greatly influences biological responses in all applications. cxci,cxcii 
Therefore, the evaluation of surface properties of biomaterials is of paramount 
important. Surfaces have free energy associated with the discontinuity and 
asymmetry of the interface that tends to actively minimize through continual 
processes of molecule adsorption, restructuring, and chemical reactions. When 
an object is inserted in a biological environment, the first molecule it comes in 
contact is water with. Wetting is the ability of water (or in general of a liquid) to 
maintain contact with a solid surface. The balance between adhesive and 
cohesive forces determines the degree of wetting (wettability). Adhesive forces  
compel a water drop to spread across the surface (hydrophilic surfaces) .  
Cohesive forces compel the drop to ball up and avoid contact with the surface 
(hydrophobic surfaces). Wettability influences interaction with biological 
materials.cxciii,cxciv,cxcv  
In tissue engineering, wettability influences the interaction between surface 
scaffold and cell adhesion protein (transmembrane glycoproteins) that are the 
first to attach the surface and promote cell adhesion. Adhesion proteins include 
selectins, integrins, syndecans, and cadherins. In Figure 1.14 Panel A, the 
influence of siloxane-coated polystyrene wettability on osteosarcoma cells  
(MG63) is reported. Increasing hydrophobicity of the surface (increasing 
contact angle) cell adhesion decreases.cxcvi 
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Figure 1.14. Influence of siloxane-coated rough surface PS water contact angle 
on MG63 cell adhesion. B) Attachment of Enteromorpha zoospores on 
patterned CH3/OH SAMs of varying wettabilities (𝛉AW) Figures take from 
references.cxcvi,cxcvii 
Wettability influences also bacteria adhesion (Figure 1.14, Panel B), but in this 
case increasing hydrophobicity of surfaces adhesion is favoured.cxcvii If bacteria 
spread on scaffold surface, an infection is developed with the consequent 
rejection of the scaffold from the host tissue. For this reason, bacteria adhesion 
and proliferation must be avoided (Figure 1.15).cxcviii Also other properties are 
tuned to obtain antifouling activity, such as roughness, topography, surface 
tension, surface charge etc. For example, bacterial membranes are generally 
negatively charged and so, in general, a negatively charged biomaterial surface 
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Figure 1.15. Main stages of bacteria biofilm formation. 
Wettability influences the in vivo fate of micro- and nanoparticles. Hydrophobic 
particles are normally recognized by the host immune system  (RES). To 
minimize opsonization, hydrophobic particles are coated with hydrophilic 
polymers/surfactants or bonded to them, obtaining amphiphilic copolymers. 
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CHAPTER 2 





SYNTHESIS AND CHARACTERIZATION OF PLGA-g-PVP 
COPOLYMERS  
 
“The purpose of  this research is to establish the synthetic procedures to  obtain a new family of  
amphiphilic biodegradable and bioeliminable biomaterials for the construction of  drug 
nanocarriers, core-shell nanof ibres for tissue regeneration. These new biomaterials are based on 
PLGA-g-PVP copolymers, where PLGA forms a linear backbone on which short arms of  
PVP are randomly distributed. PLGA-g-PVP copolymers were synthesised by the one-step 
one-pot radical polymerization of  1-vinylpyrrolidin-2-one (VP) in molten PLGA that acted 
as chain transf er agent . Modulating the initial VP/PLGA ratio dif f erent graf ting degrees of  
PVP chains having dif f erent molecular weights were obtained. Saponif ication of  PLGA-g-
PVP gave, besides PLGA degradation products, also un-degraded PVP. This was isolated 
and analysed by size exclusion chromatography (SEC), to evaluate the molecular weights of  
graf ted PVP. MALDI-TOF analysis allowed identif ying the chemical structure of  PVP 
terminals and unambiguously establishing that PVP chains were originally graf ted onto 
PLGA backbone. PLGA-g-PVP spontaneously formed nanoparticles when dispersed in 
water, irrespective of  PVP content .  
2.1 POLY(LACTIC-CO-GLYCOLIC) ACID 
In the last twenty years aliphatic polyester-based polymeric structuresi,ii,iii have 
been receiving special attention because they are sensitive to hydrolytic 
degradation and their physical and mechanical properties can be tailor-made by 
tuning the chemical structure of the repeating unit. Among polyesters, the most 
extensively studied one in the biomedical field is the copolymer poly(lactic-co-
glycolic) acid (PLGA). Different copolymers have been commercially developed  
and are usually identified in regard to the monomer ratio (for instance PLGA 
75:25 identifies a copolymer containing 75% lactic acid and 25% glycolic acid). 
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Two general reaction mechanisms are used to synthesize PLGA and all other 
poly (α-hydroxyesters): condensation polymerization and ring opening 
polymerization. The condensation of hydroxyl-acids monomers or mixtures of 
diacids and diols is usually conducted at high temperatures for long reaction 
times, usually leading limited molecular weight chains of few tens of thousands 
(𝑀𝑛 30 kDa) and often subjected to side reactions, such as racemization.iv 
High-molecular weight aliphatic polyesters can be prepared by ring opening 
polymerization (ROP) (in melt or in solution, emulsion or dispersion) of 
lactones of different ring-size, with or without (protected) functional groups. 
Reactions are carried out in presence of a catalyst or a initiator. Depending on 
the initiator, the polymerization proceeds according to three different major 
reaction mechanisms, i.e. cationic, anionic or coordination-insertion 
mechanisms.v 
PLGA’s properties depend on lactic/glycolic acids monomer ratio. For instance,  
PLGA 75:25 is amorphous, PLGA 80:20 semi-crystalline. The degree of 
crystallinity and melting point of PLGA copolymers are also related to their 
molecular weight. In addition, unlike poly(lactic) acid and poly(glycolic) acid  
homopolymers, PLGAs are soluble in wide range of solvents including 
chlorinated solvents, tetrahydofuran, acetone and ethyl acetate.ii 
PLGAs degrade by hydrolysis of its ester linkages, through bulk erosion, in 
aqueous environments. Lactic acid rich PLGAs are more hydrophobic than 
glycolic acid reach ones and absorb lower amounts of water and degrade more 
slowly, also due to the superior steric hindrance effect. As a rule, higher glycolic 
acid contents lead to faster degradation rates with the exception of PLGA 50:50, 
which exhibits the fastest degradation, due to a less crystallinity present in the 
copolymer.vi  
PLGA is approved by Food and Drug Administration and is mainly proposed 
as component of drug delivery systems,vii,viii as scaffold for tissue engineering ix, x 
and as structural material for hard tissue reparation.xi PLGA has been used for 
preparing nano- or microsized particles as carriers of hydrophobic drugs, but 
also DNA, RNA, vitamins, and proteins, in different parts of the body and for 
different applications.xii 
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As already described in Chapter 1 Paragraph 1.4.3, hydrophobic nanoparticles .  
are cleared by phagocytes from the circulation, PLGA nanoparticles exhibit the 
same behaviour. They are usually be taken up by the liver, followed by the spleen 
and lungs.xiii Coating strategies with hydrophilic polymers and amphiphilic 
copolymers are extensively present in literature. In particular the synthesis of 
linear PEG-PLGAxiv di-block and PEG-PLGA-PEGxv tri-block copolymers 
have been widely used in drug delivery. In both kinds of copolymers PEG is 
oriented to the external aqueous phase, instead PLGA is in the internal part of 
a micelle. PEG layer acts as a barrier and do not allow the interactions with 
foreign molecules by steric and hydrated repulsion, resulting in an enhanced  
shelf stability.xvi. Faster release kinetics from formulations of di-block 
copolymers have been observed in comparison to PLGA alone. Various 
mechanisms of targeted delivery of drugs from di-block PEG-PLGA- 
nanoparticles have also been reportedxvii xviii xix 
Despite of abundance of studies that demonstrate the positive effects of PEG 
on biocompatibility of hydrophobic nanoparticles, PEG leads to some adverse 
reactions. Indeed PEG induced blood clotting and clumping of cells, leading to 
embolism.xx It is also reported to activate complement (C),xxi leading to 
hypersensitivity reactions and ultimately to anaphylactic shock.xxii,xxiii,xxiv 
Pegylated surfaces exhibited also the accelerated blood clearance (ABC) 
phenomenon.xxv Monomethyl-PEG liposome concentration in rats was 
drastically decreased after a second injection performed after 4h the first injected  
dose (from 52.6% to 0.6% after the second injection).xxvi ABC phenomenon also 
occurred when the second injection was administered after five days.xxvii These 
results indicated that a recurring injection of Pegylated liposomes can alter the 
circulation time, affecting bioavailability of the drug. Also passive targeting is 
decreased, in fact the second dose was shown to preferentially accumulate in 
Kupffer cells of the liver, due to the action of immunological system. In liver 
accumulation could cause severe liver damage, particularly in the case of highly 
toxic therapeutics.  
A study on the ABC phenomenon induced by different hydrophilic coating on 
PLA nanoparticles showed that ABC phenomenon was not induced upon 
repeated injection of PVP-coated nanoparticles at various time intervals,  
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dosages, or frequencies, whereas it was elicited by PEG-coated nanoparticles  
(Figure 2.1).xxviii 
 
Figure 2.1. Induction of the ABC phenomenon upon injections of 
prostaglandin (PGE1)-loaded PEG/PLA NPs and PVP/PLA-NPs. A) 
PEG/PLA NPs: blue line, first dose; red line second dose administered 7 d after 
the first injection. B) PVP/PLA NPs: blue line, first dose; red line second dose 
administered 7 d after the first injection 
2.2 POLY(VINYLPYRROLIDONE) 
Poly(vinylpyrrolidone) (PVP) have been used in this work to modulate the 
hydrophobicity of PLGA. 
PVP was ﬁrst reported in 1938 by Reppe.xxix PVP has excellent physiological 
compatibility, low chemical toxicity, and good solubility in water and most 
organic solvents.xxx PVP forms complexes with numerous low molecular weight 
compounds as well as with many polymers, acting as solubilizer.xxxi,xxxii It has 
adhesion properties of pharmaceutical materials,xxxiii and in general it is used as 
glue on glass, metal and plastics, paper, fabric surface and as pressure-sensitive 
adhesive.xxxiv It is not biodegradable and for this reason the parenteral 
administration of high molecular weight PVP is not practiced. Only PVP chains,  
able to be eliminated by renal clearance, can be used. In particular PVP having 
molecular weights below 30 000, has diameter below 7 nm, the same of 
capillaries of human kidney, and is able to pass through the kidney and to be 
excreted.xxxv In low molecular weight form is widely used in many industries 
such as pharmaceuticals, cosmetics, beverages, adhesives, detergents, paints, 
electronics, and biological engineering materials. xxxvi,xxxvii,xxxviii,xxxix 
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PVP having molecular weights from 2500 to about 1 million is mainly obtained 
by radical polymerization of 1-vinyl-2-pirrolidone (VP) in aqueous solution. 
Obtained polymers have hydroxyl and carbonyl end groups. More stable end 
groups can be obtained by polymerization in solvents, which may act as chain  
transfer agents and which produce low molecular weight products.xl Different 
techniques allow synthesizing PVP in a controlled manner, tuning precisely 
number-average molar mass, dispersity, end-groups, and architecture. Organo-
cobalt-mediated radical polymerization (OCMRP)xli, organo-heteroatom-
mediated radical polymerization (OHMRP)xlii, reversible addition–
fragmentation chain transfer polymerization using xanthates 
(RAFT/MADIX)xliii, and atom transfer radical polymerization (ATRP)xliv 
allowed controlled radical polymerization of VP. 
2.3 PVP-POLYESTERS COPOLYMERS AND BLENDS 
PVP was bonded to other polyesters by different reaction mechanisms. Linear 
PVP block copolymers with polyesters such as poly-ε-caprolactone (PCL) or 
PLA have been extensively reported.xlv,xlvi,xlvii,xlviii,xlix,l,li,lii,liiiMost of these 
copolymers were prepared by ROP of ε-caprolactone or lactides with end-
hydroxylated PVP oligomers, which are obtained by conventional radical 
polymerization of N-VP in the presence of hydroxylated compounds, as for 
instance 2-isopropoxyethanol(Figure 2.2-A).livVice-versa, starting from end-
functionalized PCL and PLA oligomers that were respectively employed as 
ATRP or RAFT macroinitiators for PVP polymerization (Figure 2.2-B). PLA-
b-PVP copolymers were also synthesised by polymerization of N-VP in the 
presence of mercapto-terminated PLA (Figure 2.2-C).lv Surface-grafted PVP 
chains onto PLLA films were obtained by physical methodslvior by radical 
copolymerization of NVP with ω-methacryloxy-PLLA.lvii 
Nevertheless the ability to obtain well-tuned copolymers, reactions listed above 
have a number of flaws that limit their use, in particular in industrial field. The 
use of very complex and expensive macroinitiators, requiring very long synthetic 
procedures, at least of 3,4 steps, with a reduction of the final yield, and the use 
of heavy metal derivates, really difficult to isolate and expensive to dispose of, 
are some examples on this issue. 
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Figure 2.2. A) Synthesis of PVP-b-PLA by ring opening polymerization stating 
from hydroxylate- terminated PVP, obtained by radical polimerization of N-VP 
in the presence of 2-isopropoxyethanol, followed by KH treatment; B) Synthesis 
of PCL-b-PVP by RAFT polymerization starting from a PLA macroinitiator; C) 
Synthesis of PLA-b-PVP by radical polimerization of N-VP in presence of 
mercapto-terminated PLA; D)PLGA-b-PVP synthesis by click reaction between 
azide-terminated PVP and alkyne-terminated PLGA. 
In literature one example of linear di-block PLGA-b-PVP copolymer was 
reported, obtained by click reaction between alkyne-terminated PLGA and 
azide-terminated PVP (Figure 2.2- D).lviii Synthetic procedure consisted in three 
steps, one of which use a metallic compound as catalyst, and each step needed 
purification of product from the initial monomers and by-products, using a great  
amount of solvents. As result a really expensive process is obtained with the 
unlikelihood of easy industrial scale-up.  
Several examples of blends (PLGA/PVP) are also reported to form fibres and 
particles. PLGA/PVP fibres were prepared by coaxial electrospinning of PLGA 
and PVP.lix PLGA/PVP microparticles and nanoparticles were formed when 
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PVP acts as surfactant of PLGA particles lx or by spray-dried.lxi These systems, 
providing the only physical interaction, have a narrow stability over time, due to 
separation of the two blocks in aqueous matrix. 
Previous researches conducted by this group have discussed on ester-terminated  
PVP oligomers prepared by radical polymerization of N-VP in the presence of 
aliphatic esters, acting in the meantime as solvents and chain transfer 
agents.lxii,lxiii,lxiv,lxv,lxvi,lxvii,lxviii,lxix 
The purpose of this thesis research is to use, not aliphatic ester molecules, but 
polymeric esters, as instance PLGA, as chain transfer agents. By using of 
initiator, radicals are generated in α to the ester function on the PLGA main 
backbone, and consequently, VP monomers are radically polymerized on. This 
provides a simple and direct one-step synthesis of PLGA-g-PVP comb like 
copolymers.lxx PVP side chain molecular weight can be modulated modulating 
the initial ratio of monomer and chain transfer agents. The great benefit of this 
procedure is the easy scale up of the synthesis, thank you the absence of solvents 
and of really expensive reagents and the quantitative yield of product, that make 
useless any further purification steps. The aim of this research is to report on 
this issue, with a focusing on properties and application in drug delivery and 
tissue engineering. 
2.4 EXPERIMENTAL PART 
2.4.1 Materials 
1-Vinylpyrrolidin-2-one (VP) (99%, Sigma Aldrich) was purified by vacuum 
distillation (bp100 °C/15 tor) just before use. 2,2’-Azobis(2- 
methylpropionitrile) (AIBN) (98%, Sigma Aldrich) was recrystallized from 
methanol just before use. Ester-terminated poly(lactic-co-glycolic) acid (PLGA) 
50:50 𝑀𝑛= 45000-55000 was purchased from PolySciTech (Indiana, USA) and 
used as received. NMR analysis showed that the lactide/glycolide ratio was 
actually 52:48, meaning that the average molecular weight of the repeating units 
was 65:35. Poly(1-vinylpyrrolidin-2-one) (PVPK40, 𝑀𝑤 = 40000), anhydrous 
N,N-dimethylformamide (DMF, 99.9%) (obtained in sealed glass bottles over 
molecular sieves), diethyl ether, chloroform, deuterium oxide (D2O, 99.9 atom 
D%), hydrochloric acid (HCl, 37% w/w), sodium hydroxide (NaOH, 98.5%), 
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dithranol MALDI-MS >98%, dichloromethane (99.9%) CHROMASOLV Plus 
and methanol (99.9 %) CHROMASOLV Plus were purchased from Sigma 
Aldrich and used as received. 
2.4.2 Instruments and methods 
1H and 13C NMR spectra and 2D Heteronuclear Single-Quantum Correlation 
(HSQC) experiments were run at 25 °C on a Brüker Avance 400 spectrometer 
operating at 400.132 and 100.623 MHz, respectively. 
Size exclusion chromatography (SEC) traces of PVP samples were obtained 
using a Knauer Pump 1000 equipped with a Knauer Autosampler 3800, TKS 
gel G4000 PW and G3000 PW Toso Haas columns connected in series, light 
scattering/viscometer Viscotek 270 Dual Detector and refractive-index detector 
Waters 2410. The combination of these detectors gave a triple low-angle light 
scattering, right-angle light scattering and refractive index detector. The mobile 
phase was a 0.1 M Tris buffer pH = 8.1 ± 0.05 with 0.2 M sodium chloride. The 
sample concentration was 2% (w/v) and the flow rate 1 mL min−1.  
IR spectra were obtained with an FT-IR 4100 Jasco spectrometer on films cast  
from dichloromethane solutions onto KBr plates. 
MALDI-TOF mass analyses were obtained with a MALDI TOF-TOF 
AUTOFLEX III Brüker Daltonics instrument on samples prepared as follows: 
a 10 mg mL-1dithranol chloroform solution (20 mL) was mixed with a 7 mg mL-
1 chloroform solution (20 mL) of the polymer sample. Aliquots of the final 
solution (20 μL) were cast onto stainless steel targets and dried.  
Differential scanning calorimetric (DSC) analyses were carried out with a Mettler 
Toledo DSC823 (Mettler Toledo, Italy) equipped with the STAR Software and 
the FRS5 Mettler Toledo ceramic sensor. The instrument was calibrated with 
indium for melting point and heat of fusion. Tests were performed using 
standard aluminium pans with an empty pan as reference. Samples (5-10 mg) 
underwent a four-step thermal cycle: a) heating from 0 °C to 100 °C at 10 °C 
min−1; b) 10 min isocratic step at 100 °C; c) cooling from 100 °C to 0 °C at 10 
°C min−1; d) heating from 0 °C to 250 °C at 10 °C min−1. All tests were carried  
under 20 mL min-1 nitrogen flow. 
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TGA analyses were performed with a Perkin Elmer TGA 4000 on 10 mg 
samples in the range 30 – 600 °C, with 30 °C min-1 heating rate and under 50 
mL min-1 nitrogen flow. 
Dynamic light scattering (DLS) and ζ-potential analyses were carried out using 
a Malvern NanoZS instrument (Malvern Instruments, Worcestershire UK) with 
a laser fitted at 532 nm and fixed 173° scattering angle.  
2.4.3 Synthetic procedures 
2.4.3.1 Synthesis of PLGA-g-PVP10:1 
PLGA (2.012 g) and VP (0.203 g, 1.83 mol) were added to dichloromethane (30 
mL) in a two-necked 100 mL flask equipped with a stir bar. The resultant 
solution was purged 5 min with nitrogen and AIBN (2.1 mg, 0.013 mmol) was 
added. Dichloromethane was then eliminated at room temperature and 0.2 tor. 
After three nitrogen-vacuum cycles, the reaction mixture was heated to 100 °C, 
maintained at this temperature under nitrogen for 2.5 h, cooled to room 
temperature and dissolved in dichloromethane (100 mL). The solution was 
poured drop-wise in diethyl ether (1 L) under vigorous stirring and the resultant 
slurry stirred for further 2 h. The precipitated product was finally retrieved by 
filtration, washed with fresh ether (200 mL) and dried under vacuum. Yield: 
96.4%. This product was identified as the “main product” (MP), according to 
the fractionation scheme (Fig. 13) reported below in “Results and discussion”. 
The mother liquors were evaporated to dryness in vacuo and the small residue, 
identified as “unidentified by-products and impurities” (UBPI), analyzed by FT-
IR and NMR. It contained a little residual VP, lactic acid, glycolic acid and some 
residual tin catalyst present in the starting PLGA.  
PLGA-g-PVP10:2 and PLGA-g-PVP10:3 were prepared by the same procedure.  
The amounts of PLGA, VP and AIBN used were 2.013 g, 0.408 g, 4.2 mg and 
2.016 g, 0.6134 g, 6.1 mg, respectively. Yield: 93.0% for PLGA-g-PVP10:2 and 
95.2% for PLGA-g-PVP10:3. 
2.4.3.2 Saponification of PLGA-g-PVP MP samples (typical procedure) 
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PLGA-g-PVP10:1 (0.999 g) was suspended in a 1 M NaOH solution (22 mL) and 
stirred 30 days at room temperature. The polymer gradually dissolved. The 
resultant solution was neutralized with 1 M HCl solution and then ultrafiltered  
through a membrane with nominal molecular weight cut-off 500. The retained  
fraction was freeze-dried giving PVP as a yellowish solid. Yield: 0.093 g; 𝑀𝑛  = 
2700, 𝑀𝑤= 5600, PD = 2.07. PLGA-g-PVP10:2 and PLGA-g-PVP10:3 were 
similarly treated yielding 0.176 g and 0.234 g PVP of 𝑀𝑛= 12100,𝑀𝑤  = 31000, 
PD 2.56 and𝑀𝑛 = 28000, 𝑀𝑤= 49500, PD 1.77, respectively. 
2.4.3.3 Fractionation of PLGA-g-PVP (MP samples) 
PLGA-g-PVP (2 g) was dissolved indichloromethane (20 mL) and added drop-
wiseto a stirred 1:1 methanol/water mixture (200mL). The resultant white 
suspension wascentrifuged at 7500 rpm for 20 min and the insoluble fraction 
(F2) retrieved, re-suspended in the same solvent mixture (10 mL), centrifuged  
and retrieved again, and finally dried to constant weight at 0.2 tor. The soluble 
fraction (F1) was filtered through a 0.2 μm HPLC filter, the solvent evaporated  
and the residue dried as above. Two equal aliquots of F2 fraction were extracted  
with methanol (50 mL) and ethyl acetate (50 mL), respectively. The obtained 
suspensions were vigorously stirred for 2 h and then centrifuged at 7500 rpm 
for 30 min. The insoluble fractions (F4 and F6, respectively) were retrieved , 
extracted with fresh solvent (25 mL) and dried to constant weight. The methanol 
and ethyl acetate phases (F3 and F5, respectively) were separately evaporated to 
dryness and the resultant solids retrieved. 
2.4.3.4 Preparation and fractionation of PLGA/PVPK40 blends  
Measured volumes of chloroform PLGA and PVP solutions containing 0.2 g 
polymer in 6 mL solvent were mixed and poured in 50 volumes diethyl ether.  
After drying to constant weight, the precipitate was extracted either with ethyl 
acetate or methanol, leaving an insoluble portion that, in turn, was completely 
soluble either in methanol or in ethyl acetate, respectively.  
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2.4.3.5 Synthesis of low molecular weight PVP in DMF solution (PVPDMF) 
A 500 mL two-necked flask, equipped with a stir bar and a thermometer, was 
charged with VP (5.713 g, 0.052 mol) and DMF (136.78 g, 1.871 mol). The 
solution was purged with nitrogen for 5 min at 75 °C, then AIBN (57.1 mg) was 
added and the reaction mixture allowed reacting for 2 days. After cooling to 
room temperature, the mixture was added drop-wise to diethyl ether (1 L) under 
vigorous stirring and left under stirring for 2 h. The reaction produ ct was 
recovered by filtration, extracted overnight with fresh ether (150 mL) and dried 
to constant weight at room temperature and 0.2 tor. Yield: 5.35 g.𝑀𝑛 = 4500, 
𝑀𝑤= 7300, PD = 1.62. 
2.4.3.6 Preparation of PLGA/PVP blends (PLGA/PVPDMF 10:1) 
PLGA (1.016 g) and PVPDMF (0.103 g) were dissolved in dichloromethane (2 
mL), precipitated in diethyl ether (30 mL), centrifuged 5 min at 7500 rpm, the 
supernatant discarded, the precipitate extracted with a fresh portion of diethyl 
ether, centrifuged again, retrieved and dried to constant weight under vacuum. 
PLGA/PVPDMF 10:2 and 10:3 w/w blends were prepared following the same 
procedure and the amounts of PLGA and PVPDMF were 1.020 g and 0.200 g, 
1.103 g and 0.334 g, respectively.  
2.4.3.7 Fractionation of PLGA/PVPDMF blends 
PLGA/PVPDMF blends (0.12 g) were dissolved in dichloromethane (2 mL) and 
precipitated in a 1:1 methanol/water mixture (30 mL), obtaining white 
suspensions that were centrifuged 10 min at 7500 rpm. The insoluble portion 
was extracted with the same methanol/water mixture, centrifuged again, 
retrieved and dried to constant weight at 0.2 tor. The remaining solutions were 
filtered through a 0.2 µm HPLC filter, evaporated to dryness in vacuo and the 
residues brought to constant weight at 0.2 tor.  
2.4.3.8 Synthesis of PVP in water 
In a round bottom flask VP (3.000 g, 0.027 mol) was dissolved in water (10 mL). 
The solution was purged 3 min with nitrogen, then AIBN (20.0 mg, 0.122 mmol) 
was added. The solution was then immersed in an oil bath pre-heated to 100 °C 
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and allowed to polymerize 2 h. The product was finally recovered by 
liophilization: 𝑀𝑛  =128200, 𝑀𝑤 =197000, PD 1.54. 
2.4.3.9 Determination of the IR calibration curve relevant to the 
ester/amide C=O stretching  
The FT-IR spectra of PLGA/PVP blends with compositions ranging from 9:1 
to 0.5:1 w/w were obtained by casting onto KBr plates 300 µL aliquots of mixed 
PLGA/PVP dichloromethane solutions prepared by dissolving the relevant 
amounts of PLGA50:50 and PVPK40 in 4 mL solvent (Table 1). These spectra 
were analyzed in the absorption mode, and the areas of the C=OPLGA and 
C=OPVP bands, centered at 1760 cm -1 and 1660 cm -1 respectively, obtained using 
the valley-to-valley method to determine the peak baselines. (Figure 2-A). All 
band area measurements were performed in triplicate on spectra obtained from 
at least two distinct PLGA/PVP films. The calibration curve (Figure 2-B) was 
obtained by plotting the PLGA/PVP weight ratio against the corresponding 
C=OPLGA/C=OPVP band area ratio. 
2.4.3.10 PLGA-g-PVP-based aqueous nanodispersions 
All fractions of PLGA-g-PVP copolymer were tested to form nanoparticles in 
water, without using of stabilizers or surfactants. In details, 3 mg of each 
fractions were dissolved in acetone (1% w/v) and diluted with 10 volumes of 
water. Later, acetone was removed by flashing for 30 min at room temperature.  
Obtained nanodispersions (NDS) were stored at room temperature (about 
22°C) or 4°C. 
The same procedure was followed with native PLGA, 10:1, 10:2 and 10:3 w/w 
native PLGA/PVPDMF blends, and 8:2 w/w PLGA/PLGA-g-PVP10:1, PLGA-
g-PVP10:2 and PLGA-g-PVP10:3 blends. Particle size, ζ-potential, stability on time 
(1h, 24h, 7d) and re-dispersion in water after lyophylization of the resultant NDS 
were assessed. 
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2.5 RESULTS AND DISCUSSIONS 
2.5.1 Synthesis 
End-functionalized PVP oligomers were previously prepared by radical 
polymerization of VP in presence of aliphatic esters acting as both solvents and 
chain transfer agents. In the present study, it was found that running the reaction 
at 100 °C and substituting PLGA for the esters provided a one-step procedure 
to PLGA-g-PVP copolymers. At that temperature, the reaction mixture was in 
the fluid state. The reaction scheme is reported in Figure 2.3. Three batches were 
performed with 10:1, 10:2 and 10:3 w/w PLGA/VP ratios and 1% w/w (based 
on VP) AIBN as initiator. As the AIBN decomposition rate at 100 °C is kd= 
1.5 x 10-3 s-1, with less than 10 min half-life, the reaction was considered  
completed within 2.5 hours. All reaction mixtures were homogeneous, highly 
viscous liquids that solidified on cooling. After cooling, they were dissolved in 
dichloromethane and re-precipitated with ether for eliminating residual VP. No 
dichloromethane-insoluble fractions were noticed, indicating absence of cross-
linked byproducts. 
 
Figure 2.3. Synthesis of PLGA-g-PVP copolymers by radical polymerization of 
NVP in molten PLGA. 
Evaporating to dryness the mother liquors and drying the residue at room 
temperature and 0.1 tor yielded small amounts of unidentified by-products and 
impurities (UBPI) that were no further processed. 
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The precipitate main products, henceforth collectively named PLGA-g-PVP MP 
or individually PLGA-g-PVP10:1, PLGA-g-PVP10:2 and PLGA-g-PVP10:3, were 
extracted several times with ether and dried to constant weight at room 
temperature and 0.1 tor. Their FT-IR spectra, reported in Figure 2.4, clearly 
showed both ester and amide C=O bands. The composition of all PLGA-g-PVP 
samples were determined after these band ratio using a calibration curve 
obtained from PLGA/PVP blends of known composition as reported in Table 
2.1 and Figures 2.5 (A and B). The found values for PLGA-g-PVP10:1, PLGA-g-
PVP10:2 and PLGA-g-PVP10:3 expressed as PVP wt % were, respectively, 6.7, 18.8 
and 23.5. 
The 1H and 13C NMR spectra of the MP samples were consistent with the 
presence of both PLGA and PVP portions. The NMR spectra of PLGA-g-
PVP10:3 MP samples are shown in Figure 2.6. 
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band area ratio 
22.0 44.0 0.50 0.54 
36.6 41.1 0.89 1.07 
46.6 20.0 2.33 2.38 
82.0 22.0 3.73 3.74 
100.0 19.8 5.05 5.10 
140.0 21.0 6.67 6.87 
154.4 18.0 8.33 8.65 
 
 
Figure 2.5. A) FT-IR spectra of PLGA/PVP blends with different w/w ratios 
in the 2000 - 1500 cm -1 range.(--) PLGA/PVP 0.50; (--) PLGA/PVP 0.89;(--)  
PLGA/PVP 2.33;(--) PLGA/PVP 3.73; (--) PLGA/PVP 5.05; (--) PLGA/PVP 
6.67; (--) PLGA/PVP 8.33. B) FT-IR calibration curve. 
A B 
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Figure 2.6. (a)PLGA-g-PVP copolymer’s structure and assessments.(b) 1H-
NMR and (c) 13C-NMR spectra of PLGA-g-PVP10:1in CDCl3. (d) 1H-NMR and 
(e) 13C-NMR spectra of PLGA-g-PVP10:2in CDCl3. (f) 1H-NMR and (g) 13C-
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2.5.2 Thermal analysis 
The DSC thermograms of PLGA-g-PVP10:1, PLGA-g-PVP10:2 and PLGA-g-
PVP10:3 MP samples were compared with those of virgin PLGA and PVPK40 
(Figures 2.7a and 2.7b, respectively). The glass transition temperatures, Tg, of 
the PLGA and PVP portions of PLGA-g-PVP MP and of virgin PLGA and 
PVP are reported in Table 2.2. It may be noticed that the Tg of the PLGA 
portion was higher than that of virgin PLGA and steadily increased with the 
PVP content following the same trend of PLGA/PVP mixtures, as previous ly 
observed and attributed to partial phase miscibility of the two components. lxxi 
 
Figure 2.7.(a) DSC traces of PLGA-g-PVP MP samples and (b) of PLGA 50:50 
and PVPK40. Second heating cycle, heating rate: 10 °C min -1. 
The Tg of the PVP portions were hardly detectable in the spectra of PLGA-g-
PVP10:1 and PLGA-g-PVP10:3, whereas the spectrum of PLGA-g-PVP10:2 showed 
a barely detectable inflection roughly corresponding to the Tg of pure PVPK40. 
The TGA thermograms of PLGA-g-PVP10:1, PLGA-g- PVP10:2 and PLGA-g-
PVP10:3 (MP samples) are reported in Figure 2.8. All thermograms showed two 
distinct zones, ascribed to the degradation of the PLGA and PVP portions, with 
a decomposition temperatures at 5% weight loss of 308 °C and 387 °C, 
respectively, in line with the values normally reported for the virgin 
polymers.lxxiilxxiii 
Passing from PLGA-g-PVP10:1 to PLGA-g-PVP10:2 and PLGA-g-PVP10:3 the 
thermograms showed the expected increase of the PVP-related portions. The 
TGA estimates of the wt% PVP, namely 5.0, 13.2 and 21.9 were fairly consistent 
with the IR assessments. 
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Figure 2.8. TGA thermograms of PLGA-g-PVP10:1, PLGA-g-PVP10:2 and 
PLGA-g-PVP10:3 (MP samples). 
Table 2.2. Glass transition temperatures, Tg, of the PLGA and PVP portions 
of PLGA-g-PVP10:1, PLGA-g-PVP10:2 and PLGA-g-PVP10:3 (MP samples) as 
well as those of virgin PLGA and PVP 
Sample Tg-PLGAa) (°C) Tg-PVPb) (°C) 
 onset offset onset offset 
PLGA-g-PVP10:1 38.3 58.3 ndc) ndc) 
PLGA-g-PVP10:2 45.0 58.3 ~180.0 ~190.0 
PLGA-g-PVP10:3 49.2 55.0 ndc) ndc) 
PLGA 50:50 33.0 50.0 - - 
PVPK40 - - 162.4 185.6 
a) Tg-PLGA = Tg of the PLGA portion. b) Tg-PVP = Tg of the PVP portion. c)nd = 
not detected. 
2.5.3 Estimate of the average Chain Transfer Constant of PLGA repeating 
units 
The PLGA main chains of PLGA-g-PVP MP samples were saponified with 
dilute aqueous sodium hydroxide at room temperature (~20 °C) and the side 
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PVP chains isolated by acidifying the reaction mixture to pH ~ 3, ultrafiltering 
the resultant clear solution through a membrane with nominal molecular weight 
cut-off 500 and lyophilizing the retained portion. The molecular weights of the 
PVP side chains were then determined by SEC-LALS (Table 2.3). 
The average chain transfer constant (CT) of the PLGA units under the adopted 
conditions was estimated by means of Eq. 2.1, previously developed and 
successfully employed for determining the CT values of low molecular weight 
aliphatic esters employed as both solvents and chain transfer agents in VP 
polymerizations aimed at obtaining end-functionalized PVP oligomers.lxxiv 





log(1 − 𝑌𝑡)  
                     𝐸𝑞. 2.1 
Where 𝑋n,t= cumulative number average polymerization degree at t time; [M]o 
and [T]o = initial monomer and chain transfer agent concentrations; Yt= 
monomer conversion at t time. Eq. 2.1 was obtained from the well-known Lewis  
and Mayo equation (Eq. 2.2) by a mathematical elaboration of its simplified 









                   𝐸𝑞. 2.2 





                                𝐸𝑞. 2.3 
where 𝑋𝑛 is the instantaneous number averagepolymerization degree and 𝑋𝑛 ,𝑜is 
theinstantaneous number average polymerizationdegree in the absence of the 
chain transfer agent. 
Eq. 2.3 is valid if 1/𝑋𝑛,𝑜 is negligible compared with 1/𝑋𝑛  , that is, if a 
sufficiently high [T]o/[M]o ratio (which depends on CT) renders chain  
termination much less frequent than chain transfer. Bulk VP polymerization was 
ruled out as a mean to estimate the 𝑋𝑛 ,𝑜value of PVP under the same 
polymerization conditions, since at medium -high conversions the so-called  
“gel” effect was likely to occur and, in the meanwhile, it was difficult to stop the 
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reaction at low conversions. A PVP sample prepared by polymerizing N-VP at 
100 °C as 30% aqueous solution had 𝑋𝑛= 1200. This was considered as a 
reasonable approximation of 𝑋𝑛 ,𝑜. By comparing this value with the 𝑋𝑛values 
of the PVP side chains of the three PLGA-g- PVP MP samples (Table 3), it 
appeared that the validity condition of Eq. 2.1 was fulfilled for PLGA-g-PVP10:1,  
whereas PLGA-g-PVP10:2 was borderline and PLGA-g-PVP10:3 was off limits. All 
considered, it was reasonably concluded that the average CT of the PLGA units 
at 100 °C was approximately 1 x 10-3, that is, fell in the 1 x 10-2 ÷ 5 x 10-4 range 
of the CT values of low molecular weight esters previously determined at 70 - 
80°C.lxxv The grafting degree, that is, the average number of PVP side chains per 
PLGA main chain of PLGA-g-PVP MP samples (calculated from the number 
average molecular weight of the PLGA main chain, the number average of the 
PVP pendants and the PLGA/PVP w/w ratio) were 1.5, 1.1 and 1.0. The 
grafting degree was proportional to the [T]/[M] ratio, therefore decreased by 
increasing the VP content in the feed. By contrast, the molecular weight of the 
PVP side chains was inversely proportional to the [T]/[M] ratio, hence the 
PVP/PLGA w/w ratio in the resultant PLGA-g-PVP increased. 
Table 2.3. Molecular weights of the PVP side chains and average CT of the 
















PLGA-g-PVP10:1 17.0 2700 5600 24 0.88 1.02 1.5 
PLGA-g-PVP10:2 8.5 12100 31000 109 0.69 0.64 1.1 
PLGA-g-PVP10:3 5.7 28000 49500 252 0.79 0.36 1.0 
a)PLGA repeating units. b) Number average polymerization degree. c) Monomer 
conversion, see Table 2.4. d) Average number of PVP side chains per PLGA 
main chain. 
2.5.4 MALDI-TOF analysis of PVP side chains 
The PVP samples obtained by saponification of the PLGA-g-PVP MP samples 
were analyzed by MALDI-TOF mass spectrometry. This allowed gaining 
unquestionable evidence of grafting occurrence by determining the nature of the 
PVP terminal groups. The spectra of the saponification products of all samples 
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were much similar notwithstanding the different PVP content and the different 
average molecular weight of the PVP portions. This reflected the identity of all 
fractions in the same m/z range as well as the obvious flying limits of the 
polydisperse PVP under the adopted conditions. The whole spectrum of PLGA-
g-PVP10:1 saponification product in the 800-5000 m/z range is reported in Figure 
2.9, together with its expanded 1420-1530 m/z spectral range. The 
corresponding spectral regions of the saponification products of PLGA-g-
PVP10:2 and PLGA-g-PVP10:3 are shown in Figures 2.10 and 2.11.  
 
Figure 2.9.(a) MALDI-TOF spectrum of the saponification products of 
PLGA-g-PVP10:1 MP. (b) Expanded 1420-1530 m/z spectral range. 
 
Figure 2.10. MALDI-TOF spectra of the saponification products of PLGA-g-
PVP10:2 in the ranges (a) 800 – 5000 m/z and (b)1400 – 1800 m/z.  
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Figure 2.11. MALDI-TOF spectra of the saponification products of PLGA-g-
PVP10:3 in the ranges (a) 800 – 5000 m/z and (b)1400 – 1800 m/z. 
The whole spectra of all samples consisted of a succession of ten-peak motifs 
of four moderately intense peaks followed by a single peak of paramount 
intensity and five weakly intense peaks. The m/z difference of the corresponding 
peaks belonging to consecutive motifs was constantly 111.1, that is, the mass of 
the VP unit. 
The m/z values of the recovered PVP, including terminals, was expressed by Eq. 
4: 
𝑚
𝑧𝑃𝑉𝑃⁄ = 111.1×𝑋𝑛 ,𝑃𝑉𝑃 + 𝑚𝑇2 +  𝑚𝑐𝑎𝑡𝑖𝑜𝑛     𝐸𝑞. 4 
where 111.1 is the mass of the VP unit, 𝑚𝑇1and 𝑚𝑇2are the masses of the chain  
terminals, and 𝑚𝑐𝑎𝑡𝑖𝑜𝑛 is the mass of the cation(s), mainly H+ or Na+. It may be 
noticed that T1is hydrogen, as the abstraction of a different PLGA atom by the 
propagating PVP radical could hardly be imagined. The consequent peak 
assignments are reported in Table 2.4. They were consistent with the presence 
at one chain end of residues from lactic acid (L), and glycolic acid (G), all their 
dimers (LG), the lactic-lactic-glycolic trimer (LLG), and the lactic-lactic-glyco li c-
glycolic tetramer (LLGG). No PVP homopolymer and PLGA-PVP-PLGA 
traces in MALDI-TOF spectra were highlighted. 
Table 2.4. Terminal groups of PLGA-g-PVP10:1 saponification product, 
corresponding to 𝑋𝑛  = 12. 
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a) For 𝑋𝑛  = 11. 
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2.5.5. Fractionation of PLGA-g-PVP copolymers 
The PLGA-g-PVP MP samples were fractionated to assess their compositional 
dispersion. To this purpose, preliminary tests were performed on PLGA and 
both low - and high -molecular weight PVP (the former purposely prepared by 
polymerizing VP in DMF solution). It was found that ethyl acetate and methanol 
were selective extraction solvents from blends (the IR spectra of the recovered  
solids were superimposable to those of PLGA and PVP, respectively, Figure 
2.12, while the 1:1 (v/v) water-methanol mixture was a selective precipitation 
medium from mixed dichloromethane solutions (Figure 2.13). In both cases, the 
original PLGA and PVP components were quantitatively recovered. 
 
Figure 2.12. IR spectra of the fractions retrieved from the extraction 
fractionation of PLGA/PVP blends with ethyl acetate and methanol. a) 
PLGA/PVP blend; b) ethyl acetate soluble fraction; c) methanol soluble 
fraction. 
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Figure 2.13. IR spectra of the products of PLGA/PVPDMF precipitation from 
DCM into a 1:1 methanol/water mixture. a) Methanol/water insoluble portion; 
b) methanol/water soluble portion. 
The same treatments were adopted for fractionating the PLGA-g-PVP MP 
samples. The whole fractionation scheme adopted for each PLGA-g-PVP 
copolymer is reported in Figure 2.14, which encompasses the previously 
mentioned precipitation from dichloromethane with ether of the crude reaction 
mixture, leading to the main product (MP) and leaving unidentified impurities 
and byproducts (UBPI) in the mother liquors. 
 
Figure 2.14. Fractionation scheme of PLGA-g-PVP copolymers. 
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All PLGA-g-PVP MP samples were dissolved in dichloromethane and re-
precipitated with 1:1 water-methanol. The mother liquors contained a small 
soluble fraction (F1). The insoluble fraction (F2) was further fractionated by 
selective extractions with ethyl acetate and methanol. On the whole, each 
PLGA-g-PVP copolymer was subdivided in two intermediate (MP and F2) and 
six terminal (UBPI, F1, F3, F4, F5, F6) fractions. Their compositions are 
evaluated by FTIR (Figure 2.15) reported in Table 2.5. The grafting degrees of 
the terminal fractions, defined as the number of PVP chains per PLGA chain,  
are reported in Table 6. The above results demonstrate that the fractionation 
process effectively separated PLGA-rich and PVP-rich fractions, but failed to 
isolate either PLGA or PVP. As reported in Table 2.3, the grafting degrees of 




Figure 2.15. IR spectra of F3-F6 fractions of PLGA-g-PVP copolymers. 
 
PLGA-g-PVP10:1 PLGA-g-PVP10:2 PLGA-g-PVP10:3 
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Table 2.5. Weight and composition of PLGA-g-PVP fractions 

































































































a)Not determined. b) Regarded as the VP conversion. Probably, most wanting 
VP in respect of the feed was unreacted monomer remaining in the 
dichloromethane mother liquors of the main products (MP) precipitation and 
subsequently lost while retrieving the UBPI fraction by high vacuum solvent 
elimination. 
As shown in Table 2.6, the PVP chains were not evenly distributed. All PLGA-
g-PVP MP samples contained minority PVP-rich fractions (F1, F3,F6) with 
grafting degrees ranging from 13 to 28 (PLGA-g-PVP10:1), 6.5 to 7.5 (PLGA-g-
PVP10:2) and 3 to 6 (PLGA-g-PVP10:3), together with major PLGA-rich fractions 
(F2, F4, F5) with grafting degrees ranging from 0.3 to 1.1 (PLGA-g- PVP10:1),  
0.2-to 0.4 (PLGA-g-PVP10:2) and 0.1 to 0.2 (PLGA-g-PVP10:3). It is apparent that 
the fractions of the latter group contained significant amounts of virgin PLGA. 
A possible explanation of this uneven distribution is that PVP grafting on a 
PLGA chain facilitated further grafting on the same chain. The first step of the 
chain transfer reaction was hydrogen abstraction from a PLGA chain by a PVP 
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macroradical, which preferentially approached an already PVP-grafted PLGA 
for which it had greater affinity than for virgin PLGA. 
Table 2.6. Grafting degree of PLGA-g-PVP fractions 
Grafting degree a) 
Code PLGA-g-PVP10:1 PLGA-g-PVP10:2 PLGA-g-PVP10:3 
UBPI 11.6 2.4 0.8 
F1 13.4 6.3 5.8 
F2 ndb) ndb) ndb) 
F3 28.5 6.6 3.6 
F4 1.1 0.4 0.1 
F5 0.3 0.2 0.2 
F6 28.6 7.4 3.3 
a) Average number of PVP side chains per PLGA main chain. 
b) Not determined. 
2.5.6 PLGA-g-PVP-based aqueous nanodispersions 
In preliminary experiments, all PLGA-g-PVP MP samples gave nanodispersions 
(NDS) by diluting their 1% acetone solutions with 10 volumes water and then 
getting rid of acetone by nitrogen flushing at room temperature. For comparison 
purposes, the same procedure was followed with native PLGA, 10:1, 10:2 and 
10:3 w/w native PLGA/PVPDMF blends, and 8:2 w/w PLGA/PLGA-g-PVP10:1,  
PLGA-g-PVP10:2 and PLGA-g-PVP10:3 blends. Particle size, ζ-potential, stability 
on time and re-dispersion in water after lyophylization of the resultant NDS 
were assessed. 
The properties of native PLGA NDS were recorded as formed and after 1 and 
2 days standing at room temperature. As formed, PLGA NDS had large 
dimensions (>250 nm) and highly negative surfaces (-40 mV). Their size rapidly 
increased and sediments were produced within after 1-2 days (data not shown). 
They were no further considered. 
In all other cases, the NDS size and ζ- potential were recorded after standing 1 
h, 24 h and 7 days at room temperature. The results are shown in Figure 2.16. 
The PLGA-g-PVP MP NDS were smaller (150 - 180 nm) than those of PLGA, 
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their size did not strictly depend on PVP content, remained constant and formed 
no sediments throughout the observation time. Moreover, in the absence of 
added cryoprotectors they could be lyophilized and subsequently re-dispersed  
in water with a moderate increase of size to 300-400 nm and a significant 
reduction of their negative surface charge, possibly due to structural 
rearrangement (Figure 2.17). PLGA-PVP blends gave somewhat larger NDS 
(220-350 nm) that within 48 h produced sediments and if treated with water 
after lyophilization gave a solid cake (Figure 2.18). 
 
Figure 2.16.Particle size and ζ-potential of nanodispersions from (a,b) MP 
fractions; (c,d) PLGA/PVP; (e,f) PLGA/MP blends. 
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Figure 2.17. (a) Particle size and (b) ζ-potential of pristine and lyophilized MP 
nanodispersions. 
 
Figure 2.18. PLGA/PVP 10:3 blend and PLGA-g-PVP10:3 MP sample re-
dispersed in water after lyophilization of the pristine nanodispersions.  
Interestingly, NDS of 8:2 PLGA/PLGA-g-PVP10:3 blends behaved exactly as 
those of PLGA-g-PVP, apart from the formation of little sediment by re-
dispersing after lyophilization. These results suggest that in all NDS PVP 
protruded in the aqueous phase. However, it was only loosely bound to - and 
easily extracted from PLGA/PVP blends, but stably bound to- and hardly 
extractable from both PLGA-g-PVP and PLGA/PLGA-g-PVP blends. 
The ζ-potentials of both PLGA-g-PVP and PLGA/PLGA-g-PVP blend NDS 
were the same as those of native PLGA, that is ~ - 40 mV. They did not depend 
from the PVP content and remained constant throughout the observation 
period. The ζ-potential of PLGA/PVP blend NDS was also negative, ranging 
from - 30 to - 40 mV, but depended on the PVP content and did not remain 
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constant with time, but within the observation period halved to -15- -20 mV, 
possibly owing to the gradual PVP migration to the surface. 
Size and ζ-potential of fractions F3-F6 NDS are shown in Figure 2.19 (a and b). 
Confirming the above observation, higher PVP contents did not lead to better 
performances under the experimental conditions adopted, notwithstanding 
most of the F4 and F5 fractions grafting degrees ranged in the range 0.1 - 0.4. 
Therefore, they contained significant amounts of virgin PLGA and were, in fact ,  
PLGA/PLGA-g-PVP intimate blends similar to the purposely prepared ones 
reported above. Logically, they performed similarly. 
 
 
Figure 2.19. (a) Particle size and (b) ζ-potential of nanodispersions from F3-F6 
fractions. 
For all cases, particle size and ζ-potential were collected after standing at 1h, 24h 
and 7 days at 4°C (Figure 2.20). Generally, particle sizes are smaller and less 
sensitive to spending time than those of room temperature. Also in this 
condition, NDS obtained from MP are the smallest (less of 160 nm) and 
independent on PVP content, only ζ-potential changed, in particular moduli 
decrease increasing PVP portion. PLGA/PVP NDS presented sizes of about 
a) 
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200 nm and as ζ-potentialmoduli of about -35 - -40 mV. These values did not 
vary during the observation time and respect to PVP content, on the contrary 
of room temperature standing NDS. Probably the lower temperature slows 
down agreement mechanisms in which PVP covers PLGA surface of NDS.F3-
F6 NDS confirmed the trend and values observed at room temperature. 
 
Figure 2.20. Particle size and ζ-potential of nanodispersions from (a,b) 
PLGA/PVP; (c,d) MP fractions; (e,f) from F3-F6 fractions at 4°C. 
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2.6 CONCLUSIONS 
The results reported in this paper demonstrate that the radical polymerization 
of VP dissolved in commercial medical grade PLGA at 100 8C provides a one-
step straightforward preparation of hitherto undescribed PLGA-g-PVP 
copolymers by a chain-transfer mechanism. The saponification of the PLGA 
portion allowed determining the molecular weight of the PVP side chains as a 
function of the PLGA/VP ratio in the reaction feed. This allowed estimating 
the chain-transfer constant (CT) of PLGA repeating units to be 1 x 10-3, that is, 
within the range of those previously determined for non-polymeric aliphatic 
esters, notwithstanding the PLGA high molecular weight. The resultant 
copolymers consisted of a long PLGA main chain and PVP pendants whose 
molecular mass could be kept well below the renal elimination threshold by 
adjusting the PLGA/VP ratio in the feed. Thus, they are entirely bioeliminable 
if employed as injectable drug delivery systems. 
The MALDI-TOF spectra of the PVP obtained by saponification of the PLGA-
g-PVP main products were consistent with oligomeric PVP chains terminated 
at one end by hydrogen and at the opposite end by L-, G-, LG-, LLG, and 
LLGG residues. This unequivocally demonstrated the occurrence of PVP 
grafting onto PLGA. On average, PLGA-g-PVP10:1, PLGA-g-PVP10:2, and 
PLGA-g-PVP10:3 carried, respectively, 1.5, 1.1, and 1.0 PVP side chains per 
PLGA main chain. The fractionation by the orthogonal solvent pair ethyl-
acetate/ methanol, whereas able to quantitatively separate in a pure state the 
PLGA and PVP components of PLGA/PVP intimate blends, if used to 
fractionate crude PLGA-g-PVP failed to isolate either pure PLGA or pure PVP. 
However, it separated PLGA- and PVP-rich fractions with widely different 
compositions, demonstrating that the PVP grafting was unevenly distributed. 
The mass balance of the fractions showed that one or more PVP chains grafted  
onto a PLGA chains probably facilitated further grafting on the same chain.  
Moreover, the PLGA-rich fractions probably contained some native PLGA. All 
main PLGA-g-PVP products and single fractions gave stable nanodispersions 
in water by the solvent evaporation technique, irrespective of the PVP content.  
Similar results were obtained with PLGA/PLGA-g-PVP intimate blends, but 
not with PLGA/PVP blends. Admittedly, these preliminary results need to be 
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substantiated by further, specifically addressed research. However, they suggest 
that the new PLGA-g-PVP copolymers reported in this article, notwithstanding 
the uneven distribution of PVP grafting among the PLGA chains, have a 
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FORMULATIONS OF PLGA-g-PVP COPOLYMERS  
 
“The purpose of this piece of work is to establish the best formulation technologies to 
transform PLGA-g-PVP copolymers into nanosized carriers, namely nanoparticles and lipid 
nanocapsules, for the delivery of anticancer and antimalarial drugs” 
 
3.1 NANOPARTICLES  
Polymeric nanoparticles (NPs) are colloidal structures composed of natural, 
synthetic or semi-synthetic polymers with sizes generally around 5-1000 nm, 
more centred on 100-500 nm. Depending on the process used for NP 
preparation, nanospheres or nanocapsules can be obtained (Figure 3.1).i 
Nanospheres have a homogeneous structure in the whole particle, the drug is 
dissolved, entrapped, encapsulated or uniformly attached to polymer matrix.ii 
Nanocapsules are nano-vesicular systems that exhibit a typical core-shell 
structure where the drug is confined to a reservoir or within a cavity 
surrounded by a polymer membrane or coating. The reservoir can be a liquid 
oily core or in a solid form.iii 
 
Figure 3.1. Nanosphere and nanocapsule structures.  
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3.2 NP PREPARATION METHODS  
NPs are usually prepared by bottom-up procedure, mainly based on two 
methods: solvent evaporation and solvent displacement.iv All the other 
methods proposed in the literature are derived from them, with little 
difference. 
Solvent evaporation method: the polymer and drug are dissolved in an organic 
solvent such as dichloromethane, chloroform and ethyl acetate, and then 
emulsified into an aqueous solution to make oil (O) in water (W) (O/W 
emulsion) by using a surfactant or an emulsifying agent. After the formation of 
a stable emulsion, the organic solvent is evaporated either by increasing the 
temperature under pressure or by continuous stirring. A similar procedure is 
adopted for (W/O)/W method, usually used for preparing water-soluble drug-
loaded NPs. This approach consists in two consecutive emulsions: the former 
useful to solubilise the drug in the polymer solution, and the latter to form the 
NPs.v 
Solvent displacement method/ nanoprecipitation: a water-soluble solvent with 
intermediate polarity, such as acetone, ethanol or methanol, is used to initially 
solubilise both polymer and drug. This phase is thus injected into a stirred 
aqueous solution in the presence or not of surfactants. Polymer deposition on 
water/organic solvent interface, caused by the fast diffusion of solvent, leads to 
the instantaneous formation of a colloidal suspension. The solvent 
displacement technique allows for preparing nanocapsules when a small 
volume of nontoxic oil is incorporated in the organic phase. 
Emulsification/solvent diffusion method: this is a modified version of solvent 
evaporation method. The encapsulating polymer is dissolved in a partially 
water-soluble solvent, such as propylene carbonate and saturated with water. 
The polymer-water saturated solvent phase is emulsified in an aqueous 
solution, already containing a stabilizer, leading to solvent diffusion to the 
external phase and the formation of nanospheres or nanocapsules, according to 
the oil-to-polymer ratio. Finally, the solvent is eliminated by evaporation. 
Salting out method: it is a modification of the solvent displacement method, in 
which the separation of a water miscible solvent from aqueous solution is via a 
salting out effect. Polymer and drug are initially dissolved in a solvent such as 
acetone, which is subsequently emulsified into an aqueous gel containing the 
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salting-out agent (electrolytes, such as magnesium chloride, calcium chloride, 
and magnesium acetate, or non-electrolytes such as sucrose) and a colloidal 
stabilizer such as polyvinylpyrrolidone or hydroxyethylcellulose. This oil/water 
emulsion is diluted with a sufficient volume of water or aqueous solution to 
enhance the diffusion of acetone into the aqueous phase, thus inducing the 
formation of nanospheres. 
Dialysis: polymer is dissolved in a water miscible solvent and placed inside a 
dialysis tube with proper molecular weight cut off. The displacement of the 
solvent inside the membrane is followed by the progressive aggregation of 
polymer, due to a loss of solubility and the formation of homogeneous 
suspensions of nanoparticles. The solvent used in the preparation of the 
polymer solution affects the morphology and particle size distribution of the 
nanoparticles obtained. 
Supercritical fluid technology: polymer is dissolved in a supercritical fluid to form a 
solution, followed by the rapid expansion of the solution across an orifice or a 
capillary nozzle into ambient air or in an aqueous solution. The high degree of 
super saturation, accompanied by the rapid pressure reduction in the 
expansion, results in homogenous nucleation and, thereby, the formation of 
well-dispersed particles. 
Even top-down methods have been developed taking advantage of instruments 
such as desktop or high-pressure homogenizers or ball-milling equipment able 
to reduce the particle size from micrometres to nanometres.vi 
3.3 ANTITUMOUR DRUGS  
Cancers are a large family of diseases that involve abnormal cell growth with 
the potential to invade and/or spread to other parts of the body. All tumour 
cells show the five hallmarks: a) cell growth and division in absence of the 
proper signals or in presence of contrary ones; b) avoidance of programmed 
cell death; c) limitless number of cell divisions; d) promoting blood vessel 
construction; and e) tissue invasion and metastasis formation.vii 
Cancers figure among the leading causes of morbidity and mortality worldwide, 
with approximately 14.0 million new cases and 8.2 million cancer related deaths 
in 2012.viii  
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Research aims at developing ever more potent treatments, able to get definitive 
ablation of the disease. 
3.3.1 Doxorubicin 
Doxorubicin hydrochloride (Adriamycin®)ix, is one of the most potent 
antineoplastic agents approved by the Food and Drug Administration, effective 
against a wide range of cancers, including breast cancerx,xi, myelomaxii, lung 
cancerxiii, gliomaxiv, leukaemiaxv, and lymphomaxvi. 
Its cytotoxic role is explicated in nuclear compartment of cells, by binding 
DNA associated enzymesxvii and intercalating the base pairs of the DNA’s 
double helix with consequently inhibition of both DNA replication and RNA 
transcription. xviii,xix  
Doxorubicin in form of hydrochloride salt (Dox) achieves a high degree of 
solubility in water; conversely, doxorubicin in the free base form (DoxB) is 
hydrophobic. Dox has a high biodistribution, it is quickly accumulated into 
many tissues (like liver, kidney, bone marrow), leading to a rapid extinction in 
the blood stream.xx,xxi It is not selective against tumour cells, therefore it results 
toxic for the healthy cells, in particular is considered cardiotoxic.xxii  
Modification of biodistribution and reducing of toxicity toward healthy cells 
can be achieved by entrapping the drug in carriers.  
Dox-loaded PLGA carriers are intensively studied in the literature. These 
systems include PLGA microparticles,xxiii,xxiv,xxv,xxvi,xxvii PLGA 
NPs,xxviii,xxix,xxx,xxxi,xxxii,xxxiii,xxxiv PLGA-PEG micelles,xxxv,xxxvi,xxxvii,xxxviii covalently 
bounded PLGA-Dox NPs,xxxix PLGA-Dextran micelles,xl [P(NIPAAm-co-
DMAAm)-PLGA micelle,xli hyaluronic acid NPs coated with PLGA-PEI,xlii,xliii 
magnetic NPs coated with PLGA,xliv,xlv,xlvi PLGA-Vitamin E TPGS NPs,xlvii 
PLGA-laponite-F68 nanocomposite (PNC) vesicles,xlviii magnetic NPs coated 
with PLGA-PEG,xlix PEG-PLGA-porphirin NPsl.  
3.3.3 Aim of research 
In this research work PLGA-g-PVP NPs are prepared by solvent displacement 
method to be used in antitumor treatment.  
Despite great benefits obtained by using above carriers in Dox delivery, they 
suffer of some drawbacks in term of efficacy and stability over time, as already 
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mentioned. Microparticles cannot reach tumour and need to be in situ 
implanted. Micelles are prone to dilution phenomenon that occurred when 
intravenous injected, leading to premature drug release.li Hydrophobic NPs 
coated by hydrophilic had poor affinity, sometimes leading to separation of the 
two blocks over time. NPs based on amphiphilic copolymers, like those 
obtained from PLGA-g-PVP copolymers, should not be prone to these pitfalls. 
Modulating PVP content in the initial PLGA-g-PVP copolymer, it was possible 
to vary the hydrophobicity degree of NPs matrix and, thus, affinity of 
nanocarrier with drugs with different lipophilicity. Drugs used to study NPs 
properties were Dox and its basic analogue doxorubicin base (DoxB).  
Chemical-physical characterizations of NPs were conducted by evaluation of 
sizes, morphologies, ζ-potentials, pH and osmolarities. Over time stability and 
drug release kinetics were studied. To highlight efficacy against tumour cells 
Dox-loaded NPs and DoxB-loaded-NPs, 2D and 3D in vitro studies were 
carried out. 
3.4 ANTIMALARIAL DRUGS  
Malaria is the most prevalent parasitic disease in the world. By 2015, it was 
estimated that the worldwide number of malaria cases is 214 million and the 
number of deaths to 438 000.lii It is caused by the apicomplex protozoan of the 
Plasmodium genus and transmitted to humans by the bites of the female 
mosquito vector of the Anopheles genus.liii,liv P. falciparum is the most dangerous 
of the four malarial parasites that can infect humans and is most prevalent on 
the African continent. P. falciparum resists to rigorous climate and has 
developed resistance to several drugs.lv  
Nanosized carriers have been receiving special attention with the aim of 
minimizing the side effects of drug therapy, poor bioavailability and drug 
resistance. Particularly lipid-based carriers (e.g., liposomes,lvi,lvii,lviii,lix solid lipid 
nanoparticleslx,lxi,lxii and nano or microemulsionslxiii,lxiv,lxv) and polymeric 
nanocarriers lxvi,lxvii,lxviii,lxix have been already studied. All these nanocarriers are 
currently used to fight the disease with good results.  
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3.4.1 Artemisinin as antimalarial drug 
Artemisinin (Art) is a sesquiterpene lactone peroxide, extracted from the 
wormwood Artemesia annua Longa. Usually used as anti-malarial drug, anticancer 
activity of Art was discovered by Woerdenbag et al in 1990.lxx Art and its 
derivatives (dihydroartemisinin, arthemeter, and artesunate) are the most used 
antimalarial drugs together with quinine derivatives (chloroquine, primaquine 
and mefloquine). Artemisinin has a very fast action and parasite clearance times 
are shorter when compared with other malarial drugs. Cytotoxicity of Art is 
explicated by the endoperoxide moiety present in its structure that reacts with 
Fe2+ ions present in haem (Figure 3.2).lxxi  
 
Figure 3.2. Mechanism of interaction of Art with Fe2+ present in haem, 
leading to radicals. 
The malaria parasite is rich in haem-iron, derived from the proteolysis of host 
cell haemoglobin. This could explain why artemisinin is selectively toxic to 
parasites.lxxii In parasite cultures treated with Art, adducts of haem and Art have 
been isolated.lxxiii Free radicals formed by the reaction alkylate protein and 
damage the microorganelles and membranes of the parasites.lxxiv Drawbacks of 
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Art are low water and oil solubility, poor bioavailability, and a short half‑life in 
vivo (~2.5h).lxxv,lxxvi For these reasons, it is usually loaded in several drug 
delivery systems, such as nanoparticleslxxvii and liposomeslxxviii,lxxix. Liposomal 
formulation of Art for antimalarial treatments is reported.lxxx,lxxxi 
Cyclodextrinslxxxii,lxxxiii,lxxxiv and albumin-Art conjugatedlxxxv are other typical 
nanocarriers. Only one formulation study of Art-loaded PLGA NPs was 
described in the literature.lxxxvi Art derivatives loaded in PLGA carriers are 
reported, e.g. artesunate-loaded and chitosan-coated PLGA NPs,lxxxvii 
dihydroartemisinin-loaded and PLGA-coated phospholipidic NPslxxxviii.  
3.4.2 Curcumin 
Curcumin (Cur) is a polyphenolic compound derived from turmeric, Curcuma 
Longa rhizomes, possesses diverse pharmacologic effects including anti-
inflammatory,lxxxix antioxidantxc and anticancer activitiesxci,xcii In addition, 
curcumin possesses activities against bacteria,xciii fungi,xciv,xcv and protozoaxcvi. 
Cytotoxic effects of Cur on protozoan parasites have been demonstrated in 
cultures against Leishmania,xcvii Trypanosoma,xcviii and Giardiaxcix. Cur antimalarial 
effects was demonstrated against Plasmodium falciparumc,ci and Plasmodium 
Bergheicii (the latter in combination with Art). Parasitical effect is due to the 
generation of reactive oxygen species and histone acetylation.ciii An excellent 
property of Cur is its safety even at very high doses when administrated to 
various animal modelsciv and humanscv,cvi. In spite of its efficacy and safety, Cur 
has not yet been approved as a therapeutic agent, due to its low solubility and 
low bioavailability.cvii To overcome these problems several carriers have been 
developed, among which nanotized Cur,cviii liposomal carrier,cix chitosan NPs,cx 
nanoemulsion,cxi lipid based systems,cxii sodium dodecyl sulphate (SDS) 
micelles,cxiii PMMA-PHEMA nanospherescxiv, PLGA-coated magnetic 
microspherescxv and PLGA NPscxvi,cxvii,cxviii.  
3.4.3 Aim of research 
Even if a current decrease of mortality and morbidity due to malaria is reached, 
improvements are always requested, especially in formulations of monodose, 
not expensive treatments with prolonged permanence in bloodstream and 
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sustained release of drugs. This route is possible only developing carrier with 
real high drug entrapping degree and modified surface.  
Lipid nanocapsules consisting of an oily core and PLGA-g-PVP surface were 
used as delivery systems of Cur and Art. The oily core chose to dissolve great 
amounts of drug was prepared by oil in water emulsion leading to microdrops 
in aqueous solution. Nanometric sizes were reached by using of high-pressure 
homogenizer. PLGA-g-PVP copolymers with two different PVP contents were 
deposited on, employing solvent displacement method. Modified surfaces were 
useful to modulate interactions between nanocapsules and cellular membranes 
of infected red blood cells in order to favour endocytosis inside. Chemical and 
physical characterizations of Art-loaded nanocapsules and Cur-loaded 
nanocapsules were carried out. Growth inhibition assay were conducted on 
plasmodium falciparum (3D7) culture. 
3.5 ANTITUMORAL PROJECTS EXPERIMENTAL PART 
3.5.1 METHODS 
3.5.1.1 Materials 
PLGA-PVP10:1 and PLGA-PVP10:2 were prepared according to the procedure 
reported in Chapter 2, Paragraphs 2.3.4.1. Poly(lactic-co-glycolic) acid (PLGA) 
50:50 ( ̅ = 45000-55000) was purchased from PolySciTech (Indiana, USA) 
and used as received. Doxorubicin hydrochloride salt (Dox) was purchased 
from Pharmacia & Upjohn; doxorubicin base (DoxB) was prepared as 
following described and used without further purification. Pluronics F68 (Plu), 
Tween 20, Tween 80, poly(vinyl alcohol) (PVA), mucin from porcine stomach, 
bovine serum albumin (BSA) and other chemicals and solvents were supplied 
by Sigma- Aldrich (Italy) at reagent grade and used without further purification.  
For in vitro tests: 
4T1 (mouse breast cancer), MDA-MB231 and CRL-2335 (human breast 
cancer) cells were obtained from the American Type Culture Collection 
(ATCC; Manassas, VA, USA). Human HCC1806 Breast Carcinoma cell line 
was purchased from LGC Standards, Sesto San Giovanni, Italy. Dulbecco's 
Modified Eagle Medium (DMEM), penicillin-streptomycin and foetal calf 
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serum were purchased by Invitrogen, Burlington, ON, Canada. MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide, thiazolyl blue 
tetrazolium bromide, RPMI medium and ultra-low attachment (ULA) 96-wells 
flat-bottom plates were supplied by Sigma- Aldrich St Louis, MA, USA. 
Colorimetric WST-1 test was obtained from Dojindo Europe, Germany. 
3.5.1.2 Preparation of doxorubicin base 
A saturated solution of Na2CO3 (1.4 g/mL) was added in deionized water Dox 
solution drop by drop. The precipitate was recovered by filtration and washed 
several times with cold deionised water. After drying, DoxB was stored at room 
temperature in the dark. 
3.5.1.3 Preparation of PLGA-PVP10:1, PLGA-PVP10:2 blank NPs and Dox-
or DoxB-loaded NPs 
Doxorubicin-loaded and blank nanoparticles were prepared using a solvent 
displacement method. Briefly, different amount of Dox or DoxB (1, 2 or 3 mg) 
were dissolved in benzyl alcohol (15 mg/mL) and added to a solution of 21 mg 
of PLGA-PVP10:1 (or PLGA-PVP10:2) in 800 μL 85:15 v/v acetone DMSO 
solution. This solution was drop-wise added to 7 mL of a 0.1 % (w/v) 
Pluronics F68 aqueous solution heated at 40°C under vigorous magnetic 
stirring. Following acetone was removed by 30 min of magnetic stirring and the 
suspension was kept under stirring overnight. Then the suspension was 
dialyzed against water using a dialysis tube with MW cut-off of 3500 for 1 h to 
remove any not encapsulated drug, benzyl alcohol and DMSO and lastly 
lyophilized.  
Blank nanoparticles were similarly prepared. A 70:30 v/v acetone/DMSO 
polymeric solution (21 mg in 400 μL) was dripped in a 0.1 % (w/v) Pluronics 
F68 aqueous solution under vigorous magnetic stirring at 40°C. The latter was 
stirred for 30 min to remove acetone and kept under stirring overnight to form 
nanoparticles and eventually lyophilized. 
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3.5.1.4 Physical-chemical characterization of NPs 
Particle size and polydispersion index (PDI) were determined by photon 
correlation spectroscopy (PCS), employing a 90 PLUS Particle Size Analyzer at 
a fixed angle of 90° and a temperature of 25 °C. The laser light (He/Ne) 
wavelength was 678 nm. Two drops of sample were diluted directly into the 
cuvette sample holder with previously filtered water. All determinations were 
carried out in triplicate and the results were expressed as the average diameter 
(expressed in nm) and PDI as measure of the distribution width. 
Differential scanning calorimetric (DSC) analyses were performed by a Mettler 
Toledo DSC823 (Mettler Toledo, Italy), equipped with the STAR Software and 
the FRS5 Mettler Toledo ceramic sensor. The instrument was calibrated with 
indium for melting point and heat of fusion. Tests were performed using 
standard aluminium pans with an empty pan as reference. Samples (5-10 mg) 
underwent a single heating step from 0 °C to 100 °C at 10 °C min-1 under 50 
mL min-1 nitrogen flow. 
Zeta potential measurements were determined using 90 PLUS Particle Size 
Analyzer. Nanoparticle solution was diluted with few drops of a 1 mM KCl 
solution. A minimum of five runs was obtained per sample. 
Transmission electron microscopy (TEM) analysis was performed using a 
Philips CM10 instrument. Nanoparticle solution was stained with a 2% 
solution of osmium tetraoxide. 
Optical microscopy analysis was carried out using a Motic AE 31inverted 
microscope equipped with Motic MHG – 100B using Ex D350/50x, DM 
400DCLP and BA D460/50m. Magnification LWD 600x. 
Osmolarity was measured using Semi-micro osmometer K-7400 with 
measuring head for glass vessels. 300 mOsmol solution of sodium chloride 
used for reference standard. 
The pH was determined at 25°C by a calibrated pH meter 420 A (Orion). 
3.5.1.5 Assay of doxorubicin loaded into NPs 
The doxorubicin loading within NPs was determined by HPLC. HPLC system 
consists of a Shimadzu LC-9A pump C equipped with a Cromopack 
fluorescence detector and a Kinetex® 5 µm EVO C 18 100 Å column (250 
×4.6 mm2). Methanol-acetonitrile-phosphate buffer solution (10:25:65 v/v/v) 
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was used as eluent, in which buffer was a 0.01 M pH=1.4 phosphate aqueous 
solution. The flow rate was 1.0 mL min-1. The column effluent was monitored 
at excitation and emission wavelengths of 480 and 560 nm, respectively.  
A known amount of freeze-dried nanoparticles was completely dissolved in 
DMSO solution and after diluted in HPLC eluent. Drug concentration was 
calculated from the area using a calibration curve previously established.  
For the calibration curve Dox was dissolved directly in HPLC eluent, DoxB 
was firstly dissolved in DMSO and after diluted with HPLC eluent. The 
experiment was performed in triplicate for both types of drugs.  
Drug loading (DL) was calculated on the percentage amount of drug present 
per mg of nanoparticles, as follows: 
 
       
                                                     
                      
              
(Equation 1) 
 
Encapsulation efficiency (EE) was calculated based on the percentage ratio of 
the amount of doxorubicin incorporated into nanoparticles with respect to the 
initial amount used, as follows: 
 
       
                          
                    
                   (Equation 2) 
3.5.1.6 In vitro release of doxorubicin from nanoparticles 
In vitro drug release studies were performed at two different pHs by using a 
physiological solution (0.9% NaCl, pH = 5.55) and phosphate buffer solution 
(0.1 M, pH = 7.40). 1 mL of Dox-loaded and DoxB-loaded nanoparticle 
suspensions (donor solutions) were kept in contact with 1 mL of physiological 
solution or buffer solution (receiver solutions) by a dialysis membrane with 
MW cut-off 12-14K. At specific time, the receiver solution was collected for 
analysis and replaced with fresh one. The amount of released doxorubicin was 
evaluated by HPLC as previously described.  
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3.5.1.7 Determination of bovine serum albumin (BSA) adsorption on NP 
surface  
Interactions of BSA with selected NPs were monitored using a UV visible 
spectrophotometer. Lyophilized blank NPs were suspended in water (1.6 
mg/mL) and diluted with a 10 mg/mL phosphate buffer BSA solution (0.1 M, 
pH = 7.4) in 20:80 volume ratio. Solution was stirred for 90 min, centrifuged 
(7500 rpm, 10 min) and then the supernatant was collected. The amount of 
BSA adsorbed on nanoparticles surface was evaluated using Uv-visible analysis 
at 278 nm taking into account the difference between BSA concentration 
present in the supernatant and a blank BSA solution at the same dilution. Each 
sample was assayed in triplicate. 
3.5.1.8 Cell and culture conditions  
4T1 (murine breast cancer), MDA-MB231 (human breast adenocarcinoma) and 
CRL-2335 (basal-like human breast carcinoma) cell lines were grown in culture 
dishes as a monolayer in DMEM supplemented with 10% penicillin-
streptomycin and 10% foetal calf serum in a humidified atmosphere with 5% 
CO2. 
3.5.1.9 Cell proliferation test  
MTT analysis was performed in 96-well plates incubated at 37 °C, 5% CO2, for 
72 h. Briefly, 1000 cells/well were seeded in 100 µL of complete medium and 
treated with different concentrations of Dox-loaded NPs (0.002-0.2 mM) and 
compared to those treated with blank NPs and free drug solutions at the same 
dilution. Subsequently, cells were supplemented with 11 µl of 5mg/ml thiazolyl 
blue tetrazolium bromide for 2 h. Later, the medium was removed and cells 
were lysed with 100 µl of DMSO. Absorbance was recorded at 570 nm by a 96-
well-plate reader (PerkinElmer, Waltham, MA, USA). 
3.5.1.10 Data analysis 
Data concerning inhibition percentage as function of drug concentration are 
reported as average ± experimental error. A statistical analysis was performed 
with GraphPad Prism 3.0 software (San Diego, CA, USA) using the one-way 
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ANOVA and Dunnett test. IC50 (half maximal inhibitory concentration) has 
been investigated using the two tailed unpaired T test with Welch correction. 
The significance cut-off was p-value below 0.05. 
3.5.1.11 Spheroids cultures  
The human HCC1806 Breast Carcinoma cell line was grown in RPMI medium 
supplemented with 10% foetal bovine serum (FBS), 1% L-glutamine and 1% 
penicillin-streptomycin.  
For spheroids formulation, at ∼80% confluence, monolayer cells were 
dissociated with trypsin-EDTA (Ethylenediaminetetraacetic acid) into single-
cell suspensions. The cells were then seeded on ultra-low attachment (ULA) 
96-wells flat-bottom plates, at different initial concentrations, starting from 
2500 to 50000 cells per well. Optimal seeding density was established such that 
HCC1806 spheroids fell within a size range of 200 to 500 µm in diameter on 
day 5. The initial concentration of 7500 cells/well was then considered 
appropriate for experimental studies.  
After treatments with the different drug formulations, morphology was 
analysed under light microscope and cell viability by colorimetric WST-1 test.  
3.5.2 RESULTS AND DISCUSSIONS: DOXORUBICIN LOADED 
NPs 
3.5.2.1 Blank nanoparticle preparation 
PLGA-PVP blank nanoparticles (PLGA-PVP Blk NPs) were successfully 
prepared using an solvent displacement method by dissolving copolymer (26 
mg/mL) in organic solvent mixture (85:15 %v/v acetone:DMSO) and 
precipitating it as nanoparticles in an aqueous phase, having 0.1% w/v 
Pluronics F68 as a stabilizer, at 40°C (Figure 3.3). PLGA blank nanoparticles 
were similarly prepared.  
This procedure was the result of a study performed for correlating the 
relationship between formulation parameters (namely, solvent composition, 
surfactant type and concentration, copolymer concentration, pH of aqueous 
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solution and temperature) and NP diameters. The collected data corresponding 
to PLGA-PVP10:1 and PLGA-PVP10:2 NPs are summarized in Tables 1 and 2. 
As results, NP size was highly influenced by solvent composition with a 
reduction of about 30 and 200 nm for PLGA-PVP10:1 and PLGA-PVP10:2, 
respectively, passing from pure acetone (DMC in Tables 3.1 and 3.2) to 
85:15%v/v acetone:DMSO solution. This reduction can be ascribed to the 
higher solubilisation of PVP portion copolymer in DMSO. Poly(vinylalcohol) 
(PVA), glycerol, glucose and Pluronics F68 (Plu) were chosen as preferred 
surfactants; among them, Plu gave the smallest NPs with both copolymers in 
comparison with those prepared with the other surfactants in the same 
experimental condition. In addition, Plu concentration in water has proven to 
slightly affect the size distribution of PLGA-PVP10:2 NPs, but highly influence 
those of PLGA-PVP10:1 NPs. In particular, PLGA-PVP10:1 precipitated in total 
absence of surfactant and formed particles of about 1 μm in presence of 
0.5%w/v Plu solution, instead of 166 nm using 0.1%w/v one. PLGA-PVP10:2 
was able to form NPs even in absence of surfactants with formation of a thin 
film close adherent to vial walls and 134 nm particles in presence of the more 
concentrated Plu solution, minimum (131 nm) was also in this case fulfilled in 
0.1%w/v solution. Finally, temperature of aqueous Plu solution influenced the 
rate of displacement and evaporation of solvents, resulting in a decreased NP 
diameter at 40°C instead of those obtained at room temperature, but 60°C 
heated solution favoured precipitation for both copolymeric compositions. 
High-pressure homogenizer was not able to a further reduction of NPs, 
conversely 426 and 335 nm were the final diameters of PLGA-PVP10:1 and 
PLGA-PVP10:2 NPs, respectively, after 30 min of treatment. 
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Figure 3.3. Preparation of PLGA-PVP Blk NPs and DoxB loaded and Dox 
loaded NPs by solvent displacement method. Chemical structure of Dox and 
DoxB. 







Size (nm) PDI 
10 DMC/ 200 Plu 0.1 / 5 222.2 ± 1.4 0.043 ± 0.013 
10 DMC/ 200 Glycerol 2.4 / 5 280.6 ± 6.9 0.061 ± 0.029 
10a DMC/ 400 Plu 0.1 / 7 107.8 ± 0.9 0.153 ± 0.017 
10b DMC/ 400 Plu 0.1 / 7 109.3 ± 1.8 0.148 ± 0.021 
21 DMC/ 800 Plu 0.1 / 7 210.4 ± 2.1 0.125 ± 0.016 
21 DMC/ 800 PVA 0.3 / 7 216.0 ± 3.3 0.064 ± 0.013 
21 DMSO:DMC 1:2/800 Plu 0.1 / 7 184.1 ± 5.9 0.061 ± 0.028 
21c DMSO:DMC 1:2/800 Plu 0.1 / 7 426.4 ± 15.7 0.194 ± 0.031 
21d DMSO:DMC 1:10/800 Plu 0.1 / 7 181.4 ± 6.1 0,105 ± 0,024 
21d DMSO:DMC 15:85/800 Plu 0.1 / 7 166.7 ± 0.8 0.115 ± 0.028 
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21d DMSO:DMC 15:85/800 Plu 0.5 / 7 897.3 ± 28.7 0.086 ± 0.046 
21d DMSO:DMC 15:85/800 only water/ 7 precipitate -- 
21d DMSO:DMC 15:85/800 NaCl 0.9 / 7 precipitate -- 
21d DMSO:DMC 15:85/800 Glucose 5 / 7 260.4 ± 9,7 0.142 ± 0.043 
21e DMSO:DMC 15:85/800 Plu 0.1 / 7 304.9 ± 7.5 0.231± 0.051 
a) Dialysis against water milliQ; b) dialysis against 0.01M PBS buffer solution at 
pH=7.4; c) after 30 minutes of high pressure homogenization; d) temperature= 
40°C; e) temperature= 60°C.  







Size (nm) PDI 
10 DMC/200 Plu 0.1 / 5 363.9 ± 4.2 0.141 ± 0.013 
10 DMC/200 Glycerol 2.4 / 5 348.4 ± 10.7 0.238 ± 0.032 
10a DMC/400 Plu 0.1 / 7 216.0 ± 15.2 0.286 ± 0.011 
10b DMC/ 400 Plu 0.1 / 7 239.5 ± 2.5 0.274 ±0.001 
21 DMC/ 400 Plu 0.1 / 7 318.1 ± 4.7 0.105 ± 0.039 
21 DMC/ 400 PVA 0.3 / 7 329.2 ± 6.9 0.152 ± 0.022 
21 DMSO:DMC 1:1/400 Plu 0.1 / 7 168.0 ± 2.6 0.115 ± 0.028 
21c DMSO:DMC 1:1/400 Plu 0.1 / 7 335.6 ± 3.2 0.098 ± 0.047 
21d DMSO:DMC 2:8/400 Plu 0.1 / 7 160.4 ± 1.7 0.093 ± 0.039 
21d DMSO:DMC 3:7/400 Plu 0.1 / 7 161.7 ± 0.6 0.064 ± 0.008 
21d DMSO:DMC 3:7/400 Plu 0.5 / 7 164.0 ± 2.0 0.066 ± 0.022 
21d DMSO:DMC 3:7/400 only water/ 7 166.2 ± 1.0 0.046 ± 0.023 
21d DMSO:DMC 3:7/400 NaCl 0.9 / 7 187.9 ± 5.2 0.034 ± 0.029 
21d DMSO:DMC 3:7/400 Glucose 5 / 7 204.4 ± 6.8 0.068 ± 0.019 
21e DMSO:DMC 3:7/400 Plu 0.1 / 7 153.4 ± 2.9 0.157 ± 0.042 
a) Dialysis against water MilliQ; b) dialysis against 0.01M PBS buffer solution at 
pH=7.4; c) after 30 minutes of high pressure homogenization; d) temperature= 
40°C; e) temperature= 60°C. 
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3.5.2.2 Drug loaded nanoparticle preparation and drug assay 
Next step was the preparation of PLGA-PVP NPs loaded with doxorubicin 
hydrochloride salt (Dox) and doxorubicin free base (DoxB). Several water 
miscible solvents (namely, acetone, methanol, ethanol, N-methylpyrrolidone, 
and benzyl alcohol) were tested to solubilise drugs. In detail, both forms of 
doxorubicin have proven to be practically insoluble in acetone. Methanol and 
ethanol were not compatible with copolymers causing their partial 
precipitation. When drugs are solubilised in N-methylpyrrolidone and 
subsequently added to copolymer, a clear solution was obtained. Unfortunately, 
this solution became a microemulsion when dripped in water. At the end, 
benzyl alcohol has proven as the best drug solvent; indeed, 15 mg/mL Dox 
and DoxB solutions in benzyl alcohol were prepared and separately added to 
copolymeric acetone/DMSO ones giving a transparent orange and red 
solutions, respectively. These recipes were slowly added to a 0.1% Plu aqueous 
solution in order to formulate drug-loaded NPs. 
In order to assess the drug loading percentage (D.L.%) and encapsulation 
efficiency percentage (E.E. %), three drug loadings (1, 2 or 3 mg) were tested 
for each copolymer composition and drug. To this aim, samples were dialyzed, 
lyophilised and analysed by HPLC. 
As reported in Table 3.3, D.L. % of Dox was found to be between 0.73 and 
3.32% w/w depending on copolymer type, resulting in a E.E. % ranged 
between 21.16 and 55.89% w/w. PLGA-PVP10:2 always showed at least one 
percentage point more than PLGA-PVP10:1 regardless of initial Dox amount. 
This finding can be attributed to the enhanced hydrophilicity of the PLGA-
PVP10:2 copolymer, resulting to a higher affinity with hydrophilic Dox. On the 
other hand, in the case of DoxB, D.L. % varied from 0.11 to 3.20 % w/w and 
E.E.% from 19.11 to 36.24 % w/w. Save for 1mg case, in all other ones, 
PLGA-PVP10:1 showed a better affinity with DoxB than PLGA-PVP10:2. 
For comparison, Dox- and DoxB- loaded PLGA NPs and blank PLGA NPs 
were similarly prepared as control. 3 mg of initial amounts of drugs were used. 
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Really low D.L. % and E.E.% were obtained for Dox-loaded PLGA NPs, 
instead of DoxB loaded PLGA NPs that showed the greater D.L.% value 
(3.69%) among others. 
 
Table 3.3. Drug loading percentage and encapsulation efficacy varying 
doxorubicin amount initially added in solution.  
Sample 
Doxorubicin 
 initial amount (mg) 
D.L. % (w/w) E.E %(w/w) 
Dox-PLGA-PVP10:1 NPs 
1 0.73 21.2 
2 1.67 22.6 
3 2.55 21.3 
Dox-PLGA-PVP10:2 NPs  
1 1.93 55.9 
2 2.76 38.7 
3 3.32 30.9 
DoxB-PLGA-PVP10:1 NPs 
1 1.14 33.0 
2 1.30 21.5 
3 2.27 24.2 
DoxB-PLGA-PVP10:2 NPs 
1 0.65 19.1 
2 1.36 21.2 
3 3.20 36.2 
Dox-PLGA NPs 3 0.06 4.13 
DoxB-PLGA NPs 3 3.69 24.0 
Physical state of the drug in PLGA-PVP NPs were investigated by DSC. 
Thermograms of Dox, DoxB, copolymers alone, Plu, black NPs, and drug-
loaded NPs were depicted in Figure 3.4 (Panel A-C). In blank NP 
thermograms an endothermic peak is present at 40-55°C corresponding to Plu 
melting point that partially covered PLGA glass transition temperature ranged 
at 45-53°C in copolymer thermograms. In all, PVP glass transition temperature 
was not visible. Dox exhibited a single endothermic melting peak at 236°C with 
onset at 180°C. DoxB showed an exothermic peak at 220°C with onset at 
170°C, due to its degradation. 
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Figure 3.4. DSC thermograms of A) copolymers alone, pluronics, black 
PLGA-PVP NPs B) DoxB free and DoxB-loaded PLGA-PVP NPs and C) Dox 
free and Dox-loaded NPs. 
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In DSC thermograms of Dox-loaded and DoxB-loaded PLGA-PVP NPs, Dox 
melting peak disappeared, as well as the degradation one of DoxB, regardless to 
them initial loading. In addition, Plu melting point was always present. This 
indicated the absence of drug free in the delivery system and, thus, it was 
totally incorporated inside nanoparticles. Therefore, 3 mg of Dox and DoxB 
were subsequently used as the standard concentration to prepare drug-loaded 
NPs.  
3.5.2.3 Characterization of PLGA-PVP NPs 
The physicochemical properties of NPs, in terms of their average diameter, 
polydispersity index, ζ potential, morphology, pH and osmolarity were 
evaluated and listed in Table 3.4 and Figure 3.5 and 3.6. The effect drug 
incorporation on such properties was also studied by comparing the results 
obtained with those for blank NPs, whose size and polydispersity index are 
also reported in order to facilitate result interpretation.  
With respect to particle size analysis, all prepared PLGA-PVP systems were 
nanometric (average diameter <500 nm) and exhibited a narrow size 
distribution (polydispersity index <0.2). Freshly prepared blank NP 
suspensions showed unimodal size distribution having the average values in the 
range of 160 - 170 nm (Figure 3.6). PLGA Blk NPs similarly prepared had 
greater dimensions than PLGA-PVP ones and showed an aggregate at 5 μm. 
Thus, a downtrend in the particle size was observed as PVP content in 
copolymer increased. Lyophilized PLGA-PVP blank NP formulations showed 
larger particle size in the range of 300-450 nm compared to freshly prepared 
particles; lyophilisation process might induced particle aggregation. NP size 
after freeze-dry indicates that either a cryoprotectant or sonication is needed 
for maintaining the original size of the particle suspension. Sonicating for 10 
min of a suspension of lyophilized NPs in MilliQ water was successfully able to 
break the aggregate and reduce the size of the particles to almost its original 








Table 3.4. Physiochemical characterisation of PLGA-PVP NP and PLGA NP 
suspensions. 






PLGA-PVP10:1 Blk 166.7 ± 0.8 0.115 ± 0.028 -28.71 ± 2.28 4.26 320 
After 
lyophilisation 
450.3 ± 10.2 0.136 ± 0.026 N.E. N.E. N.E. 
After sonication 175.9 ± 5.6 0.125 ± 0.012 N.E. N.E. N.E. 
PLGA-PVP10:1 Dox 406.2 ± 2.09 0.053 ± 0.037 -12.33 ± 2.77 4.76 302 
PLGA-PVP10:1 
DoxB 
223.1 ± 15.5 0.162 ± 0.006 -20.12 ± 2.76 4.96 327 
PLGA-PVP10:2 Blk 161.7 ± 0.6 0.064 ± 0.008 -17.03 ± 2.50 4.10 318 
After 
lyophilisation 
312.7 ± 6.4 0.067 ± 0.023 N.E. N.E. N.E. 
After sonication 172.0 ± 2.3 0.103 ± 0.056 N.E. N.E. N.E. 
PLGA-PVP10:2 Dox 180.9 ± 2.8 0.065 ± 0.031 -9.88 ± 4.20 4.64 254 
PLGA-PVP10:2 
DoxB 
196.4 ± 9.4 0.121 ± 0.027 -12.56 ± 2.30 4.69 347 
PLGA Blk 240.1 ± 2.0 0.146 ± 0.026 -39.09 ± 5.40 5.09 201 
PLGA Dox 860.9 ±162.4 0.005 ± 0.003 -37.26 ± 2.61 5.82 365 
PLGA DoxB 183.3 ± 8.4 0.197 ±0.018 -40.74 ± 4.10 5.40 446 
Blk = Blank; N.E. Not evaluated 
 
Figure 3.5. Size distribution by DLS of NPs before and after lyophilisation. 
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The drug addition to the formulations caused an increase of polymer particle 
size; despite this, such increase is considered acceptable for parenteral use. Its 
extent was affected by copolymer composition and drug form. With both 
drugs, PLGA-PVP10:1 copolymer formed nanoparticles in solution always 
greater than those obtained using PLGA-PVP10:2. This finding may be 
explained taking into account that a higher copolymer amount and relative 
higher PVP density are required by the system in order to completely cover all 
nanoparticles. PLGA-PVP copolymers formed NPs having different size in 
relation to the PVP content and drug form: indeed, PLGA-PVP10:1 generated 
smaller NPs with the DoxB, while the PLGA-PVP10:2 with the Dox, 
accordingly to the drug hydrophilicity. The significant increment occurred in 
the case of Dox-loaded PLGA-PVP10:1 NPs (three times respect to the 
reference, blank NPs), is likely due to a substantial change in their form, not 
observed elsewhere. In order to confirm this hypothesis, DLS data were 
supplemented with TEM observations (Figure 3.7). Dox-loaded PLGA-PVP10:1 
NPs showed rod-like morphologies with diagonals of 510 and 70 nm, 
respectively. Conversely, the other NPs exhibited approximately spherical 
morphologies with diameters consistent to those assessed by DLS. 
  
Figure 3.6. TEM images of a) Blk-PLGA- PVP10:1 NPs; b) Dox-loaded 
PLGA- PVP10:1 NPs; c) DoxB-loaded PLGA- PVP10:1 NPs; d) Blk-PLGA- 
PVP10:2 NPs; e) Dox-loaded PLGA- PVP10:2 NPs; f) DoxB-loaded PLGA- 
PVP10:2 NPs. 
For a suspension system, zeta potential is an important index that reflects the 
intensity of repulsive forces among particles and the dispersion stability. Higher 
zeta potential modulus corresponds to higher repulsive forces.  
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Zeta potential of nanoparticles was negative due to the presence of terminal 
carboxylic groups in copolymers. Blank PLGA-PVP NPs zeta potential values 
ranged between −29 and −17 mV (PLGA-PVP10:1 and PLGA-PVP10:2, 
respectively) and were less negative than PLGA ones, namely, -39.9 mV. 
Probably, the lower negative value was due to the higher PVP density of 
copolymers, absent in PLGA NPs. The possibility that Plu chains on NP 
surface can also played a role in masking the surface charge of PLGA was also 
evaluated. No significant differences in the zeta potential values of PLGA NPs 
found in this work and typical ones reported in the literature (-40 mV) were 
observed. This showed that the residual Plu on the NP surface did not affect 
the real contribution of PVP density to surface charge reduction, hence surface 
properties of particles were only due to copolymer composition. The presence 
of Dox and DoxB in NPs always reduced the negative zeta potential value; 
probably, there was an additional masking effect of the superficial carboxylic 
groups by the drug in proximity of surface. This effect was intensified in the 
case of Dox due to the positive charge of quaternary ammonium group. 
In order to determine whether nanoparticle suspensions may be incubated in 
cell cultures, pH and osmolarity were measured. The pH values of all 
suspensions were acidic, probably due to PVP protonation in water, ranging 
from 4.1 to 5.8. The osmolarity of PLGA-PVP suspensions were close to the 
isotonicity value (300 mOsmol), instead of PLGA suspensions that resulted 
ipertonic and, thus, requiring dilution. In conclusion, PLGA-PVP NP 
suspensions could be injected and kept in contact with cell cultures without 
further modifications. By this way, these systems were proven suitable for in-
vitro tests. 
3.5.2.4 In vitro drug release 
It is well documented that the extracellular pH of tumours is slightly more 
acidic than the blood and normal tissue.cxix In addition, hypothesizing that 
nanoparticles are taken up by cells via an endocytosis process, pH drops to 5.5-
6.0 in endosomes and approaches pH 4.5-5.0 in lysosomes.cxx 
Therefore, in vitro release studies were performed in PBS (0.01 M, pH 7.4) and 
in physiological solutions (NaCl 0.9 %, pH 5.5) in order to evaluate the release 
kinetic of Dox or DoxB loaded NPs at the two different pHs. The cumulative 
release of drugs is shown in Figure 3.7. In Figure 3.8, release over 6 hours of 
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both drugs from Dox- and DoxB-loaded PLGA NPs is reported. For all kinds 
of nanoparticles, the drug release followed a two-phase kinetics. In the first 
phase, the amount of drug released rapidly increases (burst effect). The second 
phase corresponds to a pseudo steady-state for which the release rate is 
constant and very slow.  
 
Figure 3.7. In vitro release profile of drug loaded in PLGA-PVP nanoparticles 
at different pHs. 
 


























Doxo Base - PBS 5.5 Doxo Base - PBS 7.4
Doxo HCl - PBS 5.5 Doxo HCl - PBS 7.4
PLGA-DoxB pH=5.5                 PLGA-DoxB pH=7.4
PLGA-Dox pH= .5                  PLGA-Dox pH= 7.4
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At pH 7.4 both drugs were released in a lesser extent from different PLGA-
PVP and PLGA NPs compared to those studied at pH 5.5. Specifically, within 
6 h only about 10 - 20% of the doxorubicin was released; after 24 h the release 
rose to 25% as maximum, in the case  of PLGA-PVP NPs. Lower amounts of 
drug released were detected, increasing PVP grating densities onto PLGA. PVP 
chains are easily oriented towards the NP surface, leading to effective surface 
coverage in the case of PLGA-PVP NPs, thus reducing the premature 
diffusion of drug towards the buffer aqueous phase. This might indicate the 
ability of the PLGA-PVP NP formulation to efficiently entrap and control 
Dox and DoxB release over a prolonged period of circulation time, enough to 
reach tumour cells.  
At pH 5.5, release percentage ranged between 30 and 65 % after 6 h for 
PLGA-PVP NPs, instead of 15-55 % in the case of PLGA NPs. The high 
extent of drug release was obtained in the case of DoxB-loaded PLGA-PVP10:2 
NPs, in opposition to DoxB-loaded PLGA NPs that released only the 15% of 
total amount of encapsulated drug. Other drug-loaded NPs had intermediate 
trend. 
In literature, several mathematical models were developed in order to 
investigate the mechanism of drug release from 
nanoparticles/microparticles.cxxi The drug release depends on: i) adsorption or 
diffusion through the NP matrix, ii) particle erosion, iii) a combined erosion 
and diffusion process and iv) polymer degradation (chemical or enzymatic 
hydrolysis). The application of the correct mathematical model allowed for 
having informations about the release rate and mechanisms of drug 
release.cxxii,cxxiii  
To study the mechanism of doxorubicin release from PLGA-PVP NPs, five 
mathematical models were taken in consideration: zero-order (F=kt)cxxiv, first-
order (ln(1-F)= -kt)cxxv, Higuchi´s model (F=kt1/2)cxxvi, Hixon-Crowell´s model 
(1-(1-F)1/3= kt)cxxvii and Korsmeyer-Peppas model, or “the power law”, 
(F=ktn)cxxviii. The squared correlation coefficients (R2) and slope (rate constant, 
k) obtained after linear regression by mathematical models considering drug 
release fraction (F) and time (t), as respectively y and x variables, are listed in 
Table 3.5.  
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In zero-order model, drug release would be directly proportional at time and 
totally independent of drug concentration; this means that release proceeds 
until the drug is totally consumed. Zero order release is typical of several types 
of delivery systems loaded with drugs with low solubility in water.cvliii In a first-
order process, the rate of diffusion is directly proportional to concentration of 
the drug. First-order model describes the release profile from the delivery 
systems containing hydrophilic drugs dispersed in porous matrices.cxxix Hixon-
Crowell model can be applied to the delivery systems whose drug release rate is 
proportional to the surface area of the system such as the erosion-dependent 
release systems. This model is used to describe the release profile keeping in 
mind the surface of the drug particles is diminished during the drug 
dissolution. 
Using these three models to fit release curve of doxorubicin from PLGA-PVP 
NPs, the obtained squared correlation coefficients, that indicates how much 
the regression equation truly represent the set of data, is low. In particular, R2 
obtained with the zero-order model was ranged between 0.6 and 0.7. First-
order kinetics gave a R2 of 0.6-0.8. Hixson-Crowell’s cube root model provided 
a R2 of 0.6-0.8. Hence, these models cannot be used for describing the release 
from PLGA-PVP systems. A possible explanation was that DoxB solubility in 
water is higher than the released amounts from NPs, thus it not represents the 
only threshold to diffusion of drug. In addition, PLGA-PVP NPs had not a 
porous matrix and this matrix were not prone to erosion, at least in the time 
interval of analysis. 
Table 3.5. Squared correlation coefficient (R2) and coefficients obtained after 
linear regression of the release data utilizing mathematical models for all drug-
loaded PLGA-PVP NPs. 
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St.Error =Standard error 
Higuchi´s model provided the highest values of R2 (0.8 to 0.97). Higuchi’s 
model has been based on the Fick’s Law, where the release occurs by the 
diffusion of drugs within the delivery system. In this case, the cumulative 
released amount of the drug is proportional at square root of time. Under some 
experimental conditions, the release mechanism can deviate from Fickian 
diffusion, following an anomalous transport (no-Fickian release). In these 
Sample 
Mathematical model (Part A) 
F=kt ln(1-F)=-kt F=kt1/2 
k R2 k R2 k R2 
Value St.Error Value St.Error Value St.Error 
PLGA-g-PVP10:1- Dox pH 5.5 0.028 0.004 0.776 0.040 0.005 0.841 0.130 0.007 0.957 
PLGA-g-PVP10:2-Dox pH 5.5 0.021 0.003 0.799 0.027 0.003 0.849 0.099 0.004 0.974 
PLGA-g-PVP10:1- DoxB pH 5.5 0.033 0.007 0.618 0.051 0.009 0.706 0.166 0.016 0.887 
PLGA-g-PVP10:2-DoxB pH 5.5 0.037 0.007 0.639 0.062 0.010 0.735 0.182 0.016 0.898 
PLGA-g-PVP10:1- Dox pH 7.4 0.013 0.002 0.659 0.015 0.003 0.685 0.065 0.005 0.911 
PLGA-g-PVP10:2-Dox pH 7.4 0.010 0.002 0.670 0.011 0.002 0.688 0.047 0.004 0.917 
PLGA-g-PVP10:1- DoxB pH 7.4 0.010 0.002 0.686 0.011 0.002 0.705 0.050 0.004 0.925 
PLGA-g-PVP10:2-DoxB pH 7.4 0.008 0.001 0.711 0.009 0.001 0.725 0.038 0.003 0.935 
Sample 
Mathematical model (Part B) 
1-(1-F)1/3=kt F=ktn 
R2 k R2 k n R2 
Value St.Error Value St.Error Value St.Error 
PLGA-g-PVP10:1- Dox pH 5.5 0.957 0.012 0.001 0.820 0.168 0.906 0.402 0.046 0.906 
PLGA-g-PVP10:2-Dox pH 5.5 0.974 0.008 0.001 0.833 0.128 0.955 0.400 0.030 0.955 
PLGA-g-PVP10:1- DoxB pH 5.5 0.887 0.015 0.003 0.676 0.309 0.874 0.254 0.031 0.874 
PLGA-g-PVP10:2-DoxB pH 5.5 0.898 0.017 0.003 0.701 0.319 0.859 0.280 0.037 0.859 
PLGA-g-PVP10:1- Dox pH 7.4 0.911 0.005 0.001 0.676 0.113 0.903 0.281 0.030 0.903 
PLGA-g-PVP10:2-Dox pH 7.4 0.917 0.003 0.001 0.682 0.080 0.895 0.294 0.033 0.895 
PLGA-g-PVP10:1- DoxB pH 7.4 0.925 0.004 0.001 0.699 0.081 0.900 0.308 0.034 0.900 
PLGA-g-PVP10:2-DoxB pH 7.4 0.935 0.003 0.000 0.720 0.058 0.895 0.335 0.039 0.895 
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cases, Korsmeier-Peppas model based on a more generic equation can be used. 
This mathematical model relates the exponential drug release versus the elapsed 
time. The model used the release exponent (n) in order to characterize 
different release mechanism. If the n value is 0.5 or less, as in PLGA-PVP NPs 
cases, the release mechanism follow Fickian diffusion (Higuchi model), and 
higher values 0.5 < n < 1 for mass transfer follow a non-Fickian model 
denominates anomalous transport.cxlii 
Thus results obtained with the Korsmeyer-Peppas model corroborated the data 
obtained with the Higuchi model. The result suggests that the release of 
doxorubicin from PLGA-PVP NPs is controlled only by diffusion.  
3.5.2.5 Plasma protein adsorption 
Phagocytosis is mainly initiated by the attachment of the foreign nanoparticles 
to the surface receptors of the phagocytic cells.cxxx This phenomenon, leading 
to nanoparticle elimination, is facilitated by the adsorption of plasma proteins 
to the particle surface.cxxxi Therefore, possibility of plasma protein adsorption 
onto the NP surface was investigated and also the influence of different 
copolymeric matrix on it. Bovine serum albumin (BSA) is the most abundant 
protein in serum and for this reason was chosen for plasma protein adsorption 
study.  
To estimate the potential interaction of BSA with nanoparticles, blank NPs 
were incubated with BSA (10 mg/mL in PBS) under physiological conditions 
for 1 hour, subsequently centrifuged at 7500 rpm for 10 min and supernatant 
recovered. UV-visible spectroscopy at 500 nm was used to determine percent 
adsorbed BSA on PLGA-PVP blank NPs. PLGA blank NPs was also included 
for comparison. Collected data are reported in Table 3.6. As expected, the level 
of protein adsorption gradually reduced along with the density of PVP chain in 
the copolymers. PLGA-PVP10:2 blank NPs did not practically interact with 
BSA molecules. While PLGA showed a clear BSA adsorption tendency with 
average value of about 80%. 
Table 6: Percentage of bovine serum albumin (BSA) adsorbed on PLGA-PVP 
blank NPs and PLGA blank NPs after incubation with BSA physiological 
solution. 
CHAPTER 3 




Sample Percentage of BSA adsorbed 
PLGA Blk NPs 81.6 ± 2.5 
PLGA-PVP10:1 Blk NPs 25.0 ± 2.4 
PLGA-PVP10:2 Blk NPs 3.87 ± 1.6 
3.5.2.6 Proliferation cell inhibition in vitro. 
To test the response of cells to both Dox and DoxB loaded NPs, cell viability 
was assessed by MTT assay, after an exposure of 72 h, and compared with 
blank NPs and free drugs. Figure 3.9, 3.10 and 3.11 show the inhibition of 
MDA-MB-231 cells induced by drug loaded PLGA-PVP and PLGA 
formulations. In general, Dox was more ablative against tumour cell respect of 
DoxB. This trend was confirmed in drug loaded NPs. Analyses revealed for all 
that inhibition trend was dose dependent. Inhibition of 30-35% was reached in 
cases of DoxB-loaded PLGA and PLGA-PVP NPs, in contrast with the only 
7% of free drug, at 0.2 M concentration. A maximum of activity was reached 
by DoxB-loaded PLGA NPs.  
A significant difference in inhibition between Dox-loaded PLGA-PVP10:2 NPs 
and drug in free form was evident at all concentrations used. In particular in 
the case of 0.02 μM, Dox-loaded PLGA-PVP10:2 NPs showed a high inhibition 
of vitality, more than 75%, instead of Dox free showed a moderate inhibition 
of vitality, less than 45%. At same concentration, Dox-loaded PLGA-PVP10:2 
NPs was significantly more ablative also respect to Dox-loaded PLGA-PVP10:1 
NPs and Dox-loaded PLGA NPs that showed an inhibition trend and values 
similar to those explicated by Dox in free form. The blank NPs did not show 
any toxicity even at highest doses, and the MTT values were similar to those 
obtained in untreated cells (data not shown).  
To confirm efficacy of Dox-loaded PLGA-PVP NPs against tumour cells, 
human breast cancer cell line, namely 4T1 and CRL-2335 cell lines, were 
incubated with NPs and viability by MTT test evaluated (Figure 3.12 and 3.13). 
As previously reported, blank NPs did not explicated toxicity against cells at 
any concentrations. The inhibition effect was concentration dependent with 
some differences between the two cell lines and substances. Dox free form 
presented a percent inhibition of 70 and 65 % respectively against 4T1 and 
CRL-2335 cells at 0.2 μM. Similarly, Dox-loaded PLGA-PVP10:1 NPs showed 
an inhibition percentage respectively of 50 and 70 %, while PLGA-PVP10:2 
ones had an inhibition values of 85 and 80 %. At a dose 10 time lower, 
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inhibition by Dox free form turned down to 30 and 10 % and by Dox- loaded 
PLGA-PVP10:1 NPs to 15 and 20 %, instead of Dox-loaded PLGA-PVP10:2 
NPs that kept at high level inhibition, 65 and 70 %.  
 
Figure 3.9. Inhibition percentage of DoxB free and loaded in PLGA-PVP NPs 
on MDA-MB-231 cell line. 
 
Figure 3.10. Inhibition percentage of Dox and DoxB free and loaded in PLGA 
NPs on MDA-MB-231 cell line. 
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Figure 3.11. Inhibition percentage of Dox free and loaded in PLGA-PVP NPs 
on MDA-MB-231 cell line. 
 
Figure 3.12. Inhibition percentage of Dox free and loaded in PLGA-PVP NPs 
on 4T1 cell line. 
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Figure 3.13. Inhibition percentage of Dox free and loaded in PLGA-PVP NPs 
on CRL-2335 cell line. 
3.5.2.7 Viability of PLGA-PVP10:2 NPs on spheroid cultures 
3D cell culture spheroids, present a powerful alternative to standard 2D cell 
culture for in vitro studies.cxxxii The 3D spheroid model is particularly useful to 
mimic solid-tumours from a physiologically relevant architectural perspective. 
For this reason, spheroid cultures of human breast cancer (HCC1906) cells 
were used to test viability of PLGA-PVP10:2 NPs, that gave in 2D in vitro tests 
the best performance when loaded with Dox. HCC1906 was treated with blank 
PLGA-PVP10:2 NPs, at different dilution, at day 5 from the seeding in ULA 
plates. After 72h of treatment, morphology was checked (Figure 3.14). No 
significant changes were observed even in the spheroid cultures treated with 
the highest quantity of blank PLGA-PVP10:2 NPs. 
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Figure 3.14. Spheroid cultures of HCC1906 cells treated with blank PLGA-
PVP10:2 NPs, at different dilution a) Control; b) dilution 1:100; c) dilution 
1:1000; d) dilution 1:10000. 
3.5.3 CONCLUSION: DOXORUBICIN 
In conclusion, results obtained in the present study showed that PLGA-PVP 
copolymers could be used to prepare stable nanoparticles loaded with 
doxorubicin in base and salt forms, using a solvent displacement technique. 
Blank NPs had small dimension, 160 - 170 nm and spheroidal shape as 
evidenced by DLS and TEM respectively. Drug encapsulation led to an 
increase of size and in the case PLGA-PVP10:1 a change in morphology, which 
showed a rod-like particles. Increasing initial amount of drug, in all prepared 
formulation an increase of drug loading was evidenced reaching values higher 
than 3 %. All particles presented a negative charged surface, probably due to 
carboxylic acid end-group of PLGA. Increasing PVP amount in copolymers, 
zeta potential values increase, leading to less negative surface; similar trend was 
evidenced also in the case of drug-loaded NPs. In particular Dox-loaded NPs 
had always lower negative surface than DoxB-loaded ones. pH and osmolarity 
measurements confirmed the presence cell compatible solutions. BSA 
adsorption on PLGA-PVP NP surface was meaningfully reduced respect of 
PLGA NP one, indicating that were stealth nanoparticles. Data clearly 
indicated a lower inclination of PLGA-PVP NPs for opsonization 
phenomenon, ensuring a prolonged in circulation half-life compared to PLGA 
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NPs one. Release studies of both drugs at pH 7.4 showed a doxorubicin 
retention by PLGA-PVP NPs during 24 h. An initial burst release and then 
sustained release phase were conversely typical trend at pH 5.5. At both pHs 
and for all studied systems, Higuchi kinetic model well-fitted release data 
indicating that diffusion was the principle mechanism involved. The 
cytotoxicity against MDA-MB 231 cell line of DoxB-loaded NPs was slightly 
lower than that of Dox ones and for this reason they were not further 
investigated. MTT assays on MDA-MB 231 together with 4T1 and CRL-2335 
cell lines evidenced that Dox-loaded PLGA-PVP10:2 NPs highly affected cancer 
cell proliferation, allowed an inhibition activity of about 65-95 % at 0.02M. At 
the same concentration, Dox free inhibited proliferation of only 25% of treated 
cells. Thus, it can be concluded that Dox-loaded PLGA-PVP10:2 NPs were 
capable of providing an efficient anticancer activity. In addition, in all 
considered cases blank PLGA-PVP NPs were safe and this result was 
confirmed by incubation with 3D spheroid cultures. 
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3.6 ANTIMALARIAL PROJECTS EXPERIMENTAL PART 
3.6.1 METHODS 
3.6.1.1 Materials and Instruments 
PLGA-PVP10:1 and PLGA-PVP20:1 were prepared according to the procedure 
reported in Chapter 2, Paragraphs 2.3.4.1. Epikuron® 200 (soya 
phosphatidylcholine 95%) was purchased by Degussa GmbH, Hamburg, 
Germany. Mygliol® 812 (medium-chain triglycerides containing 57% caprylic 
acid (C8), 41.4% capric acid (C10) and 0.6% lauric acid (C12))was purchased 
from Cremer Oleo division (Hamburg, Germany). Pluronics F68, Tween 80, 
isopropyl myristate, dioctyl sulfosuccinate sodium salt (DOSS) and other 
chemicals and solvents were supplied by Sigma- Aldrich (Italy) at reagent grade 
and used without further purifications. Artemisinin (Art) was purchased from 
Tocris Bioscience (United Kingdom) and Curcumin (Cur) from Sigma-Aldrich 
(Spain). Ultra-Turrax SG215 homogenizer was from IKA Staufen, Germany. 
High pressure homogenizer was Emulsiflex C5 by Avestin, Canada. For 
biological tests, 96 well plates and Gibco™ RPMI 1640 Complete Medium 
were bought from Thermo Fisher Scientific, 0.2 M L-glutamine solution, 
phosphate buffered saline (PBS) powder and Triton™ X-100 from Sigma-
Aldrich (Spain), SYTO® 11 Green Fluorescent Nucleic Acid Stain from Life 
Technologies by Thermo Fisher Scientific.  
Particle size and polydispersion index (PDI) were determined by photon 
correlation spectroscopy (PCS), employing a 90 PLUS Particle Size Analyzer at 
a fixed angle of 90° and a temperature of 25 °C. The laser light (He/Ne) 
wavelength was 678 nm. Two drops of sample were diluted directly into the 
cuvette sample holder with previously filtered water. All determinations were 
carried out in triplicate and the results were expressed as the average diameter 
(expressed in nm) and PDI as measure of the distribution width. 
Zeta potential measurements were determined using 90 PLUS Particle Size 
Analyzer. Nanoparticle solution was diluted with few drops of a 1 mM KCl 
solution. A minimum of five runs was obtained per sample. 
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Transmission electron microscopy (TEM) analysis was performed using a 
Philips CM10 instrument. Nanoparticle solution was stained with a 2% 
solution of osmium tetraoxide. 
Optical microscopy analysis was carried out using a Motic AE 31inverted 
microscope equipped with Motic MHG - 100B using Ex D350/50x, DM 
400DCLP and BA D460/50m. Magnification LWD 600x. 
Osmolarity was measured using Semi-micro osmometer K-7400 with 
measuring head for glass vessels. 300 mOsmol solution of sodium chloride 
used for reference standard. 
3.6.1.2 Formulation of drug loaded and blank nanocapsules 
7.0 mg of artemisinin or curcumin and 70.0 mg of Epikuron 200 were 
dissolved in 220.0 mg di Tween 80 in presence of 300 µL of decanol and 300 
μL isopropyl miristate under stirring at room temperature. Ultrafiltered water 
(10 mL) was added under vigorous stirring allowing to a milky mixture. This 
emulsion was dispersed for 5 minutes by Ultra-Turrax at 30000 rpm and for 1 
hour by a high pressure homogenizer. 3.5 mL of each emulsion were putted in 
a 10 mL flask at 40°C and under vigorous magnetic stirring 400 μL of 15 
mg/mL (15:75 v/v) DMSO/Acetone PLGA-PVP10:1 or PLGA-PVP10:2 
solution was drop-wise added into. After 3 hours, drug loaded nanocapsules 
were collected and stored in fridge.  
Blank nanocapsules were prepared by the same method in absence of drug. 
3.6.1.3 Artemisinin assay 
The quantitative determination of artemisinin was performed by reverse-phase 
high performance liquid chromatography using a Binary LC 250 pump (Perkin 
Elmer). Stationary phase was a Ultrasphere ODS (C18) 5-μm HPLC Columns 
(250×4.6 mm, Beckman). Mobile phase was acetonitrile/0.1% v/v acetic acid 
at a ratio 70:30 v/v; the flow rate was fixed at 1.0 ml/min and the detector UV 
(LC 95 UV/Visible detector, Perkin Elmer) at λ=254 ηm.  
Experimental conditions for standard preparation was rearranged from a 
procedure previously described in literature.cxxxiii Briefly, 1 mg/mL of 
artemisinin solution in acetone was prepared was placed in a 10 mL measuring 
flask. Three dilutions of the stock solution were prepared adding in a 10 mL 
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measuring flask as follows: a) 0.2 mL of artemisinin solution and 0.8 ml of 
acetone; b) 0.5 ml of artemisinin solution and 0.5 ml of acetone; c) 1 ml of 
artemisinin solution alone without acetone. This was followed by the addition 
of 4 ml of 0.2 % NaOH solution to the three flasks respectively, and then, 
allowed to react at 50 °C for 30 min. After that, 0.08 mol/L acetic acid solution 
was used to reach the final volume.  
In Art-loaded PLGA-PVP NCaps, Art content was evaluated preparing 
samples as follows: nanocapsules were dissolved 200 µL in 1.8 mL of acetone 
into a 5 mL measuring flask. 1 ml of 0.2 % NaOH solution was added to the 
flask and allowed to react at 50 °C for 30 min after which 0.08 mol/L acetic 
acid solution was added to fill up to the mark. All solutions were applied to 
HPLC-UV in order to evaluate Art encapsulation efficiency % (E.E. %) using 
Equation 3: 
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 [    ]        





         Equation 3 
where [Art]Exp was Art concentration found experimentally by and [Art]Theor 
was theoretical concentration of Art present in NCaps if all the amount of drug 
was totally encapsulated, both concentrations were expressed in mM. 
3.6.1.4 Curcumin assay 
Cur loading of NCaps was evaluated using a Beckman Coulter DU® UV/Vis 
spectrophotometer. A standard solution 0.1 mg/mL of Cur in acetone was 
prepared dissolving 1 mg was accurately weighed and transferred in a 100ml 
volumetric flask. 5, 2.5, 1.25, 0.75, 0.375 mL of Cur standard solution were 
transferred in 10 mL measuring flasks and diluted to mark with acetone. 200 
µL Cur-loaded PLGA-PVP NCaps was dissolved in acetone in a 10mL 
measuring flask. All solutions were analysed at wavelength of 425 ηm in 
triplicate. Entrapment efficacy was evaluated by equation 4: 
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        Equation 4 
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where [Cur]Exp was Cur concentration found experimentally by and [Cur]Theor 
was theoretical concentration of Cur present in NCaps if all the amount of 
drug was totally encapsulated, both concentrations were expressed in mM. 
3.6.1.5 Stability studies 
Blank, Art-loaded and Cur-loaded NCaps were stored at room temperature 
(about 27°C) for thirty days. Stability was evaluated by comparing the initial 
particle size, PdI (polydispersity index) with those obtained from samples 
withdrawn after 1, 7, 14, 21, and 28 days of storage. 
3.6.1.6 Growth Inhibition Assay 
In order to perform a growth inhibition assay, Plasmodium falciparum (3D7) 
culture was synchronize by 5% sorbitol lysis before the experiment. Seventy-
five µL of P. falciparum were plated in 96-well plate at 1.5% parasitemia and 
3% haematocrit. Samples (2x) were added to the culture dissolved in 75 µL of 
RPMI complete medium as the culture. After 48h parasitemia was analysed by 
fluorescent-assisted cell sorting (FACS). 
3.6.1.7 Haemolysis Assay 
Human blood collected in citrate-phosphate-dextrose (CPD) buffer was 
washed and diluted in PBS to make a solution with 3% haematocrit. 100 µL of 
RBCs were placed into 96-well plate and 100 µL of each PLGA-g-PVP in 
different concentrations (2x) were added. Same amount of PLGA-g-PVP than 
in the GIA’s was here tested. As controls, 1% Triton X-100, for the positive 
one, and PBS for the negative one were used. After incubating with the 
samples for 3h and 24h at 37°C, plates were centrifuge at 1500 rpm during 5 
min and supernatants were measured at 541ηm. 
3.6.2 RESULTS AND DISCUSSIONS: ARTEMISIMIN AND 
CURCUMIN LOADED NANOCAPSULES. 
3.6.2.1 Polymeric lipid nanocapsules preparation 
Polymeric nanocapsules (NCaps) are submicronic carriers consisted of an oily 
core surrounded by a polymeric shell with lipophilic and/or hydrophilic 
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surfactants assembled at the interface.cxxxiv The main advantages of polymeric 
NCaps are the possibility of loading high amount of water insoluble drug 
molecules into the oil core, their physicochemical stability, and protection 
against enzymatic degradation due to the presence of the polymeric 
wall.cxxxv,cxxxvi For these reasons NCaps were chosen as delivery system of 
artemisinin and curcumin, hydrophobic drugs, for antimalarial activity. PLGA-
PVP copolymers were used as polymeric shell of NCaps, thank to their stealth 
properties, long term stability and drug retention as demonstrated in a previous 
work.  
PLGA-PVP copolymers due to ester groups along PLGA chain and, in 
particular way, to the carboxylic acid as one terminal, present a negative zeta 
potential when used to form nanoparticles. This negative surface charge was 
here used to form stable shell on oily core of a nanocapsules, by ionic 
interactions. Oily core was thus prepared in order to have a positive surface 
charge. Epikuron 200 consisted in purified phosphatidylcholine was used as 
hydrophobic surfactant of mygliol 812, a triglyceride of the fractionated plant 
fatty acids with alkyl chains of C8 and C10, in presence of hydrophilic 
surfactants such as dioctylsulfosuccinate (DOSS), Pluronics F68 or Tween 80. 
Solids were firstly solubilised in mygliol and after the whole solution diluted 
with water under stirring. Microemulsion was obtained homogenizing for 5 
min at 30000 rpm by Ultra-Turrax, and nanosized droplets after 1 hour 
treatment by high pressure homogenizer. Particle sizes and zeta potentials of 
obtained emulsions were evaluated and listed in Table 7. The smallest oily 
droplets (93 nm) with the most positive surface charge (+24 mV) was reached 
by using Tween 80 as surfactant. A further trials were attempted changing the 
oil and using ones with a longer alkyl chain, i.e. isopropyl-myristate (i-pr-myr, 
C14+C3), and oleic acid (C18). I-pr-myr in presence of Tween 80 and 
Epikuron 200 gave drop size of 94 nm and comparable zeta potential value of 
those obtained using mygliol 812. Probably size reduction was due to a more 
affinity between isopropyl groups and apolar chains in the hydrophilic head of 
both surfactants. Instead of oleic acid had similar behaviour of mygliol 812. 
Therefore, isopropyl-myristate was successively used to form nanocapsules. 
Amount of Tween 80 in recipe was adjusted. Both lower and higher amounts 
of surfactant caused droplet aggregation, but decreasing Tween 80 zeta 
potential increased. Despite last findings, 200 mg of Tween 80 was chosen. 
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Table 7. Zeta potentials and size of lipid core of nanoparticles varying 
emulsifier and lipid. 
Sample 
ζ Potential ± 
σ (mV) 
Size ± σ (nm) PDI ± σ 
Epika), DOSSb), Mygliolc) +20.04 ± 3.93 133.1 ± 16.1 0.30 ± 0.04 
Epik, Plud), Mygliol +18.12 ± 1.00 160.9 ± 12.2 0.301 ± 0.003 
Epik, Tween 80, Mygliol +20.18 ± 1.50 128.5 ± 1.4 0.280 ± 0.005 
Epik, Tween 80, oleic acid +21.89 ± 3.65 113.8 ± 2.7 0.304 ± 0.022 
Epik, (200 mg) Tween 80, i-pr-myre) +23.57 ± 1.19 94.7 ± 4.0 0.210 ± 0.02 
Epik, (100 mg) Tween 80, i-pr-myre +24.75 ± 1.85 118.2 ± 2.2 0.340 ± 0.008 
Epik, (400 mg)Tween 80, i-pr-myre) +16.89 ± 2.42 115.2 ± 1.2 0.299 ± 0.015 
a) Epikuron 200; b) DOSS= dioctylsulfosuccinate; c)Mygliol 810; d) Pluronic F68; 
e) isopropyl-myristate. 
Influence of different alcohols on droplet size was evaluated. Butanol was 
knew to influence arrangements in lipid monolayercxxxvii and it was 
hypothesised that could contribute also in rearrangement in oily droplet. 
Butanol like ethanol and other short chain alcohols (up to C6), by hydrogen 
bonds to carbonyl groups in the lipid headgroups, leads reducing interlipid van 
der Waals attraction, and increasing membrane elasticity.cxxxviii,cxxxix When used 
with mixture of satured and unsatured lipids, it reduced the tail mismatch 
between the two lipids.clv 
In droplets, it was hypothesised that butanol and other alcohols act similarly, 
reducing tail mismatch between surfactant and i-pr-myristate, leading to size 
reduction. Results are depicted in Table 8. 
In this study methanol, ethanol and propanol was not used, because they are 
incompatible with PLGA-PVP copolymers, leading to their precipitation. Thus, 
the first alcohol tested was butanol by using different volume to dissolve oil 
and surfactants. In all three tests a reducing of size was obtained, but the 
smallest dimension (39.9 nm) was reached using 300 µL of butanol. Using the 
same volume, hexanol, heptanol, decanol and benzyl alcohol were evaluated as 
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lipid compatibilizer. Benzyl alcohol did not affect droplet size, confirming that 
a long alkyl chain in alcohol structure was fundamental. 1-decanol gave the best 
result, reaching droplet size of 28.9 nm, instead of 94.7 nm of original recipe. 
Table 8. Size dependence by kind and amount of alcohol used to dissolve oil 
and surfactants. 
Alcohol Volume (µL) Particles size ±σ (nm) PDI ±σ 
No alcohol -- 94.7 ± 4.0 0.210 ± 0.02 
1-Butanol 500 57.9 ± 3.0 0.295 ± 0.015 
1-Butanol 300 39.9 ± 3.0 0.308 ± 0.017 
1-Butanol 200 66.8 ± 2.4 0.258 ± 0.013 
1-Hexanol 300 43.2 ± 3.3 0.211 ± 0.024 
1-Heptanol 300 53.8 ± 2.2 0.237 ± 0.014 
1-Decanol 300 28.9 ± 0.5 0.231 ± 0.012 
Benzyl alcohol 300 84.7 ± 3.9 0.344 ± 0.005 
 
3.6.2.2 Drug encapsulation 
Once optimized formulation parameters for obtaining empty oily nanodroplets 
having small dimensions, anti-malarial drugs encapsulation was studied. 
Three different concentrations of artemisinin and curcumin were prepared, 0.4, 
0.7 and 1.0 mg/mL of each drug, and resulting droplet size and morphology 
were evaluated by DLS and optical microscopy. Results are listed in Table 9 
and depicted in Figure 15. 
In all cases a slight increase in size was observed. Focusing on Art 
encapsulation, it was possible to appreciate a droplet size decreasing, when 
drug concentration in recipe was increased. Nevertheless, in 1.0 mg/mL Art-
loaded droplet, several crystals of not encapsulated Art were visible at optical 
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microscope and thus 0.7 mg/mL solution was chosen for nanocapsule 
formation. On the other hand, Cur behaved differently with a minimum in size 
at 0.7 mg/mL. No crystals were detected when analysed by optical microscope 
(Figure 15). 
 
Figure 15. Optical microscopy pictures of Art-loaded droplets and Cur-loaded 
droplets with three different drug loading. 





Particles size ±σ 
(nm) 
PDI ±σ 
Particles size ±σ 
(nm) 
PDI ±σ 
0.4 59.6 ± 0.3 0.19 ± 0.01 54.8 ± 0.7 0.21 ± 0.01 
0.7 33.2 ± 0.5 0.19 ± 0.01 34.1 ± 0.2 0.13 ± 0.03 
1.0 31.7 ± 0.5 0.22± 0.01 42.5 ± 0.5 0.20 ± 0.001 
Final concentration of Art and Cur were evaluated by HPLC-UV and UV-
Visible spectroscopy respectively, using calibration curve previously prepared 
(Figure 16 and 17). Drug concentration and encapsulation efficiency were listed 
in Table 10. Artemisinin was closely total encapsulated with an E.E.% of 99 %, 
instead of Cur that presented an E.E.% of 74%, confirming that in both case 
drugs and i-pr-myristate have a good compatibility. 
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Figure 16. Calibration curve of curcumin by UV-Visible spectroscopy. 
 
Figure 17. Calibration curve of artemisinin by HPLC-UV-Vis. 
Table 10. Concentration of encapsulated drug in oily droplets and 
encapsulation efficacy percentage (E.E.%). 
Anti-malarial drug Concentration (mM) E.E.% 
Curcumin 1.42 74 
Artemisinin 2.46 99 
3.6.2.3 Drug-loaded PLGA-PVP NCaps characterization 
Droplets were coated with PLGA-PVP copolymers by depositing of a layer of 
on oily droplet, dropping 400 µL a 30:70 DMSO/acetone copolymeric solution 
(15 mg/mL) under vigorous stirring. Schematic portrait of whole NCaps 
preparation was depicted in Figure 18 together with inserts of optical and TEM 
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image of oily droplets and final formulation of Art-loaded PLGA-PVP10:2 
NCaps.  
PLGA-PVP10:1 and PLGA-PVP10:2 were used as copolymers, in order to study 
the dependence of drug-loaded NCap properties with PVP content in 
copolymers. As greatly described in Chapter 2, PVP weight content % in 
copolymers was 6.7 and 18.8, respectively for PLGA-PVP10:1 and PLGA-
PVP10:2.  
A thick copolymeric shell was obtained for all nanocapsules as demonstrated 
by the increase in particle size by DLS analysis and the variation of surface 
charge in negative sign from positive one, characteristic of nude oily droplets 
(Table 11 and 12), as showed by zeta potential analysis. In details, for PLGA-
PVP10:1 NCaps, diameters ranged between 57 to 75 nm with an increase in size 
of about 30 nm respect of the only oily droplets. For PLGA-PVP10:2 NCaps, 
diameters ranged between 55 to 95 nm, and usually greater those obtained 
from PLGA-PVP10:1 NCaps. In regard of kind of drug, passing from Cur- to 
Art-loaded NCaps a diameter increase was detected. 
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Figure 18. Schematic portrayal of drug-loaded PLGA-PVP nanocapsules, with 
insert of image of oily droplets (a) by optical microscope and Art-loaded 
PLGA-PVP10:1 NCaps after at high pressure homogenization (HPH) treatment 
(b) by TEM. 
Zeta potentials were more dependent from the kind of copolymer used to 
coated oily droplets and in particular PLGA-PVP10:2 NCaps always showed less 
negative surface charges than PLGA-PVP10:1 NCaps. No significant 
dissimilarities were observed changing kind of drug used. In Table 12 
osmolarity values of PLGA-PVP NCaps were also listed. 
It is essential to maintain isotonicity for the intravenous application of 
formulations. Osmolarity values varied from 130 to 240 mOsmol, indicated 
that all formulation were ipotonic. Thus, non-ionic substances such as glycerol 
or carbohydrate were recommended for use to reach isotonicity, before 
biological tests in vitro will be performed.  
Table 11. Particle sizes by DLS of empty, Cur-loaded and Art-loaded 
nanocapsules with the two different copolymeric shells. 
NCaps 
PLGA-PVP10:1 PLGA-PVP10:2 
Particles size ±σ (nm) PDI ±σ Particles size ±σ (nm) PDI ±σ 
Empty  57.1 ± 0.8 0.27 ± 0.01 69.5 ± 1.0 0.30 ± 0.01 
Cur-loaded  67.6 ± 0.6 0.17 ± 0.03 54.7 ± 0.1 0.20 ± 0.01 
Art-loaded 74.7 ± 0.7 0.20 ± 0.02 94.6 ± 0.7 0.26 ± 0.01 
 
Table 12. Zeta potentials and osmolarity of empty, Cur-loaded and Art-loaded 











Empty  -11.54 ± 4.05 145 -7.56 ± 1.82 130 
Cur-loaded  -12.37 ± 4.66 241 -10.78 ± 4.93 204 
Art-loaded -14.07 ± 2.94 200 -13.03 ± 2.39 160 
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3.6.2.4 Stability studies 
Stability studies of empty and drug-loaded PLGA-PVP NCaps were performed 
in order to assess the influence of ingredients on the stability of the colloidal 
suspensions. For this purpose, mean diameter and PDI of PLGA-PVP NCaps 
dispersions were determined after different storage times (1, 7, 14, 21, 28 days) 
at room temperature (~27°C). Stability data are shown as average values and 
errors in Figure 19. After thirty days, PLGA-PVP NCaps dispersions were 
apparently homogeneous, without any visible precipitates, phase separation or 
flocculation. Furthermore, PLGA-PVP NCaps did not exhibit significant 
alterations in particle size, save at the end of experiment, slightly increase in 
size could be observed. PDI values were ranged between 0.10 and 0.30, 









Figure 19. Stability study of blank and drug-loaded PLGA-PVP NCaps after 1, 
7, 14, 21, 28 days, regarding of A) dimensional diameter (size in nm) and B) 
polydispersity (PDI) with their error bars. 
3.6.2.5 In vitro biological studies 
In an attempt to verify if PLGA-PVP NCaps could increase Art and Cur 
cytotoxicity, in vitro cytotoxicity studies were performed with FACS assay and 
Plasmodium Falciparum infected red blood cells (p-RBC) (3D7 culture lines). 
Nine different concentrations of free Cur (0.780-200 µM) and free Art (0.195-
50 nM) were added to the cell culture, which was incubated for 48 h. From 
growth inhibition curve depicted in Figure 20, it was possible to infer the IC50 









Figure 20. Growth inhibition % of pRGB in function of log of drug 
concentration: A) free curcumin; B) free artemisinin. 
Similar experiments were conducted on Cur-loaded PLGA-PVP NCaps and 
emply ones. Tested drug amounts and the corresponding NCap concentrations 
were reported in Table 13. From preliminary results, after 48h of co-
incubation, examination of p-RBC untreated group showed 100 % parasitemia, 
whereas a reduction of parasitemia was explicated after that pRBCs were 
treated with Cur-loaded PLGA-PVP NCaps (Figure 21). Also empty PLGA-
PVP NCaps caused reduction of parasitemia, but in a lower extent respect of 
drug-loaded NCaps. IC50 of Cur loaded PLGA-PVP10:1 NCaps was found to be 
0.5 μM, instead of Cur-loaded PLGA-PVP10:2 NCaps was 0.4 μM. Both IC50 
values are significantly lower than IC50 of free curcumin (~8.0 microM).  
By microscopic examinations, some p-RBCs were lysed when kept in contact 
with the formulation at highest concentration (1.56 μM). Nevertheless, more 
diluted formulations resulted not-toxic against p-RBCs, even if parasitemia was 
maintained. 
Table 13. Cur concentrations tested during growth inhibition assay of Cur-
loaded PLGA-PVP NCaps and corresponding NCap concentrations herein 
present. 





Cur loaded in 
PLGA-PVP10:2 
(μM) 
NCaps conc  
(μg/mL) 








0.78 4.24 0.58 3.17 
0.39 2.12 0.29 1.58 
0.20 1.06 0.15 0.79 
 
Figure 21. Growth inhibition curve of the free curcumin (black line), Cur-
loaded PLGA-PVP10:1 NCaps (red line) Cur-loaded PLGA-PVP10:2 NCaps (blue 
line) and empty PLGA-PVP10:1 NCaps (purple line) and empty PLGA-PVP10:2 
NCaps (green line). 
Figure 22 reported the effect of Art-loaded formulations on pRBCs after 48h 
of incubation. At tested concentrations listed in Table 14, only PLGA-PVP10:2 
NCaps resulted efficient in p-RBC ablation, but the IC50 value (38.8 nM) was 
greater than free Art (29.7 nM), indicating that Art was not easily released, but 
almost all retained inside the core of the particles. Empty NCaps did not 
inhibit p-RBC growth. No lysis of p-RBCs was evidenced during the 
experiment. 
Table 14. Art concentrations tested during growth inhibition assay of Art-
loaded PLGA-PVP NCaps and corresponding NCap concentrations herein 
present. 
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Figure 22. Growth inhibition curve of the free artemisinin, Art-loaded PLGA-
PVP NCaps and empty PLGA-PVP NCaps. 
To clarify if the lysis of pRBCs could contribute to inhibition of parasitemia, a 
haemolysis assay was performed with healthy red blood cells (RBCs) and blank 
PLGA-PVP NCaps. Seven dilution of empty PLGA-PVP NCaps were tested, 
covering all dilution range used in growth inhibition assays of drug-loaded 
NCaps (Table 15). After 3 h, no haemolysis properties was noted. After 24 h, 
only D1 caused slightly haemolysis, but further dilutions resulting totally safe. 
D1 dilution corresponded to double of first concentration used in growth 
inhibition assay. Thus, tested solutions resulted safe for healthy RBC cultures. 
Further experiments are planned to confirm all data. 
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Table 15. Dilutions of empty PLGA-PVP NCaps tested in haemolysis assay 













Figure 23. Haemolysis of RBCs at different concentration of empty PLGA-
PVP NCaps after 3 and 24 h of incubation. 
3.6.3 CONCLUSIONS: ARTEMISIMIN AND CURCUMIN LOADED 
NANOCAPSULES 
In conclusion, results obtained in the present study showed that PLGA-PVP 
copolymers could be used as shell to prepare stable oily nanocapsules loaded 
with artemisinin and curcumin. Empty PLGA-PVP NCaps had small 
dimensions, about 50-60 nm as measured by DLS. Drug-loaded NCaps 
presented increased diameters, leading to 70-90 nm. High encapsulation 
efficacy was reached for all formulations, in particular in the case of 
artemisinin-loaded NCaps. Characterization of nanocapsules was conducted 
evaluating zeta potentials. All particles presented a negative charged surface, 
after PLGA-PVP deposition as shell. Increasing PVP amount in copolymers, 
zeta potential values increase, leading to less negative surface. No significantly 
difference between the two different drugs was evidenced. Stability studies of 
empty and drug-loaded PLGA-PVP NCaps were performed. After thirty days, 
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PLGA-PVP NCaps dispersions were apparently homogeneous, without any 
visible precipitates, phase separation or flocculation. Furthermore, PLGA-PVP 
NCaps did not exhibit significant alterations in particle size.  
Growth inhibition assay were evaluated after 48 h of incubation with 
Plasmodium Falciparum infected red blood cells of empty PLGA-PVP NCaps, 
drug-loaded PLGA-PVP NCaps and free drugs. Cur-loaded PLGA-PVP 
NCaps presented an IC50 ten times lower than one of free curcumin. In the 
case of Art-loaded NCaps, only PLGA-PVP10:2 one resulted efficient in p-RBC 
ablation, but the IC50 value was greater than free Art, indicating that Art was 
not easily released, but almost all retained inside the core of the particles. 
Haemolysis assay of empty NCaps evidenced only a slight activity at higher 
concentrations than ones tested in growth inhibition assay. 
This preliminary results indicated that both Cur-loaded PLGA-PVP NCaps 
were effective as antimalarial treatment. Art-loaded PLGA-PVP NCaps have to 
be perfect in order to promote drug release. Target could be reached by 
reducing PLGA-PVP shell or reducing stabiliser amounts at the start of 
preparation. Further experiments will be conducted.  
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NANOFIBRE FORMATION OF PLGA-g-PVP /PLGA BY 
ELECTROSPINNING 
“The purpose of this piece of work is to produce nanofibre based scaffolds of PLGA, having 
a modulable wettability, by incorporating PLGA-PVP copolymer in the fibre structure. 
Single and coaxial electrospinning techniques were employed for this aim.” 
 
4.1 ELECTROSPINNING TECHNIQUE 
Electrospinning technique was derived by modification the electrospraying 
phenomenon. Indeed, both processes are based on the same physical and 
electrical mechanisms, but differ in the geometry of final products, small 
droplets by electrospraying, whereas continuous fibres by electrospinning are 
formed.i The electrospray phenomenon was firstly described by Lord Rayleigh 
in 1882,ii discovering that a highly-charged droplet was unstable when passed 
through a voltage gradient with the consequence break down into smaller 
droplets. Following experiment electrosprays of dilute polymer solutions were 
performed by Dole.iii In 1934, Formhals granted a series of U.S. patents on 
electrospun fine fibres from a cellulose acetate.iv In 1966, Simons found that 
more viscous solutions favoured the formation of longer fibres.v Baumgarten 
designed an apparatus with an infusion pump to electrospun acrylic fibres, and 
discovered that the diameter of fibres could be controlled by the polymer feed 
rate from the infusion pump.vi Finally, Larrondo and Manley electrospun 
polypropylene and produced polyethylene nanofibres in 1981.vii,viii,ix 
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4.2 ELECTROSPINNING APPARATUS 
The electrospinning apparatus consists of only three major components: a high 
voltage power supply, a polymer solution reservoir (usually a syringe, with a 
small diameter needle, named spinneret) with or without a flow control pump, 
and a metal collecting screen (Figure 4.1). 
 
Figure 4.1. Schematic portrayal of a electrospinning apparatus. Figure adapted 
from reference. x 
A syringe pump is typically used to force the polymeric solution through a 
small-diameter capillary, but also gravitational forces, or pressurized gas can be 
used for this aim. As consequence of this pressure, a hemispherical droplet of 
polymer solution is formed at the tip of the needle. Successively, an electrode 
from the high voltage source is immersed in the solution (or can be directly 
attached to the capillary if a metal needle is used) and when the voltage source 
is turned on, the electrode charges the polymeric solution. x With increasing 
voltage, the polymer droplet elongates to form a conical shape, known as the 
Taylor cone, causing a raising of surface charge on droplet over time. xi,xii Once 
the surface charge overcomes the surface tension of the polymer droplet, a 
polymer jet is initiated. If the molecular cohesion of the liquid is low, jet 
breakup occurs and polymer is electrosprayed and not electrospinned.xiii 
During travel to reach the collecting screen, the solvent in the polymer jet 
evaporates, increasing the surface charge that induces instability in the polymer 
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jet when it passes through the electric field. To compensate this instability, the 
polymer jet divides geometrically, first into two jets, and then into many more 
as the process repeats itself. Eventually, fibre jet arrived by a helical motion 
(Figure 4.2) and deposited layer-by-layer on the metal collecting screen, 
forming a non-woven nanofibrous mat.xiv,xv  
 
Figure 2. Particular of Taylor cone and helicoidally motion of fibre jet. Figure 
take from reference.xvi 
Depending on the application a number of collector configurations can be 
used, including a stationary plate, rotating mandrel, solvent (e.g. water), etc. 
Typically the use of a stationary collector will result in the formation of a 
randomly oriented fibre mat. A rotating collector can be used to generate mats 
with aligned fibres, with the rotation speed playing an important role in 
determining the degree of anisotropy.xvii This technique allows for the 
production of polymer fibres with diameters varying from 3 nm to greater than 
5 μm.xviii 
4.3 PARAMETERS OF ELECTROSPINNING PROCESS 
Electrospinning is a relatively simple and versatile method for forming non-
woven fibrous mats, but a number of processing parameters must be tuned to 
adjust the properties of the generated fibres. Both extrinsic parameters, such as 
humidity and temperature, and intrinsic parameters, namely applied voltage, 
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conductivity and viscosity of the polymer solution, need to be optimized to 
produce uniform nanofibres.xix Generally, the intrinsic parameters are more 
critical in determining the nanofibre structure. 
Polymer Solution Viscosity. Polymer solution viscosity is the most critical 
factor in controlling the structural morphology of the nanofibrous structure. It 
is directly proportional to the concentration of the polymer solution and to 
molecular weight of polymer. The polymer concentration determines the 
spinnability of a solution, namely whether a fibre forms or not.xvi For the 
formation of uniform and dimensionally narrow fibres, polymer viscosity 
should be in a specific range, depending on the type of polymer and solvent 
used. If the solution is too dilute, then, the polymer fibre will break up into 
droplets before reaching the collector, due to the effects of surface tension.xx 
With increasing polymer concentration and thus viscosity, spherical beads 
become elongated into spindle-shaped ones, and number of beads in the 
structure is reduced.xxi In some cases, increasing the concentration of a 
polymer solution can also affect its surface tension.xxii For solutions that are 
too concentrated (and therefore too viscous), the droplet dries out at the tip 
before jets could be initiated, preventing electrospinning.xxiii An example of 
how polymer concentration and viscosity influence morphology and diameter 
of fibres is showed in Figure 4.3. 
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Figure 4.3. SEM Image. Effect of polymer concentration on fibre diameter. 
Fibres were electrospun from solutions containing varying concentrations of 
poly(ethylene- co -vinyl alcohol) in 70:30 (v/v) 2-propanol: DI water. Top left 
to bottom left: 5.5% (g/mL), 8.5% (g/mL) and 11.5% (g/mL) solutions. 
Bottom right plot of average fibre diameter against polymer concentration. 
Figure adapted from reference. xxiii 
Applied Charge Density. Charge density is defined as the amount of charge 
per unit surface area of the polymer droplet. It is the sum of different 
contribute, namely the applied voltage, the distance between needle and 
collector of apparatus, and the conductivity of the polymer solution. The 
distance between capillary tip and collector can also influence fibre size by 1-2 
orders of magnitude. Additionally, this distance can dictate whether the end 
result is electrospinning or electrospraying.xxiv Applied voltage ( i.e. strength of 
electric field) alters shape of surface at which Taylor cone and fibre jet are 
formed.xxv In particular, at relatively low applied voltages, a polymeric pendant 
drop is formed at the tip of the capillary, having Taylor cone at the tip of the 
pendant drop. This configuration can lead to bead defects in the fibres or at 
lower values even failure in jet formation with the subsequently formation of 
only beads (Figure 4.4, a-b).xxvi Increasing the electric field strength decreases 
bead density, leading the formation of uniform fibres (Figure 4.4, c e d). High 
voltage conditions also creates a rougher fibre structure and the jet eventually 
moves around the edge of the tip, with no visible Taylor cone; at these 
conditions, the presence of many beads can be observed.xxvii 
 
Figure 4.4. Schematic illustration of a jet spinning model of electrospinning 
from low to high voltages (from a to e). Figure take from reference.xxviii 
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Polymer Solution Conductivity. The conductivity of a polymer solution is 
mainly determined by the polymer type, solvent used, and the availability of 
ionisable salts. A more conductive polymer solution carries more electric 
charge during the electrospinning process, with the as-spun fibres generating a 
stronger repulsive force, which facilitates the formation of bead-free, uniform 
fibres (Figure 4.5).xxix,xxx In case of non-conductive polymer choice of solvent 
plays an important role. Usually solvents with high dipole moment or dielectric 
constant are preferable, such as dimethylformamide, methanol, ethanol and so 
on.xxxi,xxxii,xxxiii Also, the productivity (number of fibres produced per unit time) 
of spinning polystyrene fibres is found to correlate with the dipole moment 
and dielectric constant. xxxiv 
 
Figure 4.5. Representative SEM images (~10,000x) of 393 kDa poly SBMA 
electrospun nanofibres from solutions with varying concentrations of NaCl: (a) 
1 M, (b) 0.5 M, (c) 0.25 M, (d) 0.17 M NaCl. Figure take from reference. xxxv 
Flow rate. Flow rate was poorly investigated in literature, but the few present 
studies report that flow rate influences the homogeneity of nanofibres. In 
particular, too high flow rates result in rich bead defected mats since fibre jet 
have not a chance to dry prior to reaching the collector.xxxvi,xxxvii As well as, if 
the flow of solution through the capillary is insufficient to replace the solution 
ejected as the fibre jet, the cone shape at the tip of the capillary cannot be 
maintained.xxxviii,xxxix 
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Solvent volatility. Choice of solvent is also critical as to whether fibres are 
capable of forming, as well as influencing fibre porosity. In order for sufficient 
solvent evaporation to occur between the capillary tip and the collector a 
volatile solvent must be used. As the fibre jet travels through the atmosphere 
toward the collector a phase separation occurs before the solid polymer fibres 
are deposited, a process that is greatly influenced by the volatility of the 
solvent.xl,xli Highly volatile solvents give fibres with a high density of pores, 
resulting in an increase of surface area. Less volatile solvent leads to a 
complete loss of microtexture with the formation of smooth fibres. Example 
of this behaviour is shown in Figure 4.6, where different ratio of DMF (less 
volatile solvent; b.p.= 154°C) and THF (more volatile solvent; b.p. = 66°C) 
solutions were used to electrospun poly(styrene).xlii 
 
Figure 4.6. SEM pictures of fibres and their surfaces fabricated by 
electrospinning 20% (w/v) PS solutions with various THF/DMF ratios. (A, B) 
6:0, (C, D) 5:1, (E, F) 4:1, (G, H) 3:1, (I, J) 2:1, (K, L) 0:6, (M, N) 1:5, (O, P) 
1:4, (Q, R) 1:3, and (S, T) 1:2, v/v. RH 60%, collecting distance 15 cm, feeding 
rate 1.5 ml/h, and applied voltage 12 kV. Figure take from reference. xlii 
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Ambient parameters. Temperature and humidity are classified as ambient 
parameters of the electrospinning process, and they have some influence of 
the appearance of fibrous mats. In particular, temperature influences viscosity 
of polymeric solution, leading to a decrease of this parameter when 
temperature increases.xliii As a results, a decreased fibre diameter is usually 
observed. Humidity influences porous morphology of fibrous surfaces. 
Increasing the humidity leads to the appearance of small circular pores on the 
surface of the fibres, with further increase pores have the tendency to 
coalescing phenomenon.xliv Figure 4.7 illustrates the effects of both parameters 
on poly(caprolactone) fibres by keeping all other parameters constant. 
 
Figure 4.7. SEM micrographs of PCL fibres spun from a 15 % w/w solution 
in CHCl3 at the different temperatures and relative humidities. Figure take 
from reference. xlv 
4.4 MODIFICATION OF BASIC ELECTROSPINNING PROCESS: 
COAXIAL ELECTROSPINNING 
Modification of the spinneret and/or the type of solution can allow for the 
creation of fibres with unique structures and properties. One such 
modification that has gained much attention and holds great promise in a 
variety of applications is preparation nanofibres using “co-axial 
electrospinning” are also called “two-fluid electrospinning”.xlvi,xlvii,xlviii 
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As deducible by the name, in this process, two dissimilar materials are 
delivered independently through a co-axial capillary and drawn to generate 
nanofibres in core-sheath configuration. This opens up the possibility of 
creating composite fibres which can have a wide range of uses: for instance, a) 
to isolate and/or protect an unstable component and minimizing its chances 
of decomposition under a highly reactive environment; b) to release with time 
a substance to a particular receptor; c) to reinforce a material improving its 
mechanical properties; d) to serve as scaffold for engineering tissues in which a 
less biocompatible polymer is surrounded by a more biocompatible 
material.xlix,l,li 
The general set up adopted is quite similar to that used for electrospinning 
described before (Figure 4.8). A modification is made in the spinneret by 
inserting a smaller (inner) capillary that fits concentrically inside the bigger 
(outer) capillary to make co-axial configuration. Since the process of co-axial 
electrospinning is similar to that of the conventional electrospinning, all 
variables that govern the quality of the process and the morphology of the 
fibres in the latter also affects the behaviour in the former.lii 
 
Figure 4.8. Schematic portrayal of Coaxial electrospinning apparatus, with a 
magnification of Taylor cone. 
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4.5 AIM OF RESEARCH 
In this work, PLGA-based scaffolds were produced by electrospinning for 
biomedical applications. PLGA is a hydrophobic copolymer, as extensively 
described in chapter 2. To improve biocompatibility and cell attachment on 
PLGA-based scaffold, its hydrophobic must be reduced. Wettability of the 
PLGA-basesd scaffolds was thus modulated by the use of a new synthetic 
copolymer consisting of a main chain of PLGA with grafts lateral chains 
constituted by highly hydrophilic units of poly(vinylpyrrolidone), named 
(PLGA-g-PVP). Different strategies were followed for the production of 
highly wettable fibres. In particular, fibres of blend solutions of both 
copolymers and coaxial fibres, in which PLGA formed the core and PLGA-g-
PVP formed the shell of coaxial fibres, were produced and analysed. 
 
4.6 EXPERIMENTAL PART 
4.6.1 Materials 
PLGA-g-PVP10:1 (named PLGA-g-PVP in this work) was synthesised 
following procedure reported in Chapter 2, Paragraph 2.2.3. Poly (lactide-
glycolide) 50:50 (PLGA) was purchased from Evonik Industries AG (Essen). 
Polyvinylpyrrolidone (PVP)  ̅  360000 g/mol was obtained by Sigma-Aldrich 
(Italy). Solvents were purchased from Sigma-Aldrich and used without any 
further purification steps. 
4.6.2 Film formation by spin coating  
A Laurell WS-650MZ-23NPP/LITE spin coater was used for 60 s at 1000 
rpm with initial acceleration of 300 rpm/sec to spin-coat the polymeric 
solutions on 24 x 24 mm glass. Spin-coating was used to make a uniform 
distribution of 0.5 mL of 5 % w/v copolymeric solution (PLGA or PLGA-g-
PVP) in chloroform.  
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4.6.3 Scaffold preparation by single electrospinning 
The electrospinning apparatus was composed of a high voltage power supply 
(Spellman, SL 50 P 10/CE/230), a syringe pump (KD Scientific 200 series), a 
glass syringe, a stainless-steel blunt-ended needle (inner diameter 0.51 mm) 
connected with the power supply electrode and a grounded aluminium plate-
type collector. The polymer solution was dispensed through a teflon tube to 
the needle that was vertically placed on the collecting plate. Distance between 
needle and collector was in all cases of 20 cm. 
Electrospinning parameters for all compositions are listed in Table 4.1. 
PLGA solution was prepared at room temperature by dissolving the 
copolymer in DCM:DMF = 70:30 v/v at a concentration of 22 % and 26 % 
w/v, named respectively PLGA22 and PLGA26.  
PLGA-g-PVP scaffolds were fabricated from a solution of PLGA-g-PVP in 
DCM:DMF = 70:30 v/v, at a concentration of 30 and 37% w/v. The two 
solutions were identified as PLGA-g-PVP30 and PLGA-g-PVP37, respectively. 
PLGA/PLGA-g-PVP blend scaffolds were fabricated by using solution at 
two different concentration of PLGA-g-PVP, 13% w/w and 37% w/w, named 
Blend13 and Blend37 respectively. Blend solutions were prepared at room 
temperature dissolving both copolymers in DCM:DMF = 70:30 v/v, obtaining 
a total polymeric concentration of 25% w/v.  
Obtained electrospun mats were kept under vacuum over P2O5 at room 
temperature overnight in order to remove residual solvents. 
4.6.4 Scaffold preparation by coaxial electrospinning 
The home-made electrospinning apparatus is composed of a high voltage 
power supply (Spellman SL 50 P 10/CE/230), two syringe pumps (KD 
Scientific 200 series), a glass syringe, a stainless steel coaxial needle connected 
to the power supply electrode and a grounded aluminium collector (10 cm ×10 
cm). The coaxial needle used in the present work is constituted by an inner 
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needle (internal diameter = 0.55 mm) positioned concentrically to the outer 
needle (internal diameter = 1.5 mm). 
Core solution is constituted by 26 % w/v PLGA in 70:30 DCM:DMF 
solution. Sheath solution is formed by PLGA-g-PVP in 70:30 DCM:DMF 
solution. Three different copolymer concentrations, 13 %, 25% and 37% w/v, 
was used, giving three different mats, named Coax13, Coax25 and Coax37. 
Electrospinning parameters for all coaxial fibres were listed in the following 
Table 1. Electrospun fibres were kept under vacuum over P2O5 at room 
temperature overnight in order to remove residual solvents. 
4.6.5 Characterization of polymeric films and electrospun fibres 
Scanning Electron Microscope (SEM) were performed SEM Philips 515 
operating at 15 kV. Samples were fixed on aluminium stubs by double-sided 
carbon adhesive tape and sputter-coated with gold prior to examination. The 
distribution of electrospun fibre diameters was determined through the 
measurement of fibres by means of an acquisition and image analysis software 
(EDAX Genesis) and the results were given as the average diameter ± 
standard deviation.  
Thermogravimetric analysis (TGA) measurements were performed with a TA 
Instruments TGA2950 Thermograms were recorded on 10-15 mg of samples 
from RT to 700◦C by heating rate of 10 °C/min, using gas nitrogen to purge 
furnace (75 mL/min) and balance (55 mL/min).  
Differential scanning calorimetry (DSC) was carried out using a TA 
Instruments Q100 DSC equipped with the LNCS (Liquid Nitrogen Cooling 
System) accessory. DSC scans were performed in helium atmosphere from -
50° to 210°C. A rate of 20°C/min was used during heating scans whereas the 
cooling scans were performed at a rate of 10°C/min. 
Static water contact angle measurements were performed at room temperature 
under ambient conditions by using an optical contact angle and surface tension 
meter KSV's CAM 100 (KSV, Espoo, Finland). Milli-Q water was used for 
measurements. The water drop profile images were collected in a time range of 
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0–30 s, every 1 s. Optical contact angle and pendant drop surface tension 
software was used for image processing. Results were averaged on at 10-12 
measurements obtained at different areas of the sample. 



















PLGA22 11.8 15.2 1.2 -- 25 60 
PLGA26 11.5 15.1 0.9 -- 22 58 
PLGA-g-PVP30 / 
PLGA-g-PVP37 
12.2 18 0.9 -- 21 82 
Blend13 12.2 17.0 0.9 -- 26 76 
Blend37 12.2 16 0.9 -- 21 65 
Coax13 12.2 17.0 1.0 0.10 27 63 
Coax25 12.2 18.5 0.97 0.23 27 62 
Coax37 12.2 17.0 0.85 0.35 26 64 
4.7 RESULTS AND DISCUSSIONS 
4.7.1 Thermal characterization of native polymers. 
Starting materials, namely the PLGA copolymer, the PVP homopolymer and 
PLGA-g-PVP copolymer, were characterized in their thermal properties by 
means of thermogravimetry (TGA) and differential scanning calorimetry 
(DSC). 
The thermogravimetric analysis measuring the sample weight loss in function 
of temperature, due to substances volatilization or deriving from the thermal 
degradation. This technique allows to have information relating to the 
composition of samples. Figure 4.9 shows thermogravimetric curves of three 
starting polymers. In Table 4.2 degradation temperature and the corresponding 
weight losses of each sample are collected. 
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Figure 4.9. Overlapping of PVP (red curve), PLGA (black curve), PLGA-g-
PVP (blue curve) TGA. For each sample is reported of the weight loss 
percentage as a function of temperature (continuous line) and the 
corresponding derivative (dashed line). 
Table 4.2. Percentage of weight loss (  ) and temperatures of the maximum 

















PLGA 0.051 96 0 293 - 
PVP 2.8 0 94 - 427 
PLGA-g-PVP10:1 1.1 83 9.3 274 404 
 
PLGA degraded essentially through a single degradation step, which 
corresponds to a weight loss of about 96%, with a maximum degradation rate 
at 293 °C. Both PVP and PLGA-g-PVP, both have a small loss of weight at 
low temperatures (T <150 °C) respectively of 2.9% and 1.1% due to the 
evaporation of adsorbed water from samples. In fact, the presence of 
vinylpyrrolidone units makes these very hygroscopic polymers and, despite the 
samples are maintained under anhydrous conditions prior to analysis, in a few 
minutes in contact with atmospheric humidity absorb significant amounts of 
water. Following the loss of water, PVP degraded via a single step with a 
maximum degradation rate at 427 °C, accomplishing by a weight loss of 94%. 
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PLGA-g-PVP instead presented two weight losses, at 274 °C equal to 83% and 
a 404 °C of about 9%. By comparing the TGA curves of the PLGA-g-PVP 
with those of the PVP and the PLGA is noted that the two weight losses 
shown by the PLGA-g-PVP are respectively attributable to thermal 
degradation of PLGA backbone (T = 274 °C) and PVP side chains (T = 404 
°C). From PVP weight loss % is possible to define PVP content in 
copolymers, i.e. approximately 10%. 
The differential scanning calorimetry (DSC) was used to detect the chemical-
physical transformations taking place in the polymers and involving enthalpy 
or heat capacity changes. The DSC measurements were showed in Figure 4.10 
and DSC data listed in Table 4.3. 
 
Figure 4.10. Overlapping of PVP, PLGA and PLGA-g-PVP DSC. Second 
scan from -50°C to 210°C with a temperature ramp of 20°C/min.  
Table 4.3. Glass transition temperatures and variation of the heat capacity of 
the starting polymers. 
Sample PLGA Tg (°C) PVP Tg (°C) 




PLGA 46 - 0.60 - 
PVP - 178 - 0.33 
PLGA-g-PVP10:1 46 NDa 0.52 NDa 
aND = not detected 
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Thermogram corresponding to PLGA analysis showed a glass transition 
temperature (Tg) at 46 °C associated to a variation of heat capacity (ΔCp) equal 
to 0.60 J/g·°C. While, the PVP has Tg at 178 °C with a ΔCp equal to 0.33 J/g·
°C. PVP and PLGA homopolymers are reported to be poorly miscible.liii In 
DSC thermograms, the presence of two separated not miscible phases are 
represented in two glass transitions in correspondence of those of the 
individual component. Each glass transition is associated to ΔCp proportional 
to weight amount of each component. Thus, for PLGA-g-PVP copolymer, 
two different glass transitions were expected, with two ΔCp values 
proportional to PLGA and PVP amounts present herein. However, PLGA-g-
PVP showed only a single transition at 46 °C with a ΔCp equal to 0.52 J/g·°C, 
corresponding to PLGA Tg. The associated ΔCp was lower than that of not-
grafted PLGA (0.52 J/g·°C vs 0.60 J/g·°C). Taking advantage of 
proportionality law that correlate ΔCp to material weight and applying the 
Equation 1, it is possible to calculate the PLGA weight amount in the 
copolymer PLGA-PVP (x), amounting to 87%: 
   
             
             Equation 4.1 
TGA analysis described above provided PLGA weight content of 90%. Within 
experimental error associated with the two techniques (± 5%), the two 
characterizations provide comparable results. The absence of a glass transition 
in correspondence of the PVP Tg can be attributed to the low PVP content. 
4.7.2 Electrospinning and characterization of PLGA fibres 
Non-woven fabric was spun starting from a PLGA26 solution in 70:30 v/v 
DCM:DMF. Preliminary observations by optical microscopy evidenced fibres 
of micrometric dimensions. Several experimental observationsliv,lv,lvi have 
reported the influence of solution concentration on fibre morphology. In 
particular, at low concentrations, the polymer was spun in form of micro and 
nanobeads, increasing concentration very rich of beads thin fibres are 
obtained, further increasing allow to electrospun fibres of larger diameter 
devoid of defects. This behaviour is closely related to the number of physical 
linkages between chains in solution.lvii In consideration of the above, to 
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decrease fibre sizes under submicron diameters, polymer concentration was 
decreased to 22% w/v using the same solvent mixture, obtaining PLGA22. 
This solution was electrospun and analysed by scanning electron microscope 
and SEM images at both polymer concentration are reported in Figure 4.11. 
SEM images of Figure 4.11a and Figure 4.11b of PLGA26 fibres showed no 
beads but diameters between 0.9 and 1.9 μm. While, scaffold obtained instead 
from the solution at a lower concentration, PLGA22, presented fibres with an 
average size between 0.1 and 0.5 μm. However, having a less stable 
concentrated jet, fibrous structure possessed high number of beads and 
irregular diameter distribution. Probably, the spinning of a PLGA solution at 
an intermediate concentration would have allowed to obtain sub-micrometre 
fibres devoid of beads with homogeneous diameter distribution. But this 
optimization was not carried out, because unnecessary for the purposes of  the 
work. 
 
Figure 4.11. SEM images. a) 1000x PLGA26, b) 4000x PLGA26, C) 1000x 
PLGA22, d) 4000x PLGA22. 
Nonwoven fabric were further characterized by measuring contact angle of a 
drop of water deposited on the sample surface, providing informations on the 
wettability of the material (for more in deep information on wettability see 
chapter 1 paragraph 1.4.3). 
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Table 4.4 compares the average contact angles obtained for the two nonwoven 
fabrics PLGA and for a film of the same copolymer. 
Table 4.4. Contact angle of a water drop deposited on PLGA-based materials. 
Sample 
Average water  
contact angle ±σ (°) 
PLGA26 
(diameter: 0.9-1.9 μm) 
99 ± 4 
PLGA22 
(diameter: 0.1-0.5 μm) 
132 ± 6 
Film 69 ± 1 
Contact angle measurements provided different values, despite the same 
chemical composition of materials. In particular, wettability was greater in the 
case of the film and smaller in the case of nonwoven fabrics, probably due to 
the different surface roughness. A smooth surface, as in the case of the PLGA 
film, had a contact angle lesser than a porous material, as the case of 
electrospinned fibres. Furthermore, for the same reason, the two scaffolds had 
two different contact angle. The presence of beads and thin fibres, in the case 
PLGA22, made its surface less uniform and more wrinkled, giving greater angle 
of contact, compared to a more homogeneous surface of PLGA26. Similar 
results have been reported in the literature in the case of non-woven-fabrics of 
other polymeric materials.lviii,lix 
4.7.3 Electrospinning and characterization of PLGA-g-PVP fibres 
Preliminary electrospinning tests of PLGA-g-PVP were conducted using a 
solution of 30% w/v in 70:30 DCM:DMF. Results indicated that very thin and 
full of beads fibres were obtained (Figure 4.12a). Instead, in the case of PLGA-
g-PVP37, homogenous fibres with few imperfections were electrospinned 
(Figure 4.12b, Figure 4.12c). PLGA-g-PVP37 fibres had an average diameter 
between 0.2 and 1 μm. 
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Figure 4.12. SEM images. a) 1000x PLGA-g-PVP30, b) 1000x PLGA-g-PVP37, 
c) 4000x PLGA-g-PVP37. 
Wettability of scaffolds were evaluated by contact angle measurements. Trend 
over time is reported in Figure 4.13. Graph is representative of a single drop 
on the non-woven PLGA-g-PVP fabric and a single drop on a film of the 
same composition. 
 
Figure 4.13. Contact angle results as a function of time for a PLGA-g-PVP37 
non-woven fabric and for a PLGA-g-PVP films (representative 2 drops). 
The trend of angle of contact of fibrous scaffold was not constant over time 
and decreased rapidly within 2 seconds, after which the droplet was completely 
absorbed by the porous structure of the sample. Furthermore, the initial 




















angle values of PLGA fibres, a consequence of PVP grafts on the main 
backbone of PLGA that increased copolymer hydrophilicity. 
The PLGA-g-PVP37 films instead presented an contact angle practically 
constant over time with a mean value of 57° ± 6°. The addition of PVP chains 
on PLGA significantly increases the wettability. Indeed, comparing its contact 
angle value with those obtained from PLGA, a greater wettability was 
highlighted for PLGA-g-PVP compared to PLGA, also in the case of films. It 
is noted that the PVP is a water-soluble polymer and had not been therefore 
conducted contact measurements on this polymer. 
4.7.3 Electrospinning and characterization of PLGA/PLGA-g-PVP 
fibres 
Above described contact angle measurements have shown that the non-woven 
fabric of PLGA was strongly hydrophobic and a drop of water did not 
penetrate inside the porous structure. The scaffold of PLGA was therefore not 
wettable by water. In contrast, the PLGA-g-PVP was wet in a few seconds due 
to the addition of PVP chains grafted on PLGA chains. To modulate the 
wettability of the scaffolds, minimizing the use of non-commercial PLGA-g-
PVP, fibres of PLGA containing small amounts of PLGA-g-PVP were 
produced. 
PLGA-g-PVP was introduced into the fibres by adopting two strategies: 1) 
Electrospinning of mixtures. Copolymers were solubilised in the same solvent 
system and the obtained solution was electrospun leading to scaffolds with 
different content of PLGA-g-PVP depending on the concentration in the 
starting solution; 2) Coaxial electrospinning: were prepared two separate 
solutions of PLGA and PLGA-g-PVP and electrospunned simultaneously by 
two needles arranged in a coaxial configuration. The PLGA-g-PVP solution 
was kept in the outside needle while that of PLGA in the inner needle. The 
PLGA-g-PVP content in the fibres depended both from concentration and 
flow rate of the two solutions. 
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4.7.3.1 Electrospinning of blends 
SEM images in Figure 4.14 show in both cases, fibres with only a few beads. 
Blend13 fibre diameter was between 0.4 and 0.9 μm, while those of Blend37 
were thicker fibres with a diameter between 0.6 and 1.5 μm. 
 
Figure 4.14. SEM images. a) 1000x of Blend13 b) of 4000x Blend13 c) of 1000x 
Blend37 d) of 4000x Blend37. 
 
Figure 4.15. TGA overlapping of non-woven fabrics of Blend13, Blend37 and 
the starting polymer (PLGA, PLGA-g-PVP). temperature ramp of 10 °C/min. 
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To assess the composition of produced nonwoven fabrics, thermogravimetric 
analysis was carried out. In Figure 4.15, TGA thermograms of the blend along 
with that of the two components for comparison were depicted. Both blend 
fabrics had a small weight loss at a low temperature due to adsorbed water and 
two degradation step, one at a lower temperature (T ~ 290 °C) and one at a 
higher temperature (T ~ 400 °C). As described in paragraph 4.5.3, the second 
weight loss is attributable to the PVP degradation. PVP weight loss was of 
2.3% for the Blend13 and of 4.0% for the Blend37, index that a greater PVP 
content was present Blend37. 
The overall wettability of the non-woven fabric was evaluated by contact angle 
measurements for both samples. In both cases, contact angle values were 
constant over time. Results are collected in Table 4.5, data relating to PLGA 
scaffold were also reported for comparison. It was noted that the contact 
angles of PLGA/PLGA-g-PVP blend were independent of the PLGA-g-PVP 
content. In addition, sample wettability did not increase; contact angle values 
were similar to that of PLGA22 and PLGA26 fabrics.  
Table 4.5. Comparison of the mean contact angle of blends based on PLGA / 
PLGA-g-PVP and non-PLGA-woven fabrics. 
Sample Average contact angle (°) 
Blend13 
(fibre diameter: 0.4-0.9 μm) 
122 ± 6 
Blend37 
(fibre diameter: 0.6-1.5 μm) 
122 ± 3 
PLGA26 
(fibre diameter: 0.9-1.9 μm) 
99 ± 4 
PLGA22 
(fibre diameter: 0.1-0.5 μm) 
132 ± 6 
Results evidenced that fibre surface of Blend13 and Blend37 is not enough rich 
of PVP units to significantly decrease the hydrophobicity of the fabric when 
compared to those of only PLGA. The strategy of mixing the copolymers was 
not so effective, at least up to concentrations of PLGA-g-PVP equal to 37%. 
Evidently, the total amount of PVP in Blend37 (4.0%) was homogenously 
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distributed along the section of the fibre and was not enough to influence 
surface property. 
4.7.3.2 Coaxial electrospinning of copolymers 
In order to increase the wettability of the fibres of PLGA, without using too 
high concentrations of PLGA-g-PVP, the latter was introduced into the fibres 
by adopting a different strategy to that described in the previous paragraph. 
The electrospinning was therefore conducted using two coaxial needles, the 
outer one containing the PLGA-g-PVP solution and the internal one 
containing the PLGA solution. In this configuration, it is expected that the 
surface of so produced fibres is richer PLGA-g-PVP compared to fibres 
obtained by electrospinning of mixtures, at equal copolymer content in the 
fibre. 
The global composition of fibres was modulated by varying the flow rate of 
the two starting solutions. Three scaffolds with three PLGA-g-PVP percentage 
in the fibre (13%, 25% and 37% w/w) were electrospun and named Coax13, 
Coax25, Coax37 respectively. Figure 4.16 showed SEM images of fabrics 
obtained by coaxial electrospinning. All samples have sub-micrometre fibres. 
Morphology was not perfectly smooth, but some beads very elongated were 
present, particularly in low-PLGA-g-PVP content samples (i.e. Coax13 and 
Coax25). 
Composition of the nonwoven fabrics produced was evaluated by 
thermogravimetric analysis. Figure 4.17 shows the thermograms of the samples 
by coaxial electrospinning together with that of the two pure components for 
comparison. 
The TGA curves of Coax samples show similar trends of PLGA-g-PVP 
sample. A first weight loss at low temperature (T <150 °C) due to the loss of 
adsorbed water, a second weight loss after 200 °C, given by the degradation of 
PLGA chains, and the last weight loss around 400 °C, attributable to the 
degradation of grafted PVP chains. The last weight loss can provide 
informations on the composition of samples in terms of PVP weight amount. 
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Table 4.6 shows these values of weight loss for samples Coax and for 
comparison the values for the samples Blend. 
 
Figure 4.16. SEM images) of 1000x Coax13, b) of 4000x Coax13, c) of 1000x 
Coax25, d) of 4000x Coax25, e) of 1000x Coax37, f) of 4000x Coax37. 
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Figure 4.17. TGA overlapping tissue-non-tissue of Coax13, Coax25 and Coax37 
and of the starting polymers PLGA and PLGA-g-PVP. Temperature ramp of 
10 °C/min. 
Table 4.6. PVP weight loss% of Coax and Blend samples from TGA analysis. 
Sample 
Δm (%) 






Coax13, Coax25, Coax37 presented increasing weight amount of PVP in fibres, 
as expected by increasing flow rate of external solution. Comparing the values 
obtained from Coax13 and Coax37 and the respective Blend13 Blend37, PVP 
content was comparable. 
Contact angle values of Coax samples and for comparison also those Blend 
were reported in Table 4.7. In this case fibre diameters were not shown 
because all samples had sub-micrometre dimension and similar morphology. 
Coax13 and Coax25 samples were still hydrophobic, while Coax37 was wettable. 
In contrast, the blend with the same composition, i.e. Blend37, was 
hydrophobic. Therefore, coaxial needle favoured PLGA-g-PVP location on 
fibre surface and a quantity of 37% by weight appears to be sufficient to wet 
the scaffold. It is noted that the drop of water is absorbed by the Coax37 
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sample in about 25 seconds, time significantly greater than that of the pure 
PLGA-g-PVP non-woven fabric, about 2 sec. 
Table 4.7. Comparison of the mean contact angle of samples Blend and Coax 
samples. 
Sample Average contact angle (°) 
Coax13 126 ± 7 
Coax25 121 ± 6 
Coax37 
Decreasing trend over time 
Drop was adsorbed after 25 s 
Blend13 122 ± 6 
Blend37 122 ± 3 
 
4.8 CONCLUSIONS 
In this work, PLGA-based scaffolds were produced by electrospinning for 
biomedical applications. In order to modulate the wettability of the scaffolds 
PLGA, which is a hydrophobic copolymer, has been used in combination to a 
synthetic copolymer consisting of a main chain of PLGA with grafts lateral 
chains constituted by highly hydrophilic units of poly(vinylpyrrolidone), named 
(PLGA-g-PVP). 
Measurements of contact angle conducted on only PLGA film and only 
PLGA-g-PVP has confirmed the increased wettability of the latter with respect 
to the only PLGA. Comparing the wettability of the corresponding non-
woven-fabrics for the difference in wettability is even more obvious: the 
scaffold is PLGA is highly hydrophobic, while the scaffold is PLGA-g-PVP 
absorbs water drops in a few seconds. Then, comparing contact angle values 
obtained from the same materials but with different surface roughness, it was 
found that a film with a smooth surface by the use of a spin coater, had 
smaller contact angles and was therefore more wettable with respect to the 
fibrous scaffolds, that it is a porous material with a highly corrugated surface at 
micrometre level. 
To modulate the wettability of the scaffolds, minimizing the amount of 
synthetic PLGA-g-PVP, PLGA fibres containing small amounts of PLGA-g-
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PVP were electrospinned adopting two different strategies: (1) by 
electrospinning of mixtures of PLGA and PLGA-g-PVP to obtain fibres with 
different content of copolymers depending on their concentration in the 
starting solution; (2) by coaxial electrospinning, in which PLGA-g-PVP 
solution fed the external needle and PLGA solution fed the internal one. 
PLGA-g-PVP content in the fibres depends by solution concentrations and 
flow rates.  
The composition of the scaffolds products was verified by TGA measures and 
the wettability by contact angle measurements. 
From contact angle measurements on scaffolds produced by electrospinning 
of blends, it was concluded that the addition of PLGA-g-PVP to PLGA 
solution with w/w percentage of 37%, did not vary significantly the wettability 
of the material. Most likely, having PLGA-g-PVP a low amount of PVP (10% 
w/w , as valuated by TGA analysis), it was assumed that the few PVP chains 
were homogeneously distributed along the fibre section, and thus, did not lead 
to a significant increase of material hydrophilicity. 
Therefore, PLGA-g-PVP was tried to locate on fibre surface in order to better 
exploit the hydrophilicity of this copolymer to modify scaffold wettability, by 
using coaxial electrospinning. Analysing three products containing increasing 
percentages of PLGA-g-PVP, only the sample having 37% w/w appeared to 
be well wettable: indeed, a water drop was absorbed by the porous structure in 
approximately 25 seconds. In addition, this scaffold was more wettable than 
that of one produced by electrospinning of the mixture having similar 
composition. Therefore, it can be concluded that coaxial electrospinning was 
useful to prepare wettable PLGA-based non-woven fabric. It was also 
demonstrated that wettability of nonwoven fabrics was influenced both by the 
morphology of the same fabric, both on the chemical composition of the 
fibres.  
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HYDROGELS FOR TISSUE ENGINEERING BASED ON 
HYALURONIC ACID, GELATIN AND AGMA1 
 “Aim of this piece of work was the synthesis of a new classes of poly(saccharide-co-
amidoamine) and poly(saccharide-protein-amidoamine) 3-D-networks intended as scaffolds 
for tissue regeneration. In particular, hyaluronan-polyamidoamine and hyaluronan-gelatin-
polyamidoamine hydrogels were synthesised by amidation reaction between the carboxylate 
groups of hyaluronan and the amine groups of gelatin and of an NH2-functionalized PAA, 
promoted by 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride 
(DMTMM) as coupling agent. In order to promote hepatic cell proliferation serotonin was 
covalently linked to hydrogels, by adding it to the reaction mixture, exploiting the same 
coupling reaction.” 
5.1 HYDROGELS 
Hydrogels are made up of cross-linked polymer networks and may be 
classified as: (i) chemical hydrogels and (ii) physical hydrogels. In (i), the 
polymer network is obtained by chemical cross-linking, whereas in physical 
hydrogels (ii), chains are held together by ionic, hydrogen bonding and or 
dipolar interactions. Linear homopolymers, linear copolymers, and block or 
graft copolymers having cross-linkable functional groups are usually used to 
form chemical cross-linked hydrogel, on the other hand, polyion-, polyion–
polyion or H–bonded complexes as physical cross-linked matrix.i In both 
cases, cross-link density is crucial in determining the properties and 
applications of the gels, as it is responsible for the swelling behaviour and 
therefore for the combined solid-like and liquid-like characteristics. 
Main property of hydrogels is the ability to absorb huge amounts of water, up 
to several thousand percentages, without dissolving.ii Equilibrium state is 
reached when osmotic driving forces, which encourage water to come into the 
hydrogel matrix, and cohesive ones exerted by hydrogel macromolecules are 
balanced. Cohesive forces depend primarily on hydrogel crosslinking 
density.iii,iv In general, the higher the cross-linking extent, the lower the gel 
swelling. Equally, the more hydrophilic the polymer matrix, the higher the 
amount of water absorbed by the hydrogel.v In the swollen state, hydrogels are 
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soft and rubbery, resembling to a great extent living tissues. For this reason, 
hydrogels have become attractive to the new field of „tissue engineering‟ as 
matrices used for cell/tissue regenerating.vi,vii,viii,ix,x,xi 
In order to be used as biomaterials, hydrogels must be biocompatible. 
Inflammatory response to a hydrogel can affect the immune response toward 
the transplanted cells and vice versa.xii,xiii In particular if they are components 
of or have macromolecular properties similar to the natural extracellular matrix 
(ECM).xiv,xv,xvi 
5.2 HYALURONIC ACID 
Hyaluronic acidxvii,xviii,xix is a naturally occurring, biocompatible, and 
biodegradable polysaccharide composed of repeating disaccharide units of D-
glucuronic acid and N-acetyl-d-glucosamine linked by alternating β(1→4) and 
β(1→3) linkages. Carboxyl groups in the glucuronic acid residues are 
negatively charged at physiological pH and ionic strength, giving as result a 
polyanions sodium hyaluronate, referred as hyaluronan (HA). xx It is the 
simplest glycosaminoglycan (GAG) and an important component of ECM, it 
is ubiquitously present in many biological fluids and tissues, such as eyes, 
joints, and cartilage.xxi,xxii It is naturally synthesized by a class of integral 
membrane proteins called hyaluronan synthases,xxiii and degraded by a family 
of enzymes called hyaluronidases.xxiv Degradation products, i.e. oligomeric HA 
( ̅ <100 000), are usually found as inflammatory, immuno-stimulatory and 
angiogenic.xxv These chains are then fractionated in monosaccharide units by 
β-d-glucuronidase, and β-N-acetylhexosaminidase.xxiv 
Its function in the body is, among others, to bind water and lubricate movable 
parts of the body, such as joints and muscles. HA is highly hygroscopic and 
this property is believed to be important for modulating tissue hydration and 
osmotic balance.xxvi In addition to its function as a passive structural molecule, 
HA also acts as a signalling molecule by interacting with cell surface receptors 
and regulating cell proliferation, migration, and differentiation.xxvii,xxviii Thanks 
to these favourable properties, HA has been intensively used as component of 
scaffolds for tissue engineering.xxix,xxx,xxxi  
A pitfall of HA-based materials is the fast HA in vivo degradation. HA half-life 
after injection into skin and joints is lower than 24 h.xxxii,xxxiii This time is not 
enough to allow restoring of tissues and lost functionalities. Modifications of 
HA chemical structure are needed, in order to camouflage HA chains to 
enzymes.xxxiv 
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HA can be chemically modified by two different ways: cross-linking or 
conjugation. HA conjugation and HA cross-linking can be in principle based 
on the same chemical reactions and only differ in that, in the first case, a 
compound is grafted onto one HA chain by a single bond only, whereas in the 
second case, different HA chains are linked together by two bonds or more, as 
depicted in Figure 5.1. Some methods are performed in water while others, 
need to be performed in organic solvents, such as dimethylformamide (DMF) 
or dimethylsulfoxide (DMSO).xxxv, In the latter case, native HA sodium salt 
first needs to be converted into its acidic form. Since HA is soluble in water, 
the easiest method is to perform the reaction in water. However, treatments in 
alkaline or acidic aqueous conditions induce hydrolysis of HA chains.xxxvi,xxxvii  
 
Figure 5.1. Schematic representation of chemical conjugation and cross-
linking. 
Typical partners in cross-link/conjugation products are polysaccharides 
(alginatexxxviii, chitosanxxxix, agarosexl, etc), proteins or oligopeptide 
(fibronectinxli, fibrin,xlii gelatinxliii, collagenxliv, etc) and also synthetic polymers, 
such as PLA,xlv PLGAxlvi, PGAxlvii PHEMAxlviii and so on.xlix In addition to 
reduce degradation rate, improvement in cell adhesion onto HA-based 
scaffolds is reached when carboxylic acid groups are involved in reactions. It is 
due to a reduction of repulsive force between cell membranes (negative 
charged by presence of lipids) and carboxylic acid of HA.l 
5.3 GELATIN 
Gelatin is a soluble protein obtained by partial hydrolysis of collagen, the main 
fibrous protein constituent in bones, cartilages and skins; therefore, the source, 
age of the animal, and type of collagen, are all intrinsic factors influencing 
properties of the produced gelatin.li The acid-extracted gelatin is designated 
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“Type A” , whereas the product of the alkaline method is referred to as “Type 
B”. Traditionally, hydrogen chloride and lime or sodium hydroxide are used 
for the types A and B methods, respectively.lii  
Compared to its precursor, gelatin is economical and low-antigenic, and it has 
been presumed to retain some of the information signals, such as the RGD 
sequence of collagen,liii also if its biological activity of gelatin should be zero, 
due to the absence of the essential amino acid, i.e. tryptophan. liv The tripeptide 
arginyl-glycyl-aspartic acid (RGD) is an oligopeptide capable of reproducing 
the receptorial sites of proteins, such as fibronectin, vitronectin, and others 
playing a fundamental role in cell adhesion.lv 
Gelatin is reported to contain 18 amino acids linked together in a partially 
ordered fashion. The various amino acids obtainable from some gelatins by 
complete hydrolysis, in grams per 100 grams of dry gelatin, are listed in Table 
5.1.lvi,lvii,lviii No significant differences in the value of N-terminal residues as well 
as in the amino acid composition have been mentioned relating to the origin of 
gelatin. Type A gelatin has been reported to have an isoionic point of 7 to 9, 
and the isoionic point for lime (alkali) processed gelatin falls in the range of 4.8 
to 5.1.lix Isoionic points are important values, determining the reactivity of 
gelatin, especially in pH-dependent coupling reaction. 
Table 5.1. Amino acid composition of different type and source of gelatin. 
Amino Acid Type A (Pork skin) Type B (Calf skin) Type B (Bone) 
Alanine 8.6 10.7 9.3 11.0 10.1 14.2 
Arginine 8.3 9.1 8.55 8.8 5.0 9.0 
Aspartic acid 6.2 6.7 6.6 6.9 4.6 6.7 
Cystine 0.1  Trace Trace 
Glutamic acid 11.3 11.7 11.1 11.4 8.5 11.6 
Glcine 26.4 30.5 26.9 27.5 24.5 28.8 
Histidine 0.9 1.0 0.74 0.8 0.4 0.7 
Hydroxlysine 1.0  0.91 1.2 0.7 0.9 
Hydroxyproline 13.5  14.0 14.5 11.9 13.4 
Isoleucine 1.4  1.7 1.8 1.3 1.5 
Leucine 3.1 3.3 3.1 3.4 2.8 3.5 
Lysine 4.1 5.2 4.5 4.6 2.1 4.4 
Methionine 0.8 0.9 0.8 0.9 0.0 0.6 
Phenylalanine 2.1 2.6 2.2 2.5 1.3 2.5 
Proline 16.2 18.0 14.8 16.4 13.5 15.5 
Serine 2.9 4.1 3.2 4.2 3.4 3.8 
Threonine 2.2  2.2  2.0 2.4 
Tyrosine 0.4 0.9 0.2 1.0 0.0 0.2 
Valine 2.5 2.8 2.6 3.4 2.4 3.0 
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Since gelatin has a sol-gel transition temperature around 30 °C, it should be 
chemically cross-linked in order to avoid dissolution at body temperature. 
Thanks to the fact that gelatin is composed of a large variety of side chains, a 
wide variety of chemical modification methods, introducing cross-linkable 
groups, have been proposed.lx, lxi The choice of potential reagents is limited to 
water-stable ones because gelatin only dissolves in water and in a number of 
alcohols.lxii In most cases, bifunctional reagents including glutaraldehyde,lxiii 
diisocyanates,lxiv,lxv carbodiimides,lxvi genipin,lxvii polyepoxy-compounds,lxviii and 
acyl azideslxix have been applied. When gelatin is combined with sugars (e.g., 
agarose), 1,1-carbonyldiimidazole can be applied as cross-linker.lxx 
5.4 AGMA 1  
The linear amphoteric poly(amidoamine) nicknamed AGMA1 is prepared by 
the Michael-type polyaddition of monoprotonated 4-aminobutylguanidine 
(agmatine) and 2,2-bis(acrylamido)acetic acid (BAC).lxxi Agmatine belongs to 
the family of biogenic amines and is involved in many physiological functions. 
Agmatine derives from the arginine decarboxylase-mediated decarboxylation 
of L-arginine, a semi-essential amino acid with interesting properties mostly 
attributed to its guanidine group. Agmatine and arginine play an important role 
in cell growth and proliferation, as well as in the synthesis of proteins and 
nucleic acids.lxxii  
Table 5.2. Comparison of Some Structural Features of AGMA1 Repeating 
Unit and RGD Sequence 
Structural features AGMA 1 unit RGD sequence 
no. of guanidine groups 1 1 
no. of carboxyl groups 1 1 
no. of amidic groups 2 2 
distance between 
guanidine and carboxyl 
groups 
sequence of 10 atoms 
including 2 amidic groups 
sequence of 11 atoms 
including 2 amidic groups 
 
AGMA1 repeating unit carries both guanidine- and carboxyl groups and, 
therefore, shows a strong structural resemblance to the RGD sequence (Table 
5.2). It was reported that AGMA1 is nontoxic and non-haemolytic in vitro 
within all pH ranges tested (4-7.5).lxxi Haemolysis is usually a function of the 
overall charge, reaching low value at physiological and neutral pHs. High 
toxicity was usually associated with the polycationic character of other studied 
PAAs.lxxiii As revealed from speciation curves (Figure 5.2), AGMA1‟s 
isoelectric point is at pH 10, corresponding to the intersection of the curves 
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relative to LH+ and L-. Charge distribution profiles show that this polymer is 
prevailingly cationic at all physiological pH values, the net average charge per 
unit varying from about 0.5 at pH 7.4, to about 1.0 at pH 5. Probably, the 
RGD-like repeating units exert a stabilizing action on cell membranes, 
overshadowing the membranolytic effect of the excess positive charges. 
Grafted on a material‟s surface, RGD is capable of promoting a strong cell 
adhesion even at very low surface densities.lxxiv Similarly, AGMA1 hydrogels 
have exhibited good cell proliferation ability. In particular, AGMA1 hydrogel 
layers exhibited towards epithelial cells (Madin-Darby Canine Kidney epithelial 
cell line) a level of cell adhesion comparable to that of commercial plastic 
substrates for tissue culturing even in the presence of only 0.1% of fetal 
bovine serum.lxxv AGMA1 hydrogels were successfully used as scaffold for 
tissue engineering.lxxvi In particular, hydrogels with tubular shape proved to 
facilitate nerve regeneration, achieving good surgical outcomes with no signs 
of inflammation or neuroma.lxxvii In addition, AGMA1–montmorillonite 
composites with tunable stiffness were used as scaffolds for bone tissue-
engineering applications.lxxviii 
 
Figure 5.2. AGMA1 ionic speciation as a function of pH. Figure adapted 
from reference. lxxiii 
5.5 Chemical design of hydrogels 
Aim of this work was the production of chemical cross-linked hydrogels with 
potential as scaffolds for the regeneration of liver tissue. Sodium hyaluronate 
and gelatin (HA-Gel) were selected as scaffolding material to mimic the crucial 
components of ECM, in order to enhance cell proliferation, migration, and 
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HA-Gel scaffolds for tissue engineering were already described in literature.lxxix 
Leaving apart studies in which HA-Gel physical blends were used,lxxx,lxxxi,lxxxii all 
other works reported 3-4 step long synthetic schemes, consisting firstly in 
functionalization step of one terminus or pendant groups of both reagents 
followed by coupling reaction.lxxxiii,lxxxiv,lxxxv,lxxxvi,lxxxvii,lxxxviii 
In one instance, the use of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) as cross-linker agent in order to obtain hydrogels with a one-step 
process is reported.lxxxix In this work, HA-Gel scaffolds were fabricated by 
freeze-drying of blend solution and then immersed for 24h in EDC solution. 
In the resulting hydrogels, EDC efficacy was observed as gelatin cross-linker, 
but not for HA one. HA was only physical dispersed in the hydrogel structure, 
and gradually released when immersed in an aqueous solution. Furthermore, 
proliferation of L929 fibroblasts on the surfaces of these scaffolds after cell 
culturing showed a lower activity compared with control plate. 
In this work, introducing AGMA1 in HA-Gel hydrogels was expected bring 
many benefits: on one side it will allow forming macroscopically homogeneous 
hydrogels with HA and gelatin, thanks to its easy coupling with both polymers. 
In addition, the RGD-mimic cationic AGMA1 units and their counteracting 
HA polyanionic nature, responsible for repulsive interactions with cell 
membranes, may improve cell adhesion and proliferation. As a further 
modification, serotonin (Ser) was introduced in the hydrogel structure to 
improve liver cell adhesion and proliferation. Serotonin is a biogenic 
monoamine neurotransmitter with variable effects on many different target 
organs.xc It is derived from the L-tryptophan, which is hydroxylated to 5-
hydroxy-L-tryptophan (5-HTP) by tryptophane hydroxylase (Tph). Recent 
scientific studies highlighted the involvement of serotonin in the induction of 
hepatocyte DNA synthesis after a hepatectomy in the rat and human.xci,xcii 
Serotonin can be potentially associated with either beneficial or detrimental 
effects on liver regeneration and these actions are mediated through many 
different receptor subtypes located either centrally or peripherally.xciii 
In this work, hydrogels were synthesised by a one-pot coupling reaction 
between the carboxylate groups of HA and the amine groups of Gel, AGMA1 
and Ser, using 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4- methylmorpholinium 
chloride (DMTMM) as coupling agent. DMTMM is a water-soluble cross-
linker used for the amide bond formation of amines in presence of carboxylic 
group, without taking part in linkages.xciv According to literature reports, 
DMTMM efficacy is superior to that of EDC/NHS (1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide / N-Hydroxysuccinimide),xcv PyBOP 
((Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate)xcvi 
for ligation of amines to carboxylate anions. Furthermore, it does not require 
accurate pH control or pH shift during the reaction to be effective.xcvii 
CHAPTER 5 
HYDROGELS FOR TISSUE ENGINEERING BASED ON HYALURONIC 
ACID, GELATIN AND AGMA1 
182 
 
5.6 EXPERIMENTAL SECTION 
5.6.1 Materials 
Sodium hyaluronate (HA) with a  ̅  260 000 (evaluated by Size Exclusion 
Cromatography, SEC) was obtained from Bioiberica, Gelatin powder from 
bovine skin (type B with bloom ~225 g) was purchased from Sigma Aldrich 
(Spain). 2,2-Bis(acrylamido)acetic acid (BAC) were synthesized as previously 
described and purity determined by Nuclear Magnetic Resonance (NMR) and 
titration.xcviii 4-Aminobutylguanidine sulphate (agmatine), lithium hydroxide 
monohydrate, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium 
chloride (DMTMM), N-Boc-ethylenediamine, 37% hydrochloridic acid, 
serotonin, sodium nitrate, sodium phosphate monobasic were purchased from 
Sigma-Aldrich. Phosphate buffer solution (PBS) was prepared using Sigma 
Aldrich dry powder. All these reagents were used without further purification. 
5.6.2 Methods 
1H-, 13C-, HSQC-, and COSY- NMR spectra were recorded using a Bruker 
NMR spectrometer operating at 400 and 133.3 MHz. Spectra were recorded 
on samples dissolved in deuterium oxide (D2O). 
SEC analyses were obtained using a Shimadzu system comprising a DGU-
20A3 solvent degasser, an LC-20AD pump, a CTO-20A column oven, an SIL-
20A HT autosampler, an RID- 10A refractive index and an SPD-20A 
Shimadzu UV-VIS detector (flow rate: 1 mL min-1, temperature: 40°C). The 
instrument was equipped with three columns (300 mm x 7.5 mm, 8 mm): PL-
aquagel-OH 30 TM, PL-aquagel-OH 40TM and PLaquagel- OH 50TM, protected 
with a guard column (50 mm x 7.5 mm, 8 mm) (Polymer Laboratories). 
Calibration was performed with polysaccharide standards (Pullulan 
Polysaccharide, PL2090-0100 VARIAN) ranging from 180 to 708 000. The 
eluent was a pH 7 0.2 M NaNO3 and 0.01 M NaHPO4 buffer solution 
prepared using milli-Q water. Samples concentration 2 mg/mL. 
Fourier Transformed Infrared (FTIR) spectra in Attenuated Total Reflection 
mode (ATR-FTIR) were obtained using a Perkin Elmer Spectrum One 
instrument. Spectra of reagents and dried hydrogels were recorded in the 4000 
to 650 cm−1 range after 4 scans and with a resolution of 4 cm−1. 
Thermogravimetric analysis (TGA) was performed on 10 mg dry hydrogels 
with a TGA Q500 (TA Instruments) working from 25 to 600°C at 10°C/min 
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heating rate and under 50 mL/min nitrogen flow. Tests were repeated two 
times and data obtained as media of these measurements. 
Differential scanning calorimetric (DSC) analyses were carried out with a 
Mettler Toledo DSC823 (Mettler Toledo, Italy) equipped with the STAR 
Software and the FRS5 Mettler Toledo ceramic sensor. The instrument was 
calibrated with indium for melting point and heat of fusion. The dry samples 
(5-10 mg) were placed in aluminium pans and heated from 0 to 200°C at a 
constant rate of 10°C min-1. Empty pan was taken as reference. Tg was taken 
as the midpoint of the heat capacity transition.  
Atomic force microscopy (AFM) experiments were performed in tapping 
mode using a Multimode AFM (Veeco Instruments, Santa Barbara, CA) 
equipped with a Nanoscope IVa control system (software version 6.14r1). 
Silicon tapping probes (RTESP, Veeco) were used with a resonance frequency 
of 300 kHz and a scan rate of 0.5 Hz. 3 μm2 AFM images were taken for each 
sample. Topography was examined by topographical AFM, whereas 
composition was explored using phase imaging AFM. 
5.6.3 Synthesis of AGMA10 and AGMA20 
In a 200 mL flask, BAC (purity: 97%, 10.0 g, 0.049 mol) and lithium hydroxide 
monohydrate (2.04 g, 0.049 mol) were dissolved under stirring in distilled 
water (17 mL) and degassed with nitrogen. After complete dissolution, 4-
Aminobutylguanidine sulphate (10.056 g, 0.044 mol) and lithium hydroxide 
monohydrate (1.88 g, 0.044 mol) were added. The clear reaction mixture was 
allowed to react for 5 days at room temperature in the dark. Mono-N-BOC-
ethylenediamine (1.88 g, 0.012 mol) was then added under stirring and mixture 
allowed reacting for 1 day in the dark. After this time, the solution was 
acidified to pH 5 with few drops of a 3 M HCl aqueous solution and 
maintained under stirring for 15 min. The final product was purified by 
ultrafiltration with a membrane with nominal molecular weight cut-off 1000 
and recovered by freeze-drying. Yield = 12.7 g (63.4%).   
AGMA20 was synthesized as described for AGMA10 using the following 
reagent amounts: BAC (10.0 g, 0.049 mol), LiOH·H2O (2.04 g, 0.049 mol), 4-
Aminobutylguanidine sulphate (9.11 g, 0.039mol), LiOH·H2O (1.66 g, 0.039), 
N-BOC-ethylenediamine (3.24 g, 0.020 mol). Yield = 2.97 g (15.5%). The 
NMR spectra were as reported for AGMA10. 
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1H-NMR 400.132 MHz (D2O, δ, ppm): 1.52-1.70 (m, NCH2CH2CH2CH2NH), 
1.70-1.92 (br, NCH2CH2CH2CH2NH), 2.32-2.52 (br, NHCH2CH2NH2), 2.69-
2.88 (br, CH2CONH), 2.88-2.95 (br, NHCH2CH2NH2), 3.13-3.29 (m, 
NCH2CH2CO), 3.40-3.62 (br, NCH2CH2CH2CH2NH), 5.52 (s, CH-COO-). 
13C NMR 100 MHz (D2O, δ , ppm ) 20.5 (NHCH2CH2CH2), 25.1 
(NHCH2CH2), 29.1 (NHCOCH2CH2), 35.8 (NHCH2CH2NH2) 40.5 
(CH2NCH2), 44.4 (NHCH2CH2NH2) 49.3 (NHCOCH2), 52.2 (NHCH2), 56.0 
(COOHCH), 155.1 (NH2CNNH), 171.3 (NHCO), 173.5 (CHCOOH). 
5.6.4 Synthesis of HA-Gel-AGMA, HA-AGMA and HA-Gel hydrogels 
HA (0.500 g) and Gel (1.00 g) were dissolved in bidistilled water (10 mL) at 
50ºC under vigorous stirring for 15 min. After complete dissolution, AGMA10 
(0.100 g) was added to the solution, followed by DMTMM (0.150 g). The 
resultant clear solution was poured in the wells (1 cm diameter, 0.2 cm 
thickness) of 12-well plate using a 10 mL syringe. The reacting mixtures were 
allowed reacting for totally 48 h at 37.5ºC in a humid atmosphere, even though 
the observed setting time was 5 min. The hydrogels were retrieved and freeze-
dried.All hydrogels were prepared by following the general procedure 
described for the HA-Gel-AGMA10 hydrogel and using the amounts of 
reagents reported in Table 5.3.  














HA-Gel 0.500 1.00 - - 0.150 10 
HA-Gel-
Agma20% 0.500 1.00 - 0.100 0.150 10 
HA-Agma10 0.500 - 0.100 - 0.150 10 
HA-Agma20 0.500 - - 0.100 0.150 10 
5.6.5 Synthesis of Serotonin containing hydrogels 
HA (0.300 g), Gel (0.600 g) were dissolved in bidistilled water (6 mL) at 50ºC 
under vigorous stirring for 15 minutes. AGMA10 (0.060 g) and Serotonin 
(0.015 g , % w/w regards to HA) were added into the solution followed by 
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DMTMM (0.090 g). Reagents were mixed, transferred in a 12 well-plate and 
allowed to proceed for 48h at 37.5ºC in a humid atmosphere. The hydrogels 
were retrieved and freeze-dried. Xerogels were sterilised by UV irradiation. 
5.6.6 Water uptake measurement 
Water uptake measurements were performed in 0.01 M pH 7.4 PBS at 37.5°C. 
Dry discs with 1 cm base diameter and 0.2 cm thickness were soaked in 25 mL 
buffer solution and maintained statically until maximum swelling for 24 h. 
After this time, discs were retrieved, wiped with filter paper to remove excess 
water and then weighed. The percentage water uptake was calculated as:  
                
(  –  )
  
           Equation 5.1 
where Wo is the initial hydrogel weight and Ws the wet hydrogel weight after 
24h. Tests were performed in triplicate. Final values were expressed as the 
means ± standard error. 
5.6.7 Flory-Rehner calculations 
The hydrogel swelling ratio based on mass (QM) was calculated by dividing the 
hydrogel mass after swelling (Ws) by the xerogel mass (Wo). Flory-Rehner 
calculations were used to determine the crosslink density and mesh size of 
hydrogels. 
The average molecular weight between crosslinks,  ̅ , was calculated using a 
simplification of the Flory-Rehner equation:xcix,c  
  
    





   )       Equation 5.2 
where Qv is the volumetric swelling ratio,  ̅ is the specific volume of the dry 
polymer,  ̅  is the average molecular weight between crosslinks, V1 is the 
molar volume of the solvent (18 mol/cm3 for water), and   is the Flory 
polymer-solvent interaction parameter. Qv was determined from the degree of 
mass swelling, QM:ci 
      
  
  
 (    )     Equation 5.3 
where    is the density of the dry polymer (1.229 g/cm3) and    is the density 
of the solvent (1 g/cm3 for water). The value of   for HA was estimated to be 
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0.473, based on several assumptions. First, it was assumed that χ for HA is 
comparable to that for dextran, a well-studied polysaccharide, because HA and 
dextran have similar chemical structures. Finally, differences between soluble, 
unmodified polysaccharides and cross-linked polymers were assumed to be 
negligible. 
The effective cross-link density,   , was calculated as follows:cii 
   
  
 ̅ 
       Equation 5.4 
The swollen hydrogel mesh size, ξ, was determined with the following 
equation:ciii.civ 
     
   √  
        Equation 5.5 
where √    is the root-mean square distance between crosslinks and depends 
on the molecular weight between cross-links. For HA, the following root-






   
            Equation 5.6 
where n is the number of disaccharide repeat units for HA with a given 
molecular weight. cvi 
5.6.8 Degradation studies 
Hydrogel degradation was studied by monitoring the residual mass of 
hydrogels discs with 1 cm base diameter and 0.2 cm thickness soaked in 0.01 
M pH 7.4 PBS at 37.5°C at different time points (1, 2, 7, 14, 21, 28 days). 
Residual mass measurements were obtained after freeze-drying, as: 
               
(     )
  
       Equation 5.7 
where Wt represents the weight of dried hydrogel at time t and Wo is the initial 
weight of hydrogel. Tests were performed in triplicate. Final values were 
expressed as the means ± standard error. 
CHAPTER 5 
HYDROGELS FOR TISSUE ENGINEERING BASED ON HYALURONIC 
ACID, GELATIN AND AGMA1 
187 
 
5.6.9 Stress strain tests 
Rheological measurements were carried out using a stress-controlled 
oscillatory rheometer ARG2 TA Instruments using parallel plate geometry. 
The test geometry was a 20 mm diameter standard steel parallel-plate. A 
dynamic mechanical analysis (stress–strain tests) was carried out to determine 
the viscoelastic properties of the HG, to obtain their storage (G‟) (elastic 
behaviour) and loss (G‟‟) (viscous behaviour) moduli. Hydrogel were prepared 
putting the reaction mixture in teflon moulds (diameter 20 mm, 0.2 mm thick). 
The reaction were conducted in a humid atmosphere at 37°C. The test 
methods employed were stress sweep, temperature ramp and frequency sweep. 
The stress sweep was set up by holding the temperature (37°C) and frequency 
(1 Hz) constant while increasing the oscillation torque from 0.1 to 10000 µN 
m. At this fixed oscillation torque (30 µN m) in the linear viscoelastic region 
and temperature (37°C), the oscillatory frequency was increased from 0.01 to 
100 Hz. In the temperature ramp test, the evolution of G„ and G„„ in the range 
of 25−100°C was measured at a heating rate of 5°C/min, with the same 
oscillation torque previously decided and frequency of 1Hz. Tests were 
performed in triplicate. 
5.6.10 Biocompatibility test 
Cell viability (CV) of hydrogels and starting reagents was assessed by a 3-(4,5-
dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) assay. To 
evaluate the possibility of cytotoxic product formation, the samples were 
immerged (or solubilized) in 5 mL of FBS-free supplemented DMEM 
(Dulbecco‟s Modified Eagle‟s Medium with 4500mg L-1 glucose) and placed on 
a shaker at 37°C. The conditioned medium was collected and filtered at days 1, 
2, 3, 7, 10, 15, 21 and stored at -20°C until required. BALB/3T3 Fibroblasts 
were seeded at a density of 8×104 cells⋅mL-1 in complete medium into a sterile 
96-well plate and incubated to confluence. After 24 hours, the medium was 
replaced with the eluted extracts (100 µL /well) for each composite, the 
control sample and the Triton X-100 (positive control), and incubated at 37°C 
in humidified air with 5% CO2 for 24 hours. An MTT solution (0.5 mg⋅mL-1) 
was prepared in warm FBS-free supplemented DMEM and plates were 
incubated at 37°C for 4 hours. Excess medium and MTT were removed and 
dimethyl sulfoxide (100 μL) was added to all wells in order to dissolve MTT 
taken up by the cells. Finally, the absorbance was measured with a BioTek 
Synergy HT detector using a test wavelength of 570 nm. CV (%) was 
calculated with the following equation: 
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CV(%) = 100 × [(ODS – ODB)/(ODC – ODB)]  Equation 5.8 
ODS, ODB, and ODC are defined as the optical density for sample (S), blank 
(B) (culture medium without cells), and control (C), respectively. 
5.7 RESULTS AND DISCUSSIONS 
5.7.1 Synthesis and characterization of soluble NH2-end-capped AGMA1 
oligomers 
As previously pointed out, hydrogels were synthesised by a one-pot reaction 
between the carboxylate groups of HA and the amine groups present in Gel 
and AGMA1 and Ser, using DMTMM as coupling agent. AGMA1 precursors 
were NH2-end-capped oligomers, in turn obtained from amide-end-capped 
oligomers prepared using non-stoichiometric acrylamide/amide ratios in the 
recipe (Figure 5.3). Different excess of BAC (namely 10% and 20%) were 
used. LiOH was used to neutralize the primary amine group of agmatine the 
carboxylic acid of BAC. The acrylamide-end-capped AGMA1 was finally 
converted to the NH2-end-capped one by reaction with mono-N-BOC-
ethylenediamine (added in excess), followed by strongly acidic treatment in 
order to remove the protecting group. The final AGMA1 products were 
nicknamed AGMA10 and AGMA20, respectively. 
 
Figure 5.3. Synthesis of AGMA10 product. AGMA20 was prepared similarly by 
using a 1:0.8 BAC:agmatine ratio. 
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1H-NMR and 13C-NMR confirmed AGMA10 and AGMA20 structures and are 
depicted in Figure 5.4 together with assignments. The percentages of amine 
end-terminated groups observed by NMR were 8 and 19% for respectively 
AGMA10 and AGMA20, in agreement with the theoretical data. By 1H-NMR 
spectrum of products was possible calculate also number average molecular 




Figure 5.4. Nuclear magnetic resonance characterization of AGMA10 and 
AGMA20 with assignments: A) amine end-terminated AGMA1 structure; 
B)1H-NMR and C) 13C-NMR spectra of AGMA10; D) 1H-NMR and E) 13C-
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5.7.2 Synthesis of hydrogels and reaction parameter optimization  
Hyaluronan-gelatin-AGMA1 (HA-Gel-AGMA) hydrogels were prepared by 
chemical cross-linking of a mixture using DMTMM as a coupling agent (Figure 
5.5). For comparison purpose, also HA-AGMA and HA-Gel hydrogel were 
prepared. Serotonin (Ser) was added to hydrogel recipes only for biological 
tests, considering that its presence did not influenced chemical and physical 
properties of hydrogels. 
 
Figure 5.5. Synthesis of HA-Gel-AGMA1-Ser hydrogels. 
The reaction mechanism implies the addition of a carboxylate anion to 
DMTMM to give an activated ester, which subsequently undergoes 
nucleophilic substitution by an amine group to give the corresponding amide. 
It should be observed that, together with chemical cross-linking, the hydrogel 
structure is stabilized by hydrogen bonds and Van der Waals interactions.cvii  
In order to produce a ready-to-use hydrogels, avoiding any purification steps, 
DMTMM initial amount was adjusted until reaching biocompatible 
concentration. This choice was further dictated by the need to not use for its 
trace removal organic solvents (such as THF, methanol, acetonitrile), that even 
if present only in traces could lead to toxic effects too. Considering cell 
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viability test further reported in Figure 5.15A, selected DMTMM 
concentration was 15 mg/mL. Similarly, cell viability tests gave 10 mg/mL 
aqueous concentration of AGMA10 and AGMA20 as maximum exploitable 
concentrations. More detailed information on cell viability tests were further 
reported in paragraph 5.7.9. 
As regard the best gelatin concentration to be used in hydrogel recipe, three 
HA-Gel hydrogels with different composition (HA:Gel 1:1, 1:2 and 1:3) were 
synthesised using the previously described (15mg/mL) DMTMM 
concentration. The reaction was allowed to proceed for 24 h and stopped 
lowering the temperature to -20°C and following freeze-dried. 
Biocompatibility and rheological properties were evaluated and described in 
paragraph 5.7.9 and 5.7.6. As consequence of these results, HA-Gel 1:2 was 
chosen as final optimal hydrogel composition. 
5.7.3 FTIR characterization 
FTIR hydrogels spectra were compared with those of reagent confirming the 
presence of all components (Figure 5.6). In particular, characteristic absorption 
bands of HA, gelatin and AGMA1 were following reported and found in 
hydrogel spectra. Hyaluronate spectrum contained five important bands: C-O 
stretching vibrational band (950-1200 cm-1), symmetric stretching of COO- 
(1400 cm-1), an intense group of bands due to superposition of amides and of 
various carbonyl and carboxyl bands (1500-1700 cm-1); symmetric and 
asymmetric stretching C-H band (2900 cm-1) and a broad and intense band of 
N-H and O-H stretching bands engaged in hydrogen bonds (2500-3600 cm-1). 
The FTIR spectrum of gelatin showed the characteristic absorption bands of a 
protein structure, e.g. C-O stretching band (1230 cm-1), amide I vibrational 
band (1530-1580 cm-1), asymmetric C=O stretching of carbonyl and carboxyl 
groups (1640-1650 cm-1), H2C-H and HC-H stretching vibration (2860 cm-1 
and 2920 cm-1, respectively) and, lastly, N-H and O-H vibrational bands (3200-
3450 cm-1). AGMA10 and AGMA20 had similar FTIR spectra, with typical 
bands of AGMA1 polyamidoamine: C–H and HC-H stretching bands (2960–
2860 cm-1), asymmetric C=O stretching (1619 cm-1) and symmetric COO- 
stretching (1379 cm-1), as well as the amide I band (1523 cm-1). 
In hydrogels, a decrease of band intensities of the characteristic functional 
groups involved in the cross-link reaction was highlighted (     at 3350 cm
-1, 
    at 1620 cm-1,       at 1410 cm-1). Simultaneously, a new amide band at 
1680 was observed, which can be assigned to the new covalent amide bond 
formed between hyaluronan and gelatin or AGMA1, different to original 
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carbonyl band. Monitoring these signals, over 3 days of reaction, was possible 
to establish the end of cross-link reaction. Results indicated that after 2 days, 
no further modifications occurred in both FTIR spectra for the analysed 
hydrogels. Trend over time was reported of the only HA-AGMA20 in Figure 
5.7, highlighting the formation of a new amide band at 1680 cm-1 and 
disappearing of carboxylate one at 1410 cm-1.  
 
Figure 5.6. FTIR spectra of reagents and hydrogels at different compositions. 
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Figure 7. FTIR spectra of HA-AGMA20 hydrogels varying time reaction. 
5.7.4 Water uptake measurements and Flory-Rehner calculations 
Water uptake of hydrogels was measured at 37 °C after 24 h of immersion in 
PBS buffered solution at pH 7.4. Figure 5.8 shows the water uptake of 
hydrogels at different composition. Initially the system was in a solid state 
(xerogel), forming a rigid network. When the system started to hydrate the 
polymer chains swelled and became more flexible, allowing the diffusion of 
water molecules in the network. When the chain relaxation reached a 
minimum energy state, equilibrium between chain relaxation and contraction 
of the polymeric network was reached, getting a stable swelled state. Water 
uptake was affected noticeably by the composition due to a change of 
crosslinking density. The level of water uptake changed from 2500% for the 
HA-AGMA10 hydrogel, to 1300% for HA-Gel-AGMA20.  
These data allowed determination of the crosslinking density and the average 
molecular weight and distance between nodes, parameters that define the 
three-dimensional network structure of chemical cross-linked hydrogel. These 
parameters determine the mechanical properties, stiffness, and elastic 
behaviour of the hydrogels. Flory–Rehner equation reported in the 
experimental section, gave these important parameters, which are reported in 
Table 5.4. The Flory–Rehner model was applied to hydrogels considering the 
only HA contribute, as in the case of monocomponent matrix, without 
considering gelatin and AGMA1 influences. This coarse simplification lead to 
approximated values of  ̅ ,   , ξ. Notwithstanding, these values were useful 
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for making order-of-magnitude comparisons of the hydrogel chemistries in 
biologically relevant features in this work. 
In general, a low crosslinking density gives rise to a more open network, and a 
higher degree of hydration and higher distance between nodes. However, a 
high crosslinking density implies a lower degree of hydration and a less 
deformable hydrogel.   % ranged between 10-4 to 10-3, with a maximum in the 
case of HA-Gel-AGMA20. Regarding to mesh size, in all cases a nanometric 
pattern was calculated, in the range of 250 nm. Considering ̅  and the ̅  of 
native HA, number of cross-links per HA chain was calculated. Results 
indicated that at least one node per chain was present. Data confirming 
rheological results in which no physical interaction was detected, in the 
temperature ramp. Values increased passing from HA-AGMA1 to HA-Gel 
(1.8) and then to HA-Gel-AGMA1, with a maximum of 3.48 cross-link nodes 
per chain for HA-Gel-AGMA20.  
 
Figure 5.8. Water uptake after 24 h of immersion in PBS solution of 
hydrogels at different composition. 
Table 5.4. Flory-Rehner calculation results, average MW between crosslinks, 
 ̅ , crosslinking density %, ʋc %, number of cross-links per HA chain, swollen 
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 1.88 243 
HA-Gel-AGMA
10
 102021 1.20·10-3 2.55 227 
HA-Gel-AGMA
20
 74786 1.64·10-3 3.48 213 
HA-AGMA
10





 1.53 251 
5.7.5 Thermal characterization 
The thermal behaviour of hydrogels was assessed by means of 
thermogravimetric analysis, TGA, and differential scanning calorimetry, DSC. 
TGA traces (Figure 5.9 and Table 5.5) showed in all cases moisture loss at 
80°C in different amounts, ranging from 5 to 15%. Table 5.5 reports the onset 
decomposition temperatures, obtained by the intersection of tangent lines to 
curves, and the relevant maximum weight loss rate temperatures, obtained by 
the first derivative of TGA curves. HA and gelatin degraded by a single step 
with maximum degradation rates, Tmax, at 242 and 309°C, respectively. 
AGMA10 and AGMA20 showed a multi-step degradation with Tmax at 245, 326 
and 463°C.  
By comparing the hydrogel degradation curves with those of each single 
component, it is apparent that AGMA1 and Gel had a different influence on 
thermal stability of HA. In particular, in the case of HA-Gel, the onset 
decomposition temperatures were 5°C and 23°C lower than those of native 
HA and Gel, respectively; similarly, the Tmax decreased of 10°C and 8°C 
respectively.  
Conversely, HA-AGMA10 and HA-AGMA20 exhibited higher thermal stability 
than single component. The onset degradation temperatures of HA in 
hydrogels was higher of 18°C and 11°C than native HA, in the cases of HA-
AGMA10 and HA-AGMA20, respectively. The maximum degradation rates 
increased of 8°C and 10°C, respectively. AGMA10, AGMA20 in HA-AGMA1 
hydrogels and native ones started to degrade at similar temperatures, (212 and 
207°C vs. 210°C, respectively), but maximum degradation rate were lower of 
22 and 21°C for HA-AGMA10 and HA-AGMA20.  
In the cases of HA-Gel-AGMA1 hydrogels, all components started to degrade 
early than native ones. In particular, HA presented an onset temperature lower 
of 15 and 22°C, in the cases of HA-Gel-AGMA10 and HA-Gel-AGMA20 
respectively and, similarly, considering Tmax, a decrease of 18 and 28°C. Gel 
showed an onset temperature variation of 32 and 39°C and Tmax decrease of 60 
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and 23°C for HA-Gel-AGMA10 and HA-Gel-AGMA20 respectively. AGMA10 
and AGMA20 degradation steps were not detected.  
Notwithstanding temperature trends, the presence of Gel and AGMA1 onto 
HA chains slowed down the overall degradation of hydrogels as evidenced by 
a less steep slope of TGA curve. Residual mass at 600°C did not significantly 
varied passing from native components to hydrogels. 
 
Figure 5.9. Thermogravimetric analyses of precursors and hydrogels. 
Table 5.5. Hydration water loss temperature (THydr) and degradation 
temperature (TDegr) of reagents and hydrogels, derived by TGA. Maximum 
degradation rate temperatures (Tmax) and onset temperatures (Tonset) are 
reported for each component. 
Samples THydr (°C) 
TDegr (°C) 
1rt step 2nd step 3rd step 
Tonset Tmax Tonset Tmax Tonset Tmax 
HA 83 228 242     





 -- 210 245 304 326 432 463 
HA-Gel 83 223 232 297 308   
HA-AGMA
10
 82 140 142 212 224 246 250 
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 82 144 150 207 223 239 252 
HA-Gel-AGMA
10
 82 213 224 242 256   
HA-Gel-AGMA
20
 83 144 150 206 214 235 293 
 
Figure 5.10. Differential scanning calorimetry thermograms of reagents and 
hydrogels.  
The DSC traces (Figure 5.10 and Table 5.6) resulting from the first heating 
cycle of all polymers were characterized by broad endothermic peaks centred 
around 80°C associated with the loss of residual water, in agreement with 
TGA results. The second heating cycle lead invariably to flat curves, not 
reported below for seek of simplicity. HA-AGMA10 and HA-AGMA20 showed 
a degradation step centred at about 130°C, also observed in TGA curves, not 
present in AGMA1 and HA-Gel-AGMA1 thermograms. In the same region, 
the endothermic peak present in AGMA1 trace at 130 - 138°C does not 
correspond to any mass loss in the TGA curve.  
Table 5.6. Glass transition temperature (Tg) and hydration water loss 
temperature (THydr) and peak temperature (Tpeak) of reagents and hydrogels, 
derived by DSC. 
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Tg (°C) THydr (°C) Tpeak (°C) 
Max Onset Max Onset Max Onset 
HA -- -- 90 47 -- -- 
Gel -- -- 97 40 -- -- 
AGMA10 50 40   130 120 
AGMA20 -- --   138 127 
HA-Gel -- -- 84 32 -- -- 
HA-Gel-AGMA10 50 40 79 41 -- -- 
HA-Gel-AGMA20 57 38 104 38 -- -- 
HA-AGMA10 -- -- 74 26 152 141 
HA-AGMA20 -- -- 74 24 156 143 
5.7.6 Rheological experiments 
The cross-linked nature (chemical or physical one) of HA-Gel hydrogels was 
evaluated by rotational rheometer in oscillatory mode (Figure 5.11). Three 
experiments were carried out, evaluating G‟ and G‟‟ moduli trend variation 
with oscillation torque, oscillation frequency and temperature, respectively.  
In a first experiment, G‟ and G‟‟ were obtained operating at a fixed oscillation 
frequency, namely 1 Hz, varying oscillation torque from 0.1 to 10000 µN.m. 
All sample showed G‟‟ values lower than those of G‟, highlighting a prevailing 
elastic behaviour rather than a viscous one. The linear viscoelastic regions 
ended only for oscillation torque values higher than 2000 µN.m, indicating a 
high stability in a wide range of torque values. G‟ was not significantly sensitive 
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Figure 5.11. Rheological analyses of HA-Gel with different weight ratio (●1:1, 
□1:2, ○1:3). A) oscillation stress dependency of the modulus values G‟ and G‟‟, 
B) oscillation frequency dependency of the modulus values G′ and G′′, C) 
temperature ramp. 
In frequency sweep tests, G′ and G” were obtained operating at a fixed 
oscillation torque in the linear viscoelastic region, 30 µN.m, varying oscillatory 
frequency from 0.01 to 100 Hz (Figure 5.11, panel B). For frequencies <30 Hz 
samples showed a solid response (both sinusoidal stress and deformation) and 
G‟ and the G‟‟ were constant for a wide frequency range. At frequencies >30 
Hz, samples began to have liquid-like behaviour (sinusoidal stress and 
cosinusoidal deformation trends) in response to stress. No differences were 
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The temperature ramp tests allowed understanding the stability of samples at 
high temperatures (Figure 5.11, panel C). Tests were conducted fixing 
oscillation torque to 30 µN.m and frequency of 1Hz. In general, for chemical 
cross-linked hydrogels, increasing temperature, water tends to evaporate, 
leading the G‟ increased with temperature. This trend was observed almost for 
all studied samples. The only exception was HA-Gel 1:3 that showed a 
decreasing G‟ with temperature, in particular in the 10 to 35ºC range, meaning 
that physical interactions, such as Van der Waals interactions, were present. 
This temperature range was typical of uncross-linked gelatin,cviii,cix indicating 
that HA:Gel 1:3 contains too high gelatin content inside. For this reason, a 1:2 
weight ratio was chosen as final composition of HA-Gel hydrogels. 
All hydrogels were analysed by using the same experimental conditions 
adopted for HA-Gel hydrogel. The viscoelastic behaviour was evaluated by 
determining G‟ and G‟‟ values varying oscillation torque, frequency of 
oscillation and temperature (Figure 5.12 panel A to C).  
In the first experiment (Figure 5.12, panel A), G‟ and G‟‟ value were evaluated 
at fixed oscillation frequency 1 Hz varying oscillation torque from 0.01 to 
10000 µN.m. Hydrogels presented an extended linear viscoelastic region 
ending only after 100 Pa, thus indicating a great stability also at medium – high 
stress. In particular, HA-AGMA10 and HA-AGMA20 presented the longest 
linear viscoelastic region, more than 1000 µN.m. The G‟ modulus were higher 
for all gelatin-based hydrogels (4, 4, 6 KPa for HA-Gel, HA-Gel-AGMA10, 
HA-Gel-AGMA20 respectively) than of HA-AGMA10 and HA-AGMA20 (0.7 
and 2.3 KPa respectively). In panel B, a magnification of stress sweep is 
reported, highlighting the breakpoint of each hydrogel. HA-Gel-AGMA20 
presented the higher value, followed by HA-Gel, HA-Gel-AGMA10, HA-
AGMA20 and HA-AGMA10. Similar trend replicated the cross-link density one, 
reported before.  
Oscillation frequency dependence was evaluated fixing oscillation torque of 30 
µN.m (Figure 5.12, panel B). Hydrogels‟ behaviour did not significantly depend 
on frequency within a wide frequency range. For frequencies <15 Hz samples 
showed a solid response (both sinusoidal stress and deformation) and G‟ and 
the G‟‟ were constant for a wide frequency range. Only at really high frequency 
(15-100 Hz) samples involved liquid behaviour to the stress. 
Temperature ramp from 25 to 100°C was performed fixing oscillation torque 
at 30 µN.m and frequency at 1 Hz (Figure 5.12, panel C). All hydrogels 
resulted stable to temperature increase. Water loss was slowed down, indeed 
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only slight increase of G‟ modulus was recorded. No physical interactions were 
detected. Same G‟ value trend of  was present. Resuming all tests, the best 
performance was reached by HA-Gel-AGMA20, due to its highest G‟ modulus 
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Figure 5.12. Rheological characterization of hydrogels via: (A) oscillation 
torque dependency of the modulus values G‟ (red), G‟‟ (blue) and delta (black); 
(B) oscillation frequency dependency of the modulus values G‟ (red), G‟‟ (blue) 
and delta (black); (C) temperature dependency of G‟ (red), G‟‟ (blue) and delta 










It is important to underline that almost all synthesised hydrogels presented 
rheological properties comparable to those of human and bovine liver. In 
literature, it was reported G‟ and G‟‟ dependency by frequency, measured by 
oscillation rheology and multifrequency magnetic resonance elastography. 
Reported modulus values ranged between 1 and 3 KPa and between 0.4 and 
1.5 KPa for respectively G‟ and G‟‟, varying frequency from 2 to 100 Hz.cx 
Similar values were obtained in the cases of HA-Gel-AGMA20, HA-Gel-
AGMA10, HA-Gel and HA-AGMA20, lower ones in the case HA-AGMA10. 
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5.7.7 Degradation test 
Figure 5.13 shows the residual mass of hydrogels as a function of incubation 
time in PBS at 37 °C. For comparison 1:2 weight ratio HA/gel blend were 
similarly immersed in PBS, but at 37°C they are totally soluble. After one 
week, HA/Gel blend started to smell bad, probably due to their 
decomposition, but pH solution did not change. For all hydrogels, the extent 
of degradation regularly and slowly increased with time. No smells or pH 
variation were spotted during time experiment. After 1 week, only 5-10 % of 
weight loss was recorded, after 4 week 25-35%. It may be noted that the 
highest weight loss percentage occurred for HA-Gel, the lowest for HA-Gel-
AGMA20. These results corroborated the water uptake studies and cross-linked 
degrees. In particular, hydrogels presented a high degradation degree were the 
same showing low cross-linked density. As well as, HA-Gel-AGMA20 showed 
the lowest degradation degree possessed the highest cross-linked density.  
 
Figure 5.13. Residual mass % of hydrogels after immersion in PBS solution 
for 28 days at 37°C. 
5.7.8 Morphological studies by AFM 
Morphology of hydrogels was examined by AFM. Images of xerogels are 
shown in Figure 5.14 with a size bar of 3 μm. The topographical image of HA-
AGMA1 and HA-Gel-AGMA1 revealed a rough surface. However, the 
topographical image of HA-Gel was characterized by a smooth surface 
without any indication of the presence of orientated polymer chains or 
aggregates or organized systems domains. The surface characteristics of 
xerogels were composition and cross-ling degree dependent. Roughness was 
higher for xerogels presented lower values of cross-link degree, as showed in 
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the case of HA-AGMA20 and more in HA-AGMA10. Analysis of phase images 
revealed an absence of phase separation in the microdomains at all 
compositions, what can be attributed to the total miscibility of reagents. 
 
Figure 5.14. AFM images of hydrogels (3 μm bar). 
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5.7.9 Cell biocompatibility  
One of the most popular and convenient ways to determine cell viability is the 
rapid colorimetric tetrazolium dye procedure commonly referred to as the 
MTT assay. This assay is based on the cleavage of the yellow-coloured 
tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, 
into a blue-coloured formazan by the mitochondrial enzyme succinate-
dehydrogenase.cxi In order to disregard any cytotoxic product‟s influence on 
fibroblast proliferation, an MTT assay was carried out for reagents and final 
hydrogels, staying in contact with the culture medium for determined time 
periods. Cell viability of DMTMM, AGMA10 and AGMA20 PBS solutions was 
monitored for maximum 24h, incubating them with fibroblast cells dispersed 
in DMEM matrix.  
Results indicated that 15 mg/mL was the maximum concentration of 
DMTMM after 2 h of incubation, but it resulted toxic after 18 h (Figure 5.15, 
panel A). Notwithstanding, this concentration was chosen in consideration 
that the major extent of coupler agent was consumed in the first part of 
reaction.  
In the case of NH2-end-capped AGMA1 products, 10 mg/mL concentration 
as maximum biocompatible concentration for both oligomers (Figure 5.15, 
panel B).  
 
Figure 5.15. MTT tests with BALB/3T3 fibroblast cell line in presence of A) 
DMTMM and B) AGMA1 at different concentrations. 
Biocompatibility of HA-Gel hydrogels and final hydrogels were studied (Figure 
5.16 and 5.17), evaluating cell viability over 21 days on fibroblast cells and 
compared to PBS solution as control. The cell viability was approximately or 
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biocompatibility was not compromised and the samples did not produce 
cytotoxic products. 
Proliferation tests on containing serotonin hydrogels are actually in progress 
with hepatocytes in order to evaluate the adhesion, proliferation and 
morphologies of cells.  
 
Figure 5.16. Cell viability % of HA-Gel hydrogels over 21 days with 
BALB/3T3 fibroblast cell line. 
 
Figure 5.17. Cell viability of hydrogels evaluated by MTT test at determined 
times. 
5.8 CONCLUSIONS 
In this work, chemical cross-linked hydrogels intended as scaffolds for tissue 
regeneration, in particular of liver tissue, were produced. Sodium hyaluronate 
and gelatin (HA-Gel) were selected as scaffolding material to mimic the crucial 
components of ECM, in order to enhance cell proliferation, migration, and 
differentiation of liver tissue. Two different NH2-end-capped AGMA1 
oligomers were opportunely synthesised and used as co-reagent in hydrogel 
synthesis. AGMA 1 was used to favour cell adhesion on hydrogel surface by 
RGD sequence enrichment in the porous hydrogel structure. Thanks to its 
HA-Gel(1:1) HA-Gel (1:2) HA:Gel (1:3) Control 
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efficacy without control pH solution, DMTMM was chosen as coupler agent 
in the cross-link reaction between hyaluronate, gelatin and AGMA1. Reaction 
parameters were finely tuned in order to increase cross-link degree at body 
temperature. FTIR spectra of final products confirmed the presence of all 
initial components and, in particular, after 48 h of reaction, the formation of 
new amides groups and a reduction of carboxylate groups of HA. These 
results confirmed the presence of chemical cross-linked hydrogels.  
Thermal analysis showed lower onset temperatures and maximum rate ones of 
HA-Gel-AGMA1 component compared to native ones. In contrast, onset 
temperatures and maximum rate ones of HA-AGMA1 were higher of equal to 
native ones.  Huge amount of moisture was retained in hydrogel structure. 
Swelling analysis performed in PBS solution for 24 h allowed evaluating cross-
link degrees by using of Flory-Rehner equation. Cross-link density degrees and 
the other mesh properties depended on composition. At least one cross-link 
node was present in all hydrogels, but, among others, HA-Gel-AGMA20 
hydrogel showed the highest cross-link density, number of nodes per HA 
chain, and the smallest distance between two cross-links nodes. Results found 
explanation considering the amine content in AGMA20 higher than AGMA10 
and gelatin. Flory-Rehner results indicated that HA-Gel-AGMA20 should be 
the most stable hydrogel; hypothesis confirmed by degradation tests, where, it 
presented the slowest degradation rate compared to the others. 
Notwithstanding, all hydrogel presented an high stability in water, indeed a 
maximum of 35 % weight loss was recorded after 28 days in PBS solution.  
Rheological tests revealed that synthesised hydrogels presented good 
rheological properties for liver regeneration. In particular, HA-Gel-AGMA20 
gave the best performance under oscillation stress and temperature heating, 
presenting the highest G‟ modulus and highest water retention when heated.  
The in vitro results revealed that the scaffolds did not induce cytotoxic effects 
and were suitable for cell growth. Biocompatibility was not compromised and 
the samples did not produce cytotoxic products over time. On the other hand, 
the cell adhesion and proliferation tests on hydrogels are actually in progress. 
In particular, these tests will be conducted with hydrogels contained also 
serotonin, a neurotransmitter also involved in DNA synthesis activation of 
liver cells after hepatectomy in rats and humans.  
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In conclusion, HA-Gel-AGMA1 hydrogels, combining the advantages of 
hyaluronan, gelatin and AGMA1, might be a suitable candidate for use in soft 
tissue engineering. 
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